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ABSTRACT

Dietary polyphenols are non-essential phytonutrients that are extensively metabolized upon
consumption. Based on our previous studies, we hypothesized that the bioavailability of
polyphenol metabolites is more important than unmetabolized polyphenols for the healthpromoting effects of polyphenol-rich foods. We tested this hypothesis with three objectives. First
we developed a more complete polyphenol profile for almond, by characterizing its tannins and
stilbenes. Tannins and stilbenes are extensively metabolized prior to or upon absorption. In
almond, hydrolysable tannin content was 54.7 ± 2.3 mg ellagic acid and 27.4 ± 7.3 mg gallic acid
per 100 g almond among varieties. The stilbene resveratrol-3-O-glucoside was identified in
almond extracts, with 7.19–8.52 µg/100 g almond. These results suggested that almonds have a
large pool of polyphenols that would be extensively metabolized in the colon prior to absorption.
Second, we determined the efficiency by which aronia berry polyphenols are metabolized in an
acute pharmacokinetic study in humans. In this experiment, polyphenol metabolites constituted
at least 99% of the total polyphenol pool measured in plasma and urine. Third, we determined
the association between aronia polyphenol metabolites and changes in key biomarkers of CVD

risk in an intervention study. Former smokers, which were at greater risk for CVD, consumed
aronia berry extract for 12 wk. Aronia consumption reduced fasting plasma total cholesterol (TC)
level by 8% during the 12-week treatment compared with placebo group, and reduced plasma
LDL-C level by 7% and 11% at both 6 wks and 12 wks compared with placebo group. In
addition, participants in the aronia group who showed the largest decreases in TC had stronger
correlations of urinary peonidin-3-O-galactoside and cyanidin-3-O-galactoside than those who
did not respond to the intervention. These results suggested that increases in polyphenol
metabolites were more highly correlated with reduced biomarkers of chronic disease than parent
polyphenols. Thus, this study demonstrated that the cholesterol-lowering activity of polyphenolrich foods is associated in-part with its tissue metabolites.
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Chapter 1: Introduction

1

1.1 Overview
Increasing polyphenol consumption can improve dyslipidemia, inhibit inflammation, and
reduce oxidative stress in individuals with increased cardiovascular disease (CVD) risk (Vita
2005, Rahman, Biswas et al. 2006, Chiva-Blanch, Urpi-Sarda et al. 2012, Annuzzi, Bozzetto et al.
2014). Polyphenols are extensively metabolized upon consumption, leading to a greater
proportion of metabolites than parent compounds in tissues and circulation (Manach, Williamson
et al. 2005). Even minor changes to a polyphenol structure can lead to a significant change in its
biological activity (Heim, Tagliaferro et al. 2002).

Thus, it is important to determine the

polyphenol profile of foods and their metabolic fate to explain the mechanisms by which
polyphenol consumption reduces CVD risk.

1.2 Central Hypothesis and Specific Aims
The prevailing approach to determining polyphenol efficacy has been to screen
polyphenols in vitro (e.g. antioxidant activity, enzyme inhibition) or in cell culture to determine
it relative potency or mechanism(s) of action. However, this approach may need to be reevaluated for many dietary polyphenols. Polyphenols are extensively metabolized (e.g.
flavonoids, phenolic acids) or have limited bioavailability (e.g. tannins). Thus, the overall
hypothesis for this study was that the sum of polyphenol metabolites is more responsible than
polyphenol parental compounds for exerting bioactivity after consumption (Figure 1.1). In order
to test this hypothesis, we pursued three objectives: 1) characterize the polyphenol profile (e.g.
metabolic availability) of almonds; 2) define polyphenol pharmacokinetics (e.g. metabolic
efficiency) of aronia berry polyphenols; 3) determine the extent efficacy is associated with
metabolism after chronic supplementation of aronia polyphenols.

2

Figure 1.1 The overall thesis hypothesis.

1.2.1 Objective 1: Characterize the tannin and stilbene composition of
almonds.
Almond, among other nuts, is a rich source of dietary polyphenols containing phenolic
acids, flavonoids, and lignans (Smeds, Eklund et al. 2007, Bolling, Dolnikowski et al. 2010).
Despite extensive research on almond flavonoids, little is known about its other polyphenols,
especially tannins and stilbenes. Proanthocyanidins (PACs) may be the most abundant class of
polyphenols in almonds (Bolling, Chen et al. 2011). The PAC content of foods might be
underestimated because solvent extraction does not completely liberate polyphenols covalently
bound to cell walls (Arranz, Saura-Calixto et al. 2009). Flavonoids, phenolic acids, and PACs
could be released by acid or alkaline hydrolysis from other plant materials (Arranz, SauraCalixto et al. 2009, White, Howard et al. 2010). Thus, more work is needed to determine the
relative proportion of free and bound PACs in almonds. A previous study reported almond

3

contained little to no gallotannins and ellagitannins following hydrolysis (Molyneux, Mahoney et al.
2008). However, this study employed a moderate hydrolysis condition, which might not liberate these
tannins. Furthermore, the content and distribution of stilbenes in almonds was unknown. Stilbenes have
been reported to have a cardioprotective potential in in vivo studies (Baur and Sinclair 2006). The
unknown content of tannins and stilbenes might comprise a potentially large pool of polyphenols that are
extensively metabolized upon consumption.
The hypothesis for Objective 1 was that most almond polyphenols are extensively metabolized
prior to absorption (Figure 1.2). We developed qualitative and quantitative methods to more completely
characterize almond tannins and stilbenes. Furthermore, we determined the compartmentalization of
almond stilbenes, as almonds are consumed whole or blanched. Almond genotype also affects polyphenol
profile (Milbury, Chen et al. 2006, Bolling, Dolnikowski et al. 2010). Thus, we characterized tannins and
stilbenes in the top three cultivated California almond genotypes. This work is potentially applicable for
other types of foods that contain a large portion of bound polyphenols.

P: Parent polyphenols
M: Metabolites of polyphenols

P

P

P
micr

Lumen

P

firt -pass
metabolism

M

Hypothesis 1: Most almond polyphenols are
extensively metabolized prior to absorp on.

Objec ve 1: Characterize the tannin and
s lbene composi on of almonds.

Figure 1.2 Objective 1 hypothesis
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1.2.2 Objective 2: Determine the pharmacokinetics of aronia berry
polyphenols and its metabolites.
Previous studies on the pharmacokinetics of anthocyanin-rich extracts have provided
limited information about the extent of polyphenol colonic catabolism. Chokeberry (aronia
berry) is rich in polyphenol antioxidants, such as PACs and anthocyanins (Taheri, Connolly et al.
2013). PACs and anthocyanins may be extensively metabolized by phase II conjugation
reactions (e.g. glucuronidation, sulfation, methylation) or catabolized to smaller phenolic
compounds by gut microbiota. The hypothesis for Objective 2 was that the rate of first-pass
metabolism and microbiota catabolism creates a larger pool of metabolites than bioavailable
parent compounds from aronia berry extract in vivo (Figure 1.3). To test this hypothesis, we
quantitated the major aronia berry polyphenols and metabolites in plasma and urine following
consumption of aronia berry extract. We then determined pharmacokinetic parameters for
metabolites and parent compounds.
P: Parent polyphenols
M: Metabolites of polyphenols

P

micr

Lumen

P

firt -pass
metabolism

M

Hypothesis 2: the rate of first-pass metabolism
and microbiota catabolism creates a larger pool of
metabolites than bioavailable parent compounds
from aronia berry extract in vivo.
Objec ve 2: Determine the pharmacokine cs of aronia
berry polyphenols and its metabolites.

Figure 1.3 Objective 2 hypothesis
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1.2.3 Objective 3: Determine the extent to which polyphenol metabolites are
associated with changes in plasma cholesterol in former smokers after 12 wk
of chronic consumption of aronia berry extract.
Smoking increases CVD risk (Ambrose and Barua 2004). Although smoking cessation may
curve the risk, CVD risk remains elevated for 10-15 years in former smokers compared with
never-smokers (Kawachi, Colditz et al. 1993, Iso, Date et al. 2005). Consumption of a
polyphenol-rich aronia berry extract might be a promising intervention for reducing CVD risk in
former smokers. Prior human intervention studies indicated aronia berry consumption lowers
cholesterol and reduces oxidative stress in other populations with increased CVD risk
(Naruszewicz, Łaniewska et al. 2007, Broncel M 2010). Despite these studies, the compounds
responsible for these effects remain uncharacterized.
We hypothesized that following consumption of aronia berry polyphenols, increases in
polyphenol metabolites will more strongly correlate to reductions in plasma total cholesterol than
increases in unmetabolized polyphenols. Thus, the metabolites would be more responsible for
reduction in CVD risk in former smoker than parent compounds.

Protocatechuic acid, a

principal metabolite of anthocyanins could reduce serum total cholesterol level in diabetic mice
(Lin, Huang et al. 2009). Protocatechuic acid was suggested to reduce serum total cholesterol
level by increasing the hepatic LDL receptor, apo E, lecithin-cholesterol acyltransferase and
hepatic triglyceride lipase expression in rats (Tamura, Fukushima et al. 2004). Thus, our working
hypothesis for this objective was that plasma and urinary protocatechuic acid will be highly
correlated to reductions in total cholesterol after aronia berry supplementation. To test this
hypothesis, we determined metabolites and polyphenols in plasma and urine of former smokers
consuming aronia berry extract or a placebo. We used the methods developed in Objective 2 to
determine metabolites of PACs and anthocyanins in urine and plasma of participants consuming

6

aronia berry extract. With these data, we determined the association between metabolites of
PACs and anthocyanins and biomarkers of lipid metabolism.
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2.1 Introduction
Polyphenols are a class of organic compounds characterized by phenol structural units.
Polyphenols are abundant in tea, fruits, vegetables, and grains. Increased polyphenol
consumption may reduce chronic inflammation, improve antioxidant defenses, modulate lipid
metabolism, and inhibit cell-signaling pathways. Epidemiological and intervention studies have
associated increased consumption of polyphenol-rich foods or beverages with lower risk of
chronic disease, such as cancer, cardiovascular diseases (CVD), Alzheimer's, diabetes and
metabolic syndrome. Polyphenol bioactivity is limited by their absorption, distribution,
metabolism and excretion (ADME). In this chapter, dietary polyphenols and their ADME will be
presented with a focus on linking these to their putative ability to reduce biomarkers of CVD
risk.

2.2 Polyphenol variety and consumption
More than 8000 naturally occurring polyphenols have been identified, many which are
present in foods. The main classes of dietary polyphenols include phenolic acids, flavonoids,
stilbenes, lignans, and tannins, among others (Figure 2.1). Phenolic acids can be divided into
hydroxybenzoic acids and hydroxycinnamic acids. Flavonoids can be divided into 6 classes,
which are anthocyanins, flavonols, flavones, flavanones, isoflavones, and flavan-3-ols. Tannins
include both hydrolysable and condensed tannins which are also known as proanthocyanidins
(PACs).
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Figure 2.1 Chemical structure of representative polyphenol.

Dietary polyphenols are widely distributed in plant foods, such as fruits and vegetables, and
beverages, such as coffee and tea (Table 2.1). For example, black chokeberry ranks 2 of the top
100 polyphenol rich food per serving, and almonds ranks 62 (Perez-Jimenez, Neveu et al. 2010).
The average intake of total polyphenols in the adult diet is ~1 g/day (Table 2.2) (Hertog,
Hollman et al. 1993, Kimira M 1998, Kirk, Patterson et al. 1999, Wu, Beecher et al. 2006, Chun,
Chung et al. 2007, Ovaskainen, Törrönen et al. 2008, Wang, Chung et al. 2011, McCullough,
Peterson et al. 2012). Phenolic acids may be the most abundant dietary polyphenols (Table 2.2).
Flavonoids, are second largest contributor to polyphenol intake followed by condensed tannins,
hydrolyzable tannins and lignans. Among flavonoids, flavones and isoflavones contribute the
least to daily polyphenol intake in western diets. The quantity of polyphenol consumption in
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Table 2.2 is estimated based on the polyphenols reported in fruits and vegetables, which include
non-extractable and non-digestible polyphenols. For example, among the total of 95 mg/day
condensed tannins intake, only monomers (22%) and dimers (16%) are absorbed (Wang, Chung
et al. 2011). Thus, the amount of total polyphenols absorbed after consumption is likely less than
the estimated intake. A significant portion of unabsorbed metabolites would be catabolized by
gut microbiota. Dietary polyphenol intake is also influenced by cultural dietary habits. For
example, Japanese have the largest consumption of isoflavones, 40 mg/day, because soy food
products are more popular in Japan than in western countries (Kimira M 1998).

Table 2.1 Main classes of dietary polyphenols and their sources (Manach, Scalbert et al. 2004).
Classes

Subclass

Food sources

Phenolic acids

Derivatives of benzoic acid

red fruits, black radish, onions, and tea

Derivatives of cinnamic acid

most fruits, coffee, cereals, and grains

Anthocyanins

fruits, red wine, certain cereal, and certain leafy and

Flavonoids

root vegetables
Flavonols

most foods and beverages

Flavones

parsley, celery, and citrus

Flavanones

tomatoes, aromatic plants, and citrus

Isoflavones

leguminous plants and products

Flavan-3-ols

many types of fruits, red wine, tea, and chocolates

Stilbenes

wine, nuts, certain fruits

Lignans

certain cereal, grains, fruits and vegetables

Tannins

Hydrolyzable tannins

red fruits

Condensed tannins

astringent fruits and beverages, and chocolates
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Table 2.2 Estimates of dietary polyphenol intake (Hertog, Hollman et al. 1993, Kimira M 1998,
Kirk, Patterson et al. 1999, Wu, Beecher et al. 2006, Chun, Chung et al. 2007, Ovaskainen,
Törrönen et al. 2008, Wang, Chung et al. 2011, McCullough, Peterson et al. 2012).
Classes

Subclass

Intake (Country)

Phenolic acids

Derivatives of benzoic acid

33 mg/day (Finnish)1

Derivatives of cinnamic acid

608 mg/day (Finnish)

Total

23 mg/day (Netherland)
6-987 mg/day (Germany)
641 mg/day (Finnish)

Flavonoids

Anthocyanins

47 mg/day (Finnish)
12.5 mg/day (USA)
3.8-22.2 mg/day (USA)

Flavonols

5.4 mg/day (Finnish)
21 mg/day (Netherland)
6.9-27.2 mg/day (USA)

Flavones

2 mg/day (Netherland)
0.4-3.0 mg/day (USA)

Flavanones

27 mg/day (Finnish)
3.5-49.9 mg/day (USA)

Isoflavones

0.9 mg/day (Finnish)
0.024-0.713 mg/day (USA)

Flavan-3-ols

7.0-63.7 mg/day (USA)

Total

189.7 mg/day (USA)
94.5-512.5 mg/day (USA)

Stilbenes

--

--

Lignans

--

0.9 mg/day (Finnish)

Tannins

Hydrolyzable tannins

12 mg/day (Finnish)
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Total

Condensed tannins

74 mg/day (USA)

(≥2 degree of polymerization)

53.1-379.4 mg/day (USA)

--

863 mg/day (Finnish)
1 g/day (USA)

1

The results are presented as average daily intake or range of the daily intake

2.3 Polyphenol absorption
The absorption of polyphenols occurs in two major locations, the small intestine and colon.
The small intestine mainly absorbs polyphenol aglycones or glycosides with low-molecularweights (<800 Daltons) (e.g. anthocyanins, phenolic acids, and flavonoids) through passive
transport or active transport (Tamai, Sai et al. 1999, Day, Cañada et al. 2000, Kay 2006, Crozier,
Del Rio et al. 2010). In the colon, gut microbes catabolize unabsorbed small (e.g. curcumin) and
large molecular-weight polyphenols (e.g. proanthocyanidins, ellagitannins and flavonoid
rutinosides) into simple phenolics (Rios, Gonthier et al. 2003, Crozier, Del Rio et al. 2010,
González-Barrio, Edwards et al. 2011). A portion of quercetin, anthocyanins and phenolic acid
may also be absorbed through stomach, although this pathway has been poorly characterized
(Crespy, Morand et al. 2002, Konishi, Zhao et al. 2006, Fernandes, de Freitas et al. 2012).
In the small intestine, polyphenol glycosides can be transported from the lumen by
sodium–glucose co-transporters (SGLT) into small intestine cells, remaining intact (Figure 2.2)
(Day, Cañada et al. 2000, Kay 2006). Alternatively, polyphenol glycosides can be hydrolyzed at
the brush-border of the small intestine epithelial cells, and the aglycone transported to the small
intestine cell. Once inside small intestine epithelial cells, polyphenol glycosides are
transpoported to the portal circulation or hydrolyzed by broad-specificity cytosolic β-glucosidase
(CBG) within the epithelial cell to the polyphenol aglycone (Németh, Plumb et al. 2003). Then,
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polyphenol aglycones are glucuronidated, methylated or sulfated by phase II enzymes, such as
UDP-glucuronosyltransferase

(UDP-GT),

catechol-O-methyltransferase

(COMT),

or

sulfotransferase (SULT), and transported into the portal circulation. For other low-molecularweight polyphenols, such as flavan-3-ol, are transported into the small intestine epithelial cells
intact by active transport, subjected to phase II metabolism, and then transported into portal
circulation (Kuhnle, Spencer et al. 2000, Spencer 2003, Crozier, Del Rio et al. 2010). Phenolic
acids can be absorbed into the small intestine epithial cells through the monocarboxylic acid
transporter (MCT) by active transport (Tamai, Sai et al. 1999).

Lumen
Polyphenol-3-glycosides

SGLT

Polyphenol-3-glycosides

Portal
circula on

CBG

LPH
Polyphenol aglycone

Polyphenol aglycone
UDP-GT
COMT

SULT

Polyphenol-glucuronide
Polyphenol-sulfate
Polyphenol-methylate

Figure 2.2 Potential mechanisms of polyphenol glycoside absorption in small intestine.

17

High-molecular-weight polyphenols or substituted with irregular glycosides (e.g.
rutinosides, quinic acid) cannot be absorbed intact and may be catabolized before absorption.
Proanthocyanidins are oligomers or larger polymers of flavan-3-ols. Previous studies have
suggested that proanthocyanidin oligomers having degrees of polymerization ≤ 4 can be rapidly
absorbed across differentiated Caco-2 cells, a model of intestinal absorption (Deprez, Mila et al.
2001, Ou, Percival et al. 2012). In the colon, proanthocyanidins with degrees of polymerization
> 4 are degraded by microbes into low-molecular-weight phenolic acid compounds, and
subsequently absorbed into the large intestine cells (Déprez, Brezillon et al. 2000, Ou and Gu
2013). Human colonic MCT may be largely responsible for microbial-derived phenolic acid
absorption (Iwanaga, Takebe et al. 2006). The major proanthocyanidin metabolites observed in
human urine or plasma after consumption are 3-(3’-hydroxyphenyl) propionic acid, 3’hydroxyphenylacetic acid, 3’,4’-hydroxyphenylacetic acid, 3-hydroxybenzoic acid, hippuric acid,
ferulic acid and phenolic acid (Rios, Gonthier et al. 2003, Urpi-Sarda, Monagas et al. 2009).
Ellagitannins are glucose-bound hexahydroxydiphenic acids. In the colon, ellagitannins are
catabolized by colonic microflora to ellagic acid (González-Barrio, Edwards et al. 2011).
Subsequently, ellagic acids are transformed to urolithins by microbes and then aborbed into large
interstine cells.
The stomach also has a limited role in absoption of dietary polyphenols. Low molecular
weight aglycone compounds, such as quercetin or phenolic acid, can be absorbed directly by
gastric cells (McCullough, Peterson et al. 2012). Quercetin, but not quercetin-glycoside was
absorbed across the gastric lining of rats with ligated sphincters to prevent gastro-esophagus
reflux (Crespy, Morand et al. 2002). Similary, quercetin can quickly appear (15 min) in human
plasma after consumption, suggesting stomach absorption (Kaushik, O’Fallon et al. 2012).
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However, the transporters responsible for gastric polyphenol absorption are not well-defined.
Tamai, et al. suggested that stomach MCT might contribute to the gastric absorption of phenolic
acids in rats, similar to the small intestinal mechanism (Crespy, Morand et al. 2002). However,
MCT has not yet been reported in the human stomach. Further, it is unknown if pheolic acids can
be absorbed through the human stomach. The earliest appearance of phenolic acids in human
plasma is 1 h after consumption, which suggests this is plausible (Caccetta, Croft et al. 2000).
In contrast to other polyphenols, glycosylated anthocyanidins (e.g. anthocyanins) can be
absorbed by the human stomach. Anthocyanins are absorbed intact by human cultured stomach
cells in a time dependent manner, likely via a saturable transport mechanism (Fernandes, de
Freitas et al. 2012). Passamonti, et al proposed that bilitranslocase could transport anthocyanins
across gastric epithelial cells (Passamonti, Vrhovsek et al. 2002). In this study, the anthocyaninbilitranslocase interactions were modeled using rat plasma membrane vesicles. Anthocyanins,
including cyanidin-3-glucoside, behaved as competitive inhibitors of bilitranslocase transport
activity, which suggested anthocyanins have high affinities for bilitranslocase. Similar results
were also reported by using human plasma membrane vesicles (Ziberna, Tramer et al. 2012).
However, bilitranslocase has only been characterized in the rat stomach (Battiston, Macagno et
al. 1999), and not been confirmed in the human stomach. Previous study indicated that cyanidin3-glucoside can be detected by 30 min in human plasma after consumption (Miyazawa,
Nakagawa et al. 1999). Thus, a limited number of low molecular-weight polyphenols including
anthocyanins and aglycone phenolic acids or flavonols may be absorbed through the human
stomach.
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2.4 Polyphenol distribution
After absorption from the gastrointestinal tract, polyphenols are transported to the liver
through portal circulation (Figure 2.3), then distributed to tissues or excreted out of the body
(Scalbert, Morand et al. 2002). Polyphenols have been detected in the blood, urine, feces, and
tissue in vivo (Morton, Chan et al. 1997, Pan, Huang et al. 1999, Zhao and Agarwal 1999, Hong,
Kim et al. 2002, Maubach, Bracke et al. 2003, de Boer, Dihal et al. 2005, Garcea, Berry et al.
2005, Hoh, Boocock et al. 2006, Czank, Cassidy et al. 2013). Isoflavones and lignans have been
detected in human urine, plasma, prostate gland and breast tissue (Morton, Chan et al. 1997,
Hong, Kim et al. 2002, Maubach, Bracke et al. 2003). Curcumin and its metabolites, curcumin
sulfate and curcumin glucuronide, were detected in the colorectal tissue of colorectal cancer
patients supplemented with 450 to 3600 mg curcumin daily for 7 days (Garcea, Berry et al. 2005).
Silibinin, a flavonolignan from milk thistle, was detected in plasma, colorectal tissue and liver
tissue of patients with colorectal adenocarcinoma receiving silibinin at dosages of 360, 720, or
1,440 mg silibinin daily for 7 days (Hoh, Boocock et al. 2006). Resveratrol and resveratrol-3-Oglucuronide were also recovered from colorectal tissue in colorectal cancer patients consuming
supplemental resveratrol (Patel, Brown et al. 2010). In animals, polyphenols can be found in
heart, brain, skin, lung, prostate, pancreas, liver, intestine, spleen, kidney and adipose tissues,
which suggest polyphenol may be transported to a broad range of tissues (Pan, Huang et al.
1999, Zhao and Agarwal 1999, de Boer, Dihal et al. 2005, Suresh and Srinivasan 2010).
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Figure 2.3 Pathway of polyphenol distribution (Scalbert, Morand et al. 2002).

2.5 Polyphenol metabolism
Polyphenols are extensively metabolized after absorption. For example, 70% to 80% of a
single cyanidin-3-glucoside dose was recovered as metabolites after consumption (Czank,
Cassidy et al. 2013). The human intestine and liver are the two major sites of polyphenol
metabolism, although other tissues may also contribute to this process. In the small intestine,
lactase phlorizin hydrolase (LPH) at the brush-border can hydrolyze polyphenol β-glycosides of
glucose, arabinose, and galactose to its aglycone form. Inside small intestine epithelial cells,
polyphenol β-glycosides can be hydrolyzed to aglycones by CBG. Subsequently, polyphenol
aglycone hydroxyl groups can be sulfated, methylated, and/or glucuronidated by UDP-GT,
COMT, and/or SULT.
In the liver, polyphenols can be metabolized by both phase I and II enzymes. Phase I
enzymes are a family of cytochrome P450 monooxygenases (CYPs) that catalyze oxidation,
reduction, hydroxylation or demethylation reactions (Hodek, Trefil et al. 2002). For example,
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galangin and kaempferide are oxidized to kaempferol by both CYP1A2 and CYP2C9 by human
liver microsomes (Otake and Walle 2002). Isoflavones, curcumin, and hesperetin are also readily
metabolized by phase I enzymes (Kulling, Honig et al. 2001, Duarte Silva, Rodrigues et al. 1997,
Silva, Rodrigues et al. 1997, Ireson, Orr et al. 2001, Ireson, Jones et al. 2002, Garcea, Jones et al.
2004, Roberts-Kirchhoff, Crowley et al. 1999, Doostdar, Burke et al. 2000). The phase I
isoflavone

metabolites,

6,7,4’-trihydroxyisoflavone,

7,3’,4’-trihydroxyisoflavone,

7,8,4’-

trihydroxyisoflavone, 7,8,3’,4’-tetrahydroxyisoflavone, and 6,7,3’,4’-tetrahydroxyisoflavone,
were present in the urine of human consumed ~70 mg of soy isoflavones (Kulling, Honig et al.
2001).
Polyphenols and/or their phase I metabolites can be further metabolized by hepatic phase II
glucuronidation, sulfation, and/or methylation. Curcumin glucuronides and sulftates were
identified from a human hepatocyte suspension from livers of patients with hepatic metastases
(Ireson, Orr et al. 2001, Ireson, Jones et al. 2002, Garcea, Jones et al. 2004). Anthocyanins are
primarily methylated or glucuronidated after consumption (Wu, Cao et al. 2002, Czank, Cassidy
et al. 2013).
Other tissues have phase I and II enzymes, and potential capacity for polyphenol
metabolism.

Rat

kidney

microsomes

have

ethoxyresorufin-O-deethylase

(EROD),

methoxyresorufin-O-demethylase (MROD), p-nitrophenol hydroxylase (PNPH), glutathione Stransferase

(GST),

UDP-glucuronosyltransferase

(UDP-GT)

and

NAD(P)H:quinone

oxidoreductase (NQO1) activity (Krajka-Kuźniak and Baer-Dubowska 2003). The extent to
which non-hepatic and GI tissue contribute to polyphenol metabolism is an ongoing area of
interest.
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2.6 Polyphenol excretion
Polyphenols and their metabolites are mainly excreted through breath, urine or feces
(Scalbert, Morand et al. 2002, Czank, Cassidy et al. 2013). Fecal polyphenols include absorbed
polyphenols secreted back to the intestine from bile and unabsorbed dietary polyphenols
(Scalbert, Morand et al. 2002). In healthy subjects that ingested a single dose of 500 mg
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cyanidin-3-O-glucoside, 13C cyanidin-3-O-glucoside and 13C cyanidin-3-O-glucoside metabolites
were found in the feces, which suggested unabsorbed cyanidin-3-O-glucoside remain intact
through the feces (Czank, Cassidy et al. 2013). A fraction of polyphenols is excreted in bile.
After infusion of 14C genistein into the duodenum of rats for 1 h, cumulative 14C genistein as its
7-O-β-glucuronide conjugate was found in the bile (Sfakianos, Coward et al. 1997). Many
polyphenols have enterohepatic recirculation, including isoflavones (Setchell, Brown et al. 2001,
Zubik and Meydani 2003). Many transport proteins contribute to polyphenol excretion. In the
small intestine, ATP-binding cassette (ABC) transporters contribute to polyphenol efflux
(Vaidyanathan and Walle 2003, Juan, González-Pons et al. 2010). For example, (-)-epicatechin3-gallate (ECG) is transported by multidrug-associated protein 1 (MRP1, ABCC1), multidrugassociated protein 2 (MPR2, ABCC2), and P-glycoprotein (ABCB1) (Vaidyanathan and Walle
2003). MRP1 and MRP2, but not P-glycoprotein contribute to EGCG efflux (Hong, Lambert et
al. 2003). In addition, MRP2 and breast cancer resistance protein (BCRP, ABCG2) have been
associated with the efflux of trans-resveratrol glucuronide and trans-resveratrol sulfate (Juan,
González-Pons et al. 2010). However, P-glycoprotein does not efflux of trans-resveratrol and its
conjugates. The fraction of polyphenols excreted varies by route. In a tracer study, 5.37 ± 0.67%
of the
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C of cyanidin-3-glucoside was excreted through urine, 6.91 ± 1.59% was excreted

through breath, and 32.13 ± 6.3% was excreted through feces (Czank, Cassidy et al. 2013). In
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the breath, 13C was present as CO2. In the urine, 13C was present as cyanidin-3-glucoside (11%)
and its metabolites (89%).

2.7 Polyphenols and CVD Risk
Epidemiological studies, animal studies and human intervention studies suggest that
polyphenol consumption may reduce CVD risk (Arts and Hollman 2005, Chong, Macdonald et
al. 2010). According to WHO, CVD is defined as a group of disorders of the heart and blood
vessels, which include coronary heart disease, cerebrovascular disease, peripheral arterial
disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis and pulmonary
embolism (WHO 2015). In 2012, CVD led to about 17.5 million deaths globally, and was the
primary cause of non-communicable disease deaths world world-wide (WHO 2014).
Atherosclerosis is the major cause of CVD. Endothelial dysfunction is a characteristic feature
throughout the pathogenesis of atherosclerosis, and it is an independent predictor for future
cardiovascular risk (Gonzalez and Selwyn 2003). Endothelial dysfunction is initiated by plaque
formation (Libby, Ridker et al. 2002). At the beginning of plaque formation, low-density
lipoprotein (LDL) penetrates into the intima, binds to the proteoglycan matrix, and undergoes
oxidative modification to form oxidized LDL (ox-LDL) (Berliner J 1997). Monocytes and
macrophages then will uptake ox-LDL and develop into foam cells, which leads to intimal
thickening, plaque formation, and vessel narrowing (Gonzalez and Selwyn 2003). Cytokines and
growth factors secreted by activated monocytes, macrophages, endothelial cells and T cells can
promote the migration and proliferation of smooth muscle cells (SMCs). SMC enzymes can
digest the arterial extracellular matrix by hydrolyzing elastin and collagen (Libby, Ridker et al.
2002). The degradation of the arterial extracellular matrix permits the penetration of the SMCs
and a fibrous cap develops to cover the plaque (Libby, Ridker et al. 2002). Subsequently,
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thrombosis is triggered as a result of increased accumulation of lipid and foam cells, and fibrous
cap rupture leads to infarction (Fuster V 1990).
During the pathogenesis of atherosclerosis, ox-LDL can activate nuclear factor-κB (NF-κB)
in monocyte and macrophage (Brand, Eisele et al. 1997). NF-κB activation promotes the
endothelial cell monolayer to secret adhesion molecules, such as L-selectin, vascular cell
adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) (Takei, Huang
et al. 2001). NF-κB activation can also induce migration of blood monocytes, macrophages,
dendritic cells, T cells and some B-cells into the intima (Frostegård, Nilsson et al. 1990, J A
Berliner 1990, Frostegård, Wu et al. 1992, Atout R 2012). NF-κB can also active the expression
of pro-inflammatory cytokines and growth factors (Hoesel and Schmid 2013). Pro-inflammatory
cytokines and growth factors, such as IL-1, IL-6, monocyte chemotactic protein-1 (MCP-1) and
tumor necrosis factor-α (TNF-α) accelerate atherosclerosis. For example, IL-6 can stimulate the
liver to produce C-reactive protein (CRP) which can further stimulate inflammation (Saito,
Ishimitsu et al. 2003). Patients with CVD have increased plasma levels of VCAM–1, ICAM–1,
IL-6, oxidative stress, NF-κB, and CRP (Gonzalez and Selwyn 2003). Thus, the pathogenesis of
CVD is partially a consequence of chronic cardiovascular inflammation.
Free radicals also contribute to the pathogenesis of atherosclerosis. Nitric oxide (NO) is
synthesized by the endothelial nitric oxide synthase (eNOS), which is important for maintaining
vasodilation (Cannon 1998). Ox-LDL and reactive oxygen species stimulate the expression of
inducible nitric oxide synthase (iNOS) in aortic endothelial cells (Hirata, Miki et al. 1995, Cai
and Harrison 2000). iNOS overproduction promotes the formation and activation of peroxynitrite
(Buttery LD 1996). Peroxynitrite can down-regulate the eNOS production, ultimately reducing
endothelial NO (Buttery LD 1996).
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Furthermore, oxidative stress and inflammation activate protein kinase intracellular
signaling molecules such as extracellular signal-regulated kinases (ERK), jun amino-terminal
kinases (JNK) and p38 mitogen-activated protein kinases (MAPKs) (González-Gallego,
Sánchez-Campos et al. 2007) (Figure 2.4). These will activate Nrf2 and NF-κB, key
transcription factors modulating antioxidant and inflammatory responses. Activated protein
kinase intracellular signaling molecules disrupt the bonding between Nrf2 and keap1, leading to
nuclear translocation of Nrf2. In the nucleus, Nrf2 binds to the specific DNA sequence
(antioxidant response element, ARE) in the upstream promoter region of many antioxidative
genes, such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSHPx), and initiates their transcription and expression. While in an inactivated state, NF-κB is
located in the cytosol complexed with the inhibitory protein IκBα. Activated protein kinase
intracellular signaling molecules can activate the enzyme IκB kinase (IKK). IKK, in turn,
phosphorylates the IκBα protein, which results in dissociation of IκBα from NF-κB. The
activated NF-κB is then translocated into the nucleus where it binds to specific sequences of
DNA (response elements, RE) and initiate transcription and expression of gene coding
cyclooxygenase (COX-2), iNOS, CRP, cytokines and adhesion molecules, which increase
inflammation.
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Figure 2.4 The mechanism of polyphenol against CVD in mRNA level (González-Gallego,
Sánchez-Campos et al. 2007)

Previous observational cohort studies and clinical trial suggested diet rich in polyphenols,
such as anthocyanins and proanthocyanidins, could prevent the risk of CVD (Rasmussen,
Frederiksen et al. 2005, Wallace 2011, Estruch, Ros et al. 2013).

2.7.1 Anthocyanins
Preventing chronic inflammation is a promising approach to reduce CVD risk. During the
pathogenesis of atherosclerosis, NF-κB was responsible for initiating the inflammatory response
(Brand, Eisele et al. 1997). Deactivation of NF-κB could suppress the expression of proinflammatory chemokines, growth factors, and adhesion molecules in the treatment of
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inflammatory and chronic disease (Yamamoto and Gaynor 2001). In in vitro studies,
anthocyanins were observed to directly inhibit the LPS-induced NF-κB transactivation in human
monocytes (Karlsen, Retterstøl et al. 2007). In human studies, reduced plasma level of NF-κB
and IL-8 were found in human subjects with anthocyanins-rich red wine intake (Blanco-Colio,
Valderrama et al. 2000). It has been suggested that ox-LDL can stimulate CD40 production
through the function of lipoprotein receptor-1 (LOX-1), a major receptor of ox-LDL (Li, Liu et
al. 2003). Up-regulation of CD40 was associated with the pathogenesis of atherosclerosis (Mach,
Schonbeck et al. 1998, Lutgens, Cleutjens et al. 2000, Schönbeck, Sukhova et al. 2000). The
function of CD40 was to activate NF-κB and induce the release of pro-inflammatory chemokines
and cytokines through up-regulating the expression of TNF receptor-associated factor 2 (TRAF2). TRAF-2 could induce the distribution of cholesterol in lipid rafts of membrane in endothelial
cells. Anthocyanin could reduce CD40-mediated activation of NF-κB by disrupting the function
of TRAF-2 in human endothelial cells. (Xia, Ling et al. 2007).
Activated monocytes, macrophages, endothelial cells and T cells could secrete cytokines
and growth factors, such as IL-1, IL-6, MCP-1 and TNF-α. The secretion of cytokines and
growth factors may increase the inflammatory response in the pathogenesis of atherosclerosis
(Libby, Ridker et al. 2002). MCP-1 was secreted by activated macrophages and endothelial cells.
MCP-1 overproduction can induce macrophages to form plaque. Anthocyanins have the capacity
to inhibit the production of MCP-1 induced by TNF-α. In an in vitro study, TNF-α-mediated
MCP-1 production by primary human endothelial cells was inhibited by anthocyanin treatment
(García-Alonso, Rimbach et al. 2004). Anthocyanin-rich blueberry and cranberry extracts can
reduce the levels of IL-8, MCP-1 and ICAM-1 induced by TNF-α when applied to human
endothelial cells (Youdim, McDonald et al. 2002). In healthy humans, plasma MCP-1 was
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reduced by a single 12 g dose of red wine anthocyanins (Garcia-Alonso, Minihane et al. 2009).
Red-wine consumption also reduced MCP-1 in high cholesterol-fed rabbits (Feng, Chen et al.
1999). Anthocyanins can also down-regulate TNF-α expression directly in other in vivo CVD
models (Mao, van de Water et al. 2002, Kim, Tsoy et al. 2006).
Anthocyanins can also inhibit the production of adhesion molecules and CRP which
stimulate the inflammatory response during the pathogenesis of atherosclerosis (Takei, Huang et
al. 2001, Saito, Ishimitsu et al. 2003). TNF-α increased human umbilical vein endothelial ICAM1 and VCAM-1 expression and increased nuclear GATA-4, GATA-6, and IRF-1 level
(Nizamutdinova, Kim et al. 2009). Pretreatment of endothelial cells with anthocyanins inhibited
VCAM-1, GATA-4, GATA-6 and IRF-1 expression, but not ICAM-1 expression. Also,
pretreatment of cells with a specific Jak/STAT inhibitor elicited a similar response, suggesting
anthocyanins reduce inflammation by down-regulating the adhesion molecules activated by
Jak/STAT pathway. Anthocyanins can also inhibit expression of CD40-mediated adhesion
molecules. Pretreatment of endothelial cells with CD40 ligand (CD40L) significantly increased
cellular VCAM-1 and ICAM-1 (Xia, Ling et al. 2009). However, pretreatment of endothelial
cells with anthocyanins inhibited the production of VCAM-1 and ICAM-1 (Xia, Ling et al.
2009). According to previous observational cohort studies, serum CRP was significantly
inversely associated with anthocyanin intakes by adults in the U.S. (Chun, Chung et al. 2008). In
a clinical trial, consumption of anthocyanin-rich cherries in healthy people reduced plasma CRP
level but not plasma IL-6 level after 4 weeks (Kelley, Rasooly et al. 2006). Thus, anthocyanins
might reduce the inflammatory level during the pathogenesis of CVD by inhibition the
production of adhesion molecules and CRP.
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SMCs are activated by inflammatory mediators, which stimulate the production of matrix
metalloproteinase (MMP) which can hydrolyze the extracellular matrix during atherosclerosis
(Libby, Ridker et al. 2002). Direct application of anthocyanins reduces CD40L-mediated MMP-1
and MMP-9 expression in human endothelial cells (Xia, Ling et al. 2009). Vascular endothelial
growth factor (VEGF), a pro-atherosclerotic factor, is increased in SMCs during CVD
development. Anthocyanins also inhibit VEGF release in vascular SMCs by inhibiting p38MAPK and JNK pathways (Oak, Bedoui et al. 2006).
Thus, anthocyanins might prevent the CVD risk by reducing chronic inflammation in the
vascular system. The anti-inflammatory mechanisms involve inhibiting the initiation of
inflammatory response and inflammation-induced extracellular matrix break down.
Anthocyanins may also reduce CVD risk through antioxidant mechanisms. NO is a key
molecule in the pathogenesis of CVD, because it has anti-hypertension, anti-thrombosis, antiatherosclerosis, and anti-smooth muscle proliferation functions (Förstermann and Sessa 2012).
Anthocyanins increase NO and improve endothelial function in models of CVD. Aronia and
bilberry anthocyanins increased NO-mediated vasorelaxation when applied to pig coronary
artery endothelial cells (Bell and Gochenaur 2006). Black currant concentrate also had a
vasorelaxing effect when applied to rat coronary artery endothelial cells, which was specific to
NO (Nakamura, Matsumoto et al. 2002). Delphinidin, but not malvidin or cyanidin, improved
endothelium-dependent vasorelaxation in the rat artery endothelial cells (Andriambeloson,
Magnier et al. 1998). In contrast, cyanidin inducing eNOS expression and NO production via a
Src-ERK1/2-Sp1 signaling pathway in bovine artery endothelial cells (Xu, Ikeda et al. 2004).
Thus, the ability of anthocyanins to mediate NO pathways appear to depend on its chemical
structure. Anthocyanins also modulate NO in vivo. Healthy rat fed wild blueberries had better
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endothelium-dependent vasorelaxation in the arterial endothelium after 7 weeks (Kalea, Clark et
al. 2009).
Anthocyanin consumption can also increase serum antioxidant capacity. Following
consumption of 12 g of anthocyanins from freeze-dried blueberries, a serum anthocyanins and ex
vivo antioxidant capacity were correlated (Mazza, Kay et al. 2002). Previous studies have
suggested that anthocyanin consumption may indirectly increase antioxidant function (Youdim,
McDonald et al. 2002, Acquaviva, Russo et al. 2003, Broncel M 2010). Adults with metabolic
syndrome that consumed aronia extract had reduced CAT, increased SOD, and increased GSHPx in the blood, which suggested improved antioxidative enzyme function (Broncel M 2010).
Anthocyanins can also protect membrane fatty acids of endothelial cells from oxidation and
DNA cleavage induced by elevated inflammatory level (Youdim, McDonald et al. 2002,
Acquaviva, Russo et al. 2003). Similarly aronia berry extract consumption reduced ox-LDL in
patients that previously suffered a myocardial infarction (Naruszewicz, Łaniewska et al. 2007).
In conclusion, anthocyanins might have the potential in CVD prevention by reducing
chronic inflammation and improving antioxidant capacity in cardiovascular. However,
mechanistic data were mainly from cell studies.

2.7.2 Proanthocyanidins
Other than anthocyanins, clinical evidence for the anti-CVD effect of proanthocyanidins
has also been suggested. However, the mechanism might be different from other polyphenols
(Kruger, Davies et al. 2014). In in vitro studies, proanthocyanidins inhibited IL-1β-induced NFκB transactivation in human monocytes (Gentile, Allegra et al. 2012). In patients with diabetes
mellitus or had ≥3 of cardiovascular disease risk factors, the intake of 40 g proanthocyanidin-rich
cocoa powder for 4 wks decreased the expression of very late activation antigen-4 (VLA-4,
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CD49d), CD40, and CD36 in monocytes and the serum levels of P-selectin and ICAM-1
(Monagas, Khan et al. 2009). Also, proanthocyanidins can directly down-regulate TNF-α
expression in in vitro CVD models (Mao, van de Water et al. 2002).
Other than preventing the initiation of chronic inflammation, proanthocyanidins can also
prevent the expression of adhesion molecules and CRP which are responsible for stimulating
inflammatory

response

during

the

pathogenesis

of

atherosclerosis.

A

grape

seed

proanthocyanidin extract inhibited TNF-α-induced expression of VCAM-1 and ICAM-1 in
human umbilical vein endothelial cells, independent of a NF-κB-dependent pathway (Sen and
Bagchi 2001). (+)-Catechin metabolites also inhibited U937 cell adhesion to IL-1 beta-stimulated
human aortic endothelial cells and ROS generation in U937 cells (Koga and Meydani 2001).
Since (+)-catechin is one of the building blocks of proanthocyanidins, it is possible that
proanthocyanidin metabolites have similar bioactivity as (+)-catechin metabolites. Healthy adults
that consumed 30 g/d of a proanthocyanidin-rich red wine for 28 d had reduced plasma VLA-4
compared with gin (low polyphenol) consumption (Badía, Sacanella et al. 2004). Also, in ex vivo
analysis, red wine consumption decreased TNF-α-induced adhesion of human monocytes to
endothelial cells (Badía, Sacanella et al. 2004). In a prospective randomized crossover trial,
healthy adults that consumed 30 g/d proanthocyanidin-rich red wine consumption for 28 d had
reduced expression of VLA-4 and MCP-1, as well as reduced serum concentrations of hs-CRP,
VCAM-1 and ICAM-1 (Estruch, Sacanella et al. 2004). In patients with systemic sclerosis that
consumed of 100 g grape seed-derived proanthocyanidins extract for a month had reduced
plasma malondialdehyde formation and adhesion molecules (ICAM-1, VCAM-1 and E-selectin)
(Kalfin, Righi et al. 2002).
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Also, consumption of proanthocyanidins also may improve antioxidant function. In an ex
vivo study, the plasma from rats fed a proanthocyanidins-rich extract from longan flower had
increased the resistance to Cu2+-induced LDL oxidation (Tsai, Wu et al. 2008). The direct antioxidative mechanisms of proanthocyanidins were explained by da Silva Porto, et at., which
suggested the antioxidant activity increases with degree of polymerization (da Silva Porto,
Laranjinha et al. 2003).
Animal and human studies have demonstrated that proanthocyanidins may reverse vascular
endothelial function by increasing NO (Duffy and Vita 2003). Healthy rats that consumed a
proanthocyanidin-rich red wine for 7 days had progressively lower systolic blood pressure after 4
days relative to the control (Diebolt, Bucher et al. 2001). NO appeared to mediate these effects
(Diebolt, Bucher et al. 2001). Adults with impaired endothelial function that consumed a
proanthocyanidin-rich purple grape juice had improved flow-mediated vasodilation (FMD),
which might because a reduction in ox-LDL (Stein, Keevil et al. 1999).
Also, the protective effects of proanthocyanidin-rich food, such as red wine, cranberry
products, grape skin extracts, cocoa, and chocolate, have been observed in human intervention
studies, which suggests its potential capacity for reducing CVD risk (Blanco-Colio, Valderrama
et al. 2000, Garcia-Alonso, Minihane et al. 2009). However, most studies have not used pure
proanthocyanidins to investigate their mechanisms of CVD risk reduction. Thus, it is not
possible to directly attribute these effects to proanthocyanidins alone. Also, proanthocyanidins
have a low bioavailability, which might limit the bioactivity of proanthocyanidins (Manach,
Scalbert et al. 2004).
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2.8 Conclusion
Polyphenols have promise for CVD prevention. Polyphenols appear to reduce CVD risk by
anti-inflammatory or antioxidant mechanism. For anti-inflammatory effects, polyphenols may
reduce the level of many pro-inflammatory mediators, such as adhesion molecules, cytokines and
growth factors. It is unclear whether the function of polyphenols is to inhibit the initiation of
inflammatory response, the aggravation of inflammatory response or both. For antioxidant
function, polyphenols can promote the function of NO, and elevate the serum antioxidant
capacity. At the mRNA level, polyphenols can promote the Nrf2 translocation and expression of
antioxidative genes, as well as inhibit the NF-κB translocation and expression of gene amplify
inflammatory response (González-Gallego, Sánchez-Campos et al. 2007).
A limitation of the previous studies is that most evidence found were based on cell or
animal studies. Cell or animials models treated with polyphenols might not refelct the metabolic
profile of polyphenols in human. It is essential to determine whether polyphenol metabolites is
responsible for the changes in biomarker of CVD risk in human.
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3.1 Abstract
Background: Almond, among other nuts, is a rich source of dietary polyphenols containing
phenolic acids, flavonoids, and lignans. However, less is known about the content of bound
proanthocyanidins and hydrolysable tannins in almonds.
Objectives: To quantify the extractable and bound proanthocyanidins and hydrolysable tannins
content in almond.
Design: Extractable and bound proanthocyanidins and hydrolysable tannins in almond were
characterized in Nonpareil, Carmel, and Butte almond varieties from California, with n = 3
samples/variety.
Results: Bound proanthocyanidins were recovered from extracted defatted almond residue by
hydrolysis with 4 N sodium hydroxide and represented 3− 21% of the total proanthocyanidin
content among varieties. The bound proanthocyanidins were recovered primarily as monomers
and dimers. In contrast, acid hydrolysis of extracted almond residue did not yield bound
proanthocyanidins. Hydrolysable tannins were characterized in aqueous acetone extracts of
defatted almond using two-dimensional TLC and further quantitated by HPLC following acid
hydrolysis. Almond hydrolysable tannin content was 54.7 ± 2.3 mg ellagic acid and 27.4 ± 7.3
mg gallic acid per 100 g almond among varieties. The tannin contents of Nonpareil, Carmel, and
Butte almond varieties were not significantly different.
Conclusion: Bound proanthocyanidins and hydrolysable tannins significantly contribute to
almond polyphenol content.
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3.2 Introduction
Almonds (Prunus dulcis) are a rich dietary source of polyphenols (Pérez-Jiménez, Neveu et
al. 2010). The most abundant class of polyphenols in almonds is proanthocyanidins, followed by
flavonoids and phenolic acids (Bolling, Chen et al. 2011). Almond flavonoids include flavonols,
flavanones, and flavanols, while almond proanthocyanidins are composed of flavan-3-ols with
varying degrees of polymerization (Gu, Kelm et al. 2003, Gu, Kelm et al. 2004, Prior and Gu
2005, Garrido, Monagas et al. 2008, Urpi-Sarda, Monagas et al. 2009). However, while
proanthocyanidins have been characterized in almond, data about its distribution among varieties
is lacking (Gu, Kelm et al. 2004). Less is known about the content of hydrolysable tannins in
almonds.
Tannins and other polyphenols may contribute to the health-promoting potential of
almonds. Almond flavonoids and proanthocyanidins are bioavailable and extensively
metabolized in vivo by phase II enzymes or intestinal microbiota (Urpi-Sarda, Garrido et al.
2009). These polyphenols and their metabolites may contribute to the antioxidant and antiinflammatory effects of almonds observed in animal studies (Chen, Milbury et al. 2005,
Mandalari, Bisignano et al. 2011).
A growing body of research suggests that the polyphenol content of foods could be
underestimated because solvent extraction does not completely liberate polyphenols covalently
bound to cell walls (Arranz, Saura-Calixto et al. 2009, Arranz, Silván et al. 2010). Previously,
non-covalently bound phenolic acids and flavonoids (e.g. free or extractable) from almond skin
extracts were quantified by HPLC-MS (Bolling, Dolnikowski et al. 2009, Bolling, Blumberg et
al. 2010, Bolling, Dolnikowski et al. 2010). However, Mandalari and colleagues reported a
portion of almond phenolic acids, mainly p-hydroxybenzoic acid, vanillic acid and ferulic acid,
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was covalently bound and released by acid hydrolysis (Mandalari, Tomaino et al. 2010).
Flavonoids, phenolic acids, and proanthocyanidins can also be released by acid or alkaline
hydrolysis from other plant materials (Arranz, Saura-Calixto et al. 2009, White, Howard et al.
2010). Thus, more work is needed to determine the relative proportion of free and bound
polyphenols in almonds. The objectives of this study were to further characterize almond tannins
by 1) quantifying extractable and bound proanthocyanidins, and 2) screening for hydrolysable
tannins. We utilized Nonpareil, Carmel and Butte almonds, as these are the top three cultivated
California almond varieties.

3.3 Materials and Methods
3.3.1 Reagents and Materials
Methanol, dichloromethane, and acetic acid were HPLC grade from Fischer Scientific (Fair
Lawn, NJ). Water was ultrapure grade. All other chemicals and reagents were acquired from
Sigma-Aldrich (St. Louis, MO). Samples of whole, unpasteurized Butte, Carmel, and Nonpareil
California almonds from harvest year 2011 were provided by the Almond Board of California.
Each variety had 3 unique samples representing different orchards, for a total of n = 9 samples.
Almonds were stored at -20°C until analysis.

3.3.2 Extraction of Proanthocyanidins
Frozen almonds were finely ground using an IKA A11 basic grinder (Wilmington, NC).
Almond powder (4 g) was homogenized in 40 mL hexane using an IKA Ultra-Turrax T18
homogenizer for 2 min at a power setting of 4. The homogenate was centrifuged and the
supernatant was removed. The residue was similarly homogenized twice, and the resulting
supernatants were combined and dried under a nitrogen gas stream. The mass of the extracted,
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dried lipids were recorded to determine almond lipid content. The defatted almond residue was
then extracted with acidified aqueous acetone (70:29.5:0.5 mixture of acetone, distilled water,
and acetic acid), according to methods described by Prior et al. with modifications (Prior and Gu
2005). Acidified aqueous acetone (40 mL) was added to the defatted nut residue and vortexed for
30 to 40 s, and sonicated for 10 minutes at 37C (Fisher Scientific, Utrasonic cleaner, FS30). The
sample was then agitated on a tube rocker for 50 min at 23 C, centrifuged, and the supernatant
was filtered through a 0.2 µm nylon filter. The pelleted almond residue was dried under a
nitrogen gas stream and stored at -20 C until hydrolysis. The filtered supernatant was dried
under a nitrogen gas stream to remove acetone, frozen at -80 C, lyophilized to a powder, and
stored at -80 C.

3.3.3 Acid and Alkaline Hydrolysis
Residual defatted or defatted, extracted almond powder was subjected to acid or alkaline
hydrolysis. Acid hydrolysis was based on previously described methods (Singleton, Orthofer et
al. 1998, Prior and Gu 2005). Almond residue was resuspended in 20 mL of 1.2 N hydrochloric
acid in methanol:water (80:20, v/v) and 0.5 g/L tert-butylhydroquinone and heated at 75 °C in a
dry bath for 3 h. Incubates were then cooled over ice brought to pH 5.5 with 3.7 M ammonium
acetate. The hydrolysis solution was centrifuged, and the supernatant was dried of residual
methanol under nitrogen gas at 40 °C. The resulting aqueous solution was stored at -80C until
further analysis.
Base hydrolysis was performed according to a previously described method (White,
Howard et al. 2010). Defatted and extracted almond residue was resuspended in 20 mL of 4 N
aqueous sodium hydroxide. Resuspended residue was and incubated in a water bath at 60 °C for
15 min with 30 s vortexing every 3 min. The hydrolyzed sample was cooled over ice and
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neutralized with 4 N hydrochloric acid. The neutralized sample was centrifuged, and the
supernatant was frozen at -80 C, lyophilized to a powder, and stored at -80 C until further
testing.

3.3.4 Isolation of Tannins
Tannins were isolated by stepwise elution from Sephadex LH-20 columns, as described
previously (Prior and Gu 2005). Neutralized aqueous hydrolysis solutions or dried almond
extracts were reconstituted in 2 to 4 mL of 30% methanol in water, and were loaded on 1 cm
diameter column containing ~4 g Sephadex LH-20. Sugars and salts were eluted with 50 mL
methanol:water (30:70 v/v), and discarded. Proanthocyanidins were eluted with 100 mL
acetone:water (70:30 v/v). The proanthocyanidin fraction was dried of residual acetone by a
nitrogen gas stream at 37 °C. The resulting aqueous residue was frozen at -80 °C and lyophilized
to a powder prior to HPLC analysis.

3.3.5 HPLC Analysis of Proanthocyanidins
Proanthocyanidins were quantified based a modified method of Prior and colleagues using
a Dionex Ultimate 3000 HPLC equipped with a refrigerated autosampler, column oven, diode
array detector, and fluorescence detector (Sunnyvale, CA) (Prior and Gu 2005).
Proanthocyanidin isolates were reconstituted in 100 µL methanol:dichloromethane (1:1) and 20
µL was injected on a 260 × 4.60 mm Hypersil silica column (ThermoFisher, Bellefonte, PA).
Samples were resolved by a 1 mL/min gradient of 100% dichloromethane (A) and 100%
methanol (B) with a constant 4% of acetic acid:water (50:50, v/v). The gradient increased
linearly from 14% B at 0 min to 28.4% B at 30 min, to 39.6% B at 45 min, to 86 % B at 55 min
and held until 60 min, then decreased to 14% B until 75 min. Proanthocyanidins were quantified
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by fluorescence, with excitation at 276 nm and emission at 316 nm, using (+)-catechin, (-)epicatechin,

and

proanthocyanidin

B2

as

standards.

A

check

standard

of

cocoa

proanthocyanidins purified in-house was used to control for intraday variation.

3.3.6 Colorimetric Determination of Total Phenols and Proanthocyanidins
The total phenol content of almond extract and hydrolyzed residue was determined
according to the method of Singleton et al., adapted to a microtiter plate (Singleton, Orthofer et
al. 1998). Results were expressed as mg gallic acid equivalents (GAE) per 100 g whole almonds.
Proanthocyanidin content was determined by the 4-(dimethylamino)cinnamaldehyde (DMAC)
method.(Payne, Hurst et al. 2010) Samples or standards were reconstituted in 70 μL 50%
aqueous methanol and mixed with 210 μL of 0.1% DMAC (w/v) in 1: 1: 6 (v/v/v) 37%
hydrochloric acid:water:ethanol in a microtiter plate. The plate was incubated at 25 °C in a
spectrophotometer (Synergy HT Multi-Mode Microplate Reader, BioTek, Winooski, VT) and
absorbance was monitored at 640 nm in 1 min intervals for 30 min. Results were expressed as
mg (+)-catechin equivalents (CE) per 100 g whole almonds.

3.3.7 Thin-layer Chromatography (TLC) of Hydrolyzable Tannins
Almond hydrolyzable tannins were characterized by two-dimensional TLC (White,
Howard et al. 2010). Duplicate cellulose plates (20 × 20 cm, 100 µm, Selecto Scientific Inc.,
Suwanee, GA) were spotted with 50 μL of the almond tannin fraction reconstituted in 100%
methanol. Plates were developed in glass chambers saturated with 100 to 150 mL of a 14:1:5
(v/v/v) mixture of butan-2-ol/acetic acid/water until the solvent front was at least 18 cm. Plates
were then removed from the chambers and dried at ambient temperature. Plates were then rotated
90° and placed into a glass chamber saturated with 100 to 150 mL of a 2:98 (v/v) mixture of
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acetic acid/water. The plates were dried at ambient temperature. Plates were sprayed with a
saturated potassium iodate solution to detect gallotannins or 4% sodium nitrite (w/v) in 50%
aqueous acetic acid (v/v) to detect ellagitannins.

3.3.8 Gallotannin and Ellagitanin Hydrolysis
Defatted almond was hydrolyzed according to a previously described method (Lei, Jervis et
al. 2001). Defatted almond powder (20 mg) was reconstituted in 2 mL methanol in 50 mL glass
screw-top test tubes. Sulfuric acid (18% in water, 100 µL) was slowly added to samples in two
aliquots, manually swirling the solution between additions. Samples were then incubated in a dry
bath at 85 °C for 20 h, cooled over ice, and neutralized by carefully adding 4 aliquots of 50 µL
ethanolamine to each sample. Caffeic acid or trans-stilbene (5 µg/mL) were used as internal
standards for analysis of gallic acid or ellagic acid, respectively. Solutions were brought to 2 mL
with water and centrifuged. Supernatants were passed through a 0.2 µm nylon syringe filter if
cloudy or used directly for HPLC analysis.

3.3.9 HPLC Analysis of Gallic Acid and Ellagic Acid
HPLC was performed using the previously described Dionex Ultimate 3000 system.
Diluted, neutralized hydrolysis solutions or standards (20 µL) were injected onto a 50 × 2.10 mm
Dionex 2.2 µm 120Å Acclaim RSLC PolarAdvantage column (ThermoScientific, Sunnyvale,
CA). Gradients of 1% aqueous acetic acid (A) and methanol (B) and were used to resolve
samples at 0.2 mL/min. For gallic acid, 10% B was held to 3 min, followed by a linear gradient
to 40% B at 7 min, returning to 10% B at 12 min and held for 5 min. For ellagic acid, 10% A was
held for 3 min, followed by a linear gradient to 100% B at 10 min, returning to 10% B at 12 min
and held for 8 min. Gallic acid and ellagic acid were used as external standards for
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quantification. Caffeic acid and trans-stilbene were internal standards for gallic acid and ellagic
acid, respectively. Gallic acid and ellagic acid were identified in hydrolysis solution by
comparison of UV spectra analysis and retention time (RT) to authentic standards. Methyl gallate
eluted at 4.4 min but was not detected below 0.12 ng on-column in hydrolysis solutions. Gallic
acid and caffeic acid were quantified at 280 nm, and ellagic acid and trans-stilbene were
quantified at 320 nm and 250 nm, respectively. Inter- and intra-assay RSD for gallic acid
analysis were 14.55 and 7.36 %, respectively. Inter- and intra-assay RSD for ellagic acid analysis
were 1.06 and 2.98 %, respectively. Gallic acid, caffeic acid, ellagic acid and trans-stilbene
eluted at 1.9, 8.7, 12.4, and 15.2 min, respectively.

3.3.10 Statistics and Data Analysis
Data are mean ± standard deviation of at least duplicate samples. Statistical significance
was determined by two or one-way ANOVA as indicated, followed by Tukey’s multiple
comparison test using GraphPad Prism 5.01 software (GraphPad Software, Inc., La Jolla, CA).
Differences were considered significant at P < 0.05.

3.4 Results
Tannins are the most abundant class of polyphenols in almonds (Bolling, Chen et al. 2011).
Little is known about the abundance of bound proanthocyanindins and hydrolyzable tannins in
almonds or their distribution between varieties. Therefore, we characterized and quantified
extractable and bound proanthocyanidins and hydrolyzable tannins in Nonpareil, Carmel, and
Butte almond varieties.
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3.4.1 Extractable Proanthocyanidins
The extractable proanthocyanidins from almond consisted of (+)-catechin and (-)epicatechin, three dimer peaks, including proanthocyanidin B2, as well as trimers and greater
oligomers (Figure 3.1A). Among the three almond varieties, Nonpareil had ~2-fold more
extractable proanthocyanidins (107.27 mg/100 g almond) than Butte (25.35 mg/100 g almond)
and Carmel (28.09 mg/100 g almond) because of increased oligomer content (Table 3.1).
Nonpareil had 2-fold the monomers of Butte and 3-fold the monomers than Carmel. Nonpareil
had 3-fold the dimers of Butte and Carmel, and 4-fold the trimers of Butte and Carmel. Besides,
Nonpareil also had ~3 fold the oligomers (4-7) and 8mers and greater polymers than Butte and
Carmel almonds. The extractable proanthocyanidin profiles, e.g. proportion to the sum of
proanthocyanidin, varied among the three almond genotypes (Figure 3.3A). 8 mers and greater
polymers were the most abundant proanthocyanidins among the three almond genotypes, ranging
from 27.2 to 33.3 % of extractable proanthocyanidins, with the greatest polymer proportion in
Carmel. Nonpareil had the greatest relative proportion of dimer 2, trimers and 4mers. Butte had
the highest proportion of (+)-catechin (0.9%), (-)-epicatechin (6.8%), dimer 1(2.4%) and dimer 3
(15.9%). Carmel had the highest proportion of 5mers, 6mers and 7mers, which were 10.8%, 7.5%
and 7.4%, respectively.

3.4.2 Bound Proanthocyanidins
The recovery of proanthocyanidins from defatted almond residue was greatest at 3 h, as
quantified by the DMAC assay (Figure 3.5A). Alkaline hydrolysis of unextracted was
maximized at 4 N sodium hydroxide by the DMAC assay (Figure 3.5B). Alkaline hydrolysis
yielded 23 to 98% of the extractable proanthocyanidins, with the highest recovery in Carmel
(Figure 3.2) (P = 0.0002 for extraction method, P = 0.4105 for genotype, and P = 0.4004 for
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their interaction). In contrast, acid hydrolysis yielded minimal proanthocyanidin content, with <
0.2 mg catechin equivalents (CE)/100 g almond.
Following almond extraction with acidic aqueous acetone, acid hydrolysis of the residue
did not yield additional proanthocyanidins by HPLC fluorescence analysis (<0.02 mg/100 g
almond). Proanthocyanidins recovered from alkaline hydrolysis of extracted almond residue
were quantified by HPLC (Figure 3.1B). Only proanthocyanidin monomers, dimers, and
oligomers with polymerization of 8 and greater were recovered after hydrolysis (Table 3.1).
Alkaline hydrolysis of extracted almond residue yielded an additional 3.4, 6.8, and 6.4 mg
proanthocyanidin B2 equivalents (PE)/100 g almond in Nonpareil, Butte, and Carmel almonds,
respectively (Table 3.1). These yields added 22 to 66% toward monomer content and 45 to 81%
to dimer 1 content. Nonpareil almonds had the lowest recovery of bound proanthocyanidins,
despite having the highest yield of extractable proanthocyanidins among almond varieties.

3.4.3 Total Proanthocyanidins
The sum of extractable and bound proanthocyanidins almonds reflects the total
proanthocyanidin content and profile (Table 3.1, Figure 3.2B) of almonds. Nonpareil almonds
had the most proanthocyanidins with 110.6 mg/100 g, representing 3.4- and 3.2-fold of Butte and
Carmel varieties. Butte almonds had greatest relative proportion of monomers and dimers
contributing ~50% to the total proanthocyanidin content. In contrast, trimers and greater
oligomers contributed more than 70% of the proanthocyanidin content of Nonpareil and Carmel
almonds. Base hydrolysis yielded an additional 3 to 27% of the sum of extractable
proanthocyanidins (Table 3.1).
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3.4.4 Hydrolysable tannins
Extractable almond tannin fractions were resolved by 2-dimensional TLC to screen for the
presence of gallotannins and ellagitannins (Table 3.3). In each almond variety, at least 5 to 6
unique spots reacted with potassium iodate, indicating potential gallotannin content. Nonpareil
and Butte almonds each had 4 orange-brown spots after a sodium nitrate spray, indicating the
presence of ellagitannins (Mueller-Harvey 2001). Carmel almonds had a unique ellagitannin
profile, with 3 orange-brown and 3 pink spots after the sodium nitrate spray. Low retention
factors in the second TLC dimension tentatively indicated the presence of large molecularweight ellagitannin and gallotannins (Mueller-Harvey 2001).
Gallic acid and ellagic acid were present in hydrolysis solutions of defatted almonds
(Figure 3.4). Nonpareil, Butte, and Carmel almond contained 19.64 to 34.11 mg gallic acid/100
g, and 43.28 to 57.36 mg ellagic acid/100 g with no significant differences between varieties (n =
3/variety) (Table 3.2).

3.5 Discussion
3.5.1 Extractable Proanthocyanidins
Normal-phase HPLC resolution of proanthocyanidins in California almond varieties was
similar to Spanish almonds (Prodanov, Garrido et al. 2008). Almond proanthocyanidins have
(epi)afzelechin, (epi)catechin and (epi)gallocatechin as constituent units, with both A-type and
B-type linkages and an average degree of polymerization of 12.7 (Gu, Kelm et al. 2003,
Monagas, Garrido et al. 2007, Prodanov, Garrido et al. 2008). Almond proanthocyanidins with
polymerization of 6 or more have only B-type linkages (Prodanov, Garrido et al. 2008).
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Proanthocyanidins and hydrolyzable tannins contribute a significant portion of the
polyphenol content of almonds and other tree nuts.

Almonds have more extractable

proanthocyanidins than walnuts, but less than hazelnuts, pecans and pistachios (Gu, Kelm et al.
2004). Gu and colleagues reported 184.1 mg extractable proanthocyanidins/100 g almond in a
commercial almond sample using similar extraction conditions (Gu, Kelm et al. 2004). While the
distribution of proanthocyanidin polymers is similar to this study, the content was higher than the
25 to 107 mg PE/100 g obtained in the present study. The use of proanthocyanidin B2
equivalents may contribute to this difference. Also, pre-harvest factors such as climate and
environment and post-harvest factors, such as storage and processing may contribute to
differences among almond samples (Bolling, Chen et al. 2011). However, our values appear
greater than a previous study by Garrido and colleagues, adjusted by the relative proportion of
almond skins to 100 g almonds (Garrido, Monagas et al. 2008).
DMAC values of extractable proanthocyanidins were 75.1% to 89.9% less than HPLC.
DMAC reacts with terminal flavan-3-ols, so this method underestimates polymeric
proanthocyanidins (Prior, Fan et al. 2010). The present work is also limited by a lack of suitable
analytical standards for HPLC analysis. Further work is needed to purify proanthocyanidins of
similar composition, linkages, and with varying polymerization to validate methods for
quantification of almond proanthocyanidins.
The differences in extractable proanthocyanidins between Nonpareil, Carmel, and Butte
almonds are greater than other reported polyphenols. In the present study, Nonpareil had more
extractable proanthocyanidins than Butte and Carmel, while there were no differences in
flavonoid and phenolic acid between these varieties (Bolling, Dolnikowski et al. 2010).
Nonpareil almonds had significantly greater (-)-epicatechin content than the same study, with 3.4
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mg/100 g almonds.(Bolling, Dolnikowski et al. 2010) It is unclear if this difference is due to
yearly variation in polyphenol content or due to different extraction conditions.

3.5.2 Bound Proanthocyanidins
Acid hydrolysis was insufficient to release additional bound proanthocyanidins in almond,
despite previous studies that have used acid hydrolysis prior to analysis of catechins (Merken and
Beecher 2000, Harnly, Doherty et al. 2006). Alkaline hydrolysis yielded additional bound
proanthocyanidins from extracted almond residue, as monomer and dimers. This is consistent
with a previous study in cranberry pomace, where alkaline hydrolysis liberated 4-fold the
monomer to hexamer proanthocyanidins than conventional extraction (White, Howard et al.
2010). Alkaline hydrolysis of cranberry polymeric proanthocyanidins yielded primarily
monomers and dimers (White, Howard et al. 2010).
According to our results, bound proanthocyanidin yielded 3.1 to 26.8% of the extractable
proanthocyanidins (Table 3.1). This proportion was less than that of apple, peach and nectarine,
which bound proanthocyanidin were 6 to 20-fold of the extractable proanthocyanidins measured
by HPLC (Arranz, Saura-Calixto et al. 2009). Other bound polyphenols were 2 to 6-fold of the
extractable polyphenols in apple, peach and nectarine measured by LC-MS (Arranz, SauraCalixto et al. 2009). However, the bound polyphenol content of tree nuts may be less than other
fruits and vegetables. In walnuts and heartnuts, bound total phenolic contents were for 20 to 77 %
of extractable total phenolic contents measured by Folin-Ciocalteu assay (Li, Tsao et al. 2006).
In a study of 29 kinds of food, bound phenolic compounds accounted nearly the same or more
antioxidant capacity than free phenolic compounds measured (Pellegrini, Serafini et al. 2006).
Thus, the proportion of bound polyphenols may depend on plant varieties, genotypes, and
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polyphenol composition. Further work is needed to define the contribution of bound polyphenols
to almond bioactivity.

3.5.3 Total Proanthocyanidins
The proanthocyanidin profile of Butte and Carmel almonds changed after summing
extractable and bound proanthocyanidins. This was due to the high content of monomers, dimers
and trimers in Butte and Carmel almonds following alkaline hydrolysis of their extracted residue.
For oligomers (>3) and polymers, the total proanthocyanidins profile reflected the extractable
proanthocyanidin profile.

3.5.4 Hydrolyzable Tannins
Hydrolyzable tannins vary according to their polymeric level of gallic acid and ellagic acid
(Chung, Wong et al. 1998). TLC analysis indicated the presence several different gallotannins
and ellagitannins in almonds. A number of ellagitannins have been identified in walnut,
including pedunculagin, glansrins, casuarictin and others (Fukuda, Ito et al. 2003, Cerdá, TomásBarberán et al. 2005). Thus, almonds may also contain a diverse ellagitannin profile. Precaution
should be taken when selecting almond tannin TLC bands for further analysis, since potassium
iodate also reacts with catechins (Table 3.3). Further work is needed to isolate and identify these
compounds from almonds.
Walnuts and pecans contain hydrolyzable tannins (Daniel, Krupnick et al. 1989). In
comparison to previous studies, almond ellagitannins are 3 to 10-fold less than walnut, which
have 150 to 546 mg of ellagic acid/100 g (Cerdá, Tomás-Barberán et al. 2005, Li, Tsao et al.
2006). A previous study reported almond contain little to no gallotannins and ellagitannins
following hydrolysis (Molyneux 2008). However, this study employed a more moderate
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hydrolysis condition than the present study. Thus, almond hydrolysable tannin content may have
been previously underestimated. Ellagic acid consumption in the United States is estimated to be
3.4 to 15.1 mg/1000 kcal energy in adult females, varying by whether they meet fruit and
vegetable intake recommendations (Murphy, Barraj et al. 2012). Therefore, consuming a 43 g
(1.5 oz) serving of almond could more than double the estimated ellagic acid intake.
While originally recognized as anti-nutrients, a number of putative health effects are
attributed to tannins. Gallic acid is antioxidant and apoptotic to SH-SY5Y and U 937 cancer cells
in vitro (Saeki, Yuo et al. 2000, Lu, Nie et al. 2006). Likewise, ellagic acid has in vitro
antioxidant

potential,

anti-inflammatory,

estrogenic

and/or

anti-estrogenic

roles

and

antimicrobial and prebiotic effects (Landete 2011). However, ellagic acid is not bioavailable
from ellagitannins, and is metabolized to the bioavailable urolithins, which may be a marker for
nut intake (Tulipani, Urpi-Sarda et al. 2012). Almond proanthocyanidins are bioavailable, and
tend to be metabolized to (epi)catechin conjugated metabolites by phase II enzymes after 2 to 6 h
consumption in healthy adults (Garrido, Urpi-Sarda et al. 2010). There is a need to characterize
the bioaccessability of bound phenolics in almonds and other polyphenol-rich foods. Thus, future
studies characterizing the effects of almond polyphenol consumption, should consider of
hydrolyzable tannins and bound proanthocyanidins.

3.6 Conclusion
In conclusion, almonds are a source of diverse polyphenols, including phenolic acids,
flavonoids, proanthocyanidins, ellagitannins, gallotannins, and likely other uncharacterized
constituents. Base hydrolysis yielded additional polyphenols from extracted almond residue,
increasing total proanthocyanidin content 3 to 21 % in California almonds. Almonds were also
found to contain 27.43 mg gallic acid and 54.69 mg ellagic acid/100 g following hydrolysis.
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Database values and future analytical research efforts should consider the presence of “bound”
polyphenols, ellagitannins, and gallotannins in California almonds.
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3.7 Chapter 3 Tables and Figures
Table 3.1 Proanthocyanidin content and the extractable proanthocyanidin proportion of California almond cultivars
Nonpareil

Butte
Base

Carmel
Base

Base

Extractable

hydrolysis

Total

Extractable

hydrolysis

Total

Extractable

hydrolysis

Total

(+)-catechin

0.33 ± 0.10

0.10 ± 0.05

0.43 ± 0.13

0.14 ± 0.13

0.18 ± 0.06

0.32 ± 0.10

0.10 ± 0.03

0.22 ± 0.10

0.31 ± 0.08

(-)-epicatechin

3.44 ± 0.50

1.17 ± 0.89

4.61 ± 1.20

1.24 ± 1.25

2.64 ± 1.14

3.88 ± 1.08

0.76 ± 0.31

1.80 ± 1.03

2.56 ± 1.16

PAC dimer 1

1.99 ±1.60

1.45 ± 0.93

3.43 ± 1.38

0.43 ± 0.40

1.80 ± 0.54

2.23 ± 0.14

0.37 ± 0.06

1.89 ± 1.22

2.26 ± 1.29

PAC B2

8.29 ± 2.88

0.03 ± 0.03

8.31 ± 2.90

1.53 ± 1.83

0.79 ± 1.32

2.32 ± 1.52

1.17 ± 0.46

0.05 ± 0.03

1.22 ± 0.47

PAC dimer-3

8.39 ± 2.17

0.02 ± 0.01

8.41 ± 2.18

2.49 ± 2.01

0.21 ± 0.25

2.69 ± 1.83

2.43 ± 0.18

0.11 ± 0.06

2.55 ± 0.20

trimers

14.03 ± 3.26

14.03 ± 3.26

2.97 ± 3.84

2.97 ± 3.84

2.68 ± 1.46

2.68 ± 1.46

4-mers

15.10 ± 3.53

15.10 ± 3.53

3.15 ± 4.00

3.15 ± 4.00

3.34 ± 2.09

3.34 ± 2.09

5-mers

10.87 ± 4.10

10.87 ± 4.10

2.23 ± 2.86

2.23 ± 2.86

3.08 ± 1.88

3.08 ± 1.88

6-mers

7.23 ± 2.33

7.23 ± 2.33

1.61 ± 2.09

1.61 ± 2.09

2.22 ± 1.57

2.22 ± 1.57

7-mers

6.33 ± 2.11

6.33 ± 2.11

1.65 ±2.14

1.65 ± 2.14

2.21 ± 1.63

2.21 ± 1.63
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PACs

8-mers

and

greater

31.28 ± 8.87

0.61 ± 0.07

31.89 ± 8.81

7.91 ±10.45

1.18 ± 0.98

9.09 ± 10.12

9.74 ± 6.72

2.29 ± 0.33

12.03 ± 7.04

Sum

107.27

3.37

110.6

25.35

6.80

32.15

28.09

6.37

34.46

Table 3.2 Hydrolyzable tannin content of California almond cultivars determined by methanolysis and HPLC analysis.
Hydrolyzable Tannin

mg gallic acid/100 g

mg ellagic acid /100 g

Value

Almond Cultivar
Nonpareil

Butte

Carmel

mean

34.11± 2.36

28.54 ± 10.45

19.64 ± 5.00

range

32.6-32.8

22.4-40.6

14.1-23.8

mean

57.36 ± 6.44

53.28 ± 1.45

53.44 ± 5.36

range

50.5-63.2

54.6-54.3

48.7-59.3
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Data are mean ± standard deviation, n = 3/cultivar. Statistical significances among almond cultivars by ANOVA were P = 0.1016 for
gallotannins, and P = 0.5490 for ellagitannins.

Table 3.3 Two dimensional TLC profiles of almond tannins.
Genotype

Sample

Spray Reagent
Gallotannins (KIO3)
Colorb

Rf1

Rf2

Color

0.234 (B a) 0

brown

0.435 (B)

0

orange-brown

0.208 (B)

0.138

brown

--

--

--

0.734

0.225

brown

--

--

--

0.833 (B)

0

brown

0.723 (B)

0

orange-brown

0.303 (B)

0.180

brown

0.730

0.222 orange

0.877

0.066

brown

--

--

--

0.809

0.216

brown

--

--

--

0.950 (B)

0

brown

0.712 (B)

0

orange-brown

0.256 (B)

0.129

brown

0.600

0.216 orange

0.844

0.082

brown

0.689

0.252 orange

0.750

0.224

brown

--

--

--

0.862 (B)

0

brown

0.700 (B)

0

orange-brown

0.745

0.083

brown

0.680

0.222 orange

0.655

0.232

brown

--

--

--

0.258 (B)

0

brown

0.323 (B)

0

orange-brown

brown

0.194 (B)

0.205 orange-brown

Rf1
Nonpareil

2079

2080

2081

Butte

2082

2083

Ellagitannins (NaNO2)

Rf2

0.136
0
(B)
0.182

0.178

brown

0.684

0.211 orange-brown

0.711

0.201

brown

--

--
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--

2084

Carmel

2085

2086

2087

0.312 (B)

0

brown

0.388 (B)

0

0.243 (B)

0.139

brown

0.273 (B)

0.151 orange-brown

0.832

0.208

brown

0.792

0.235 orange

0.205 (B)

0

brown

0.440 ( B)

0

pink

0.325 (B)

0

brown

0.217 (B)

0

orange-brown

0.723

0.224

brown

0.464

0.135 pink

--

--

--

0.512

0

pink

--

--

--

0.602

0

pink

0.823 (B)

0

brown

0.351 (B)

0

orange-brown

0.253

0.194

brown

0

0.136 orange-brown

--

--

--

0.225 (B)

0.183 orange-brown

0.477 (B)

0

brown

0.433 (B)

0

0.151
0

brown

0.205

orange-brown

0.128
0

(B)
0.305(B)

orange-brown

orange-brown
(B)

brown

0.293 (B)

0.151 orange-brown

For standard compounds, potassium iodate spray gave an orange spot for (+)-catechin (0.739,
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Figure 3.1 A. Representative HPLC fluorescence chromatogram of solvent-extractable almond
proanthocyanidin fraction. B. Representative HPLC fluorescence chromatogram of base
hydrolyzed almond proanthocyanidin fraction.
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Figure 3.2 A. Relative extractable proanthocyanidin profile of California almond genotypes.
Data are mean ± SEM of Nonpareil, Butte, and Carmel almonds (n=3/genotype). By 2-way
ANOVA, P =0.2921 for genotype, P <0.0001 for proanthocyanidin type, with P =0.0087 for their
interaction. B. Relative total proanthocyanidin profile of California almond genotypes. Data are
mean ± SEM of Nonpareil, Butte, and Carmel almonds (n=3/genotype). By 2-way ANOVA, P
=0.5959 for genotype, P <0.0001 for proanthocyanidin type, with P =0.0019 for their interaction.
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Figure 3.3 Proanthocyanidin content of extracted and hydrolyzed residues from California
almond genotypes determined by the DMAC (4-(dimethylamino)cinnamaldehyde) assay. CE:
catechin equivalents. By 2-way ANOVA, P = 0.0002 for extraction method, P = 0.4105 for
genotype, and P = 0.4004 for their interaction.
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Figure 3.4 A. Representative HPLC fluorescence chromatogram of almond gallic acid fraction.
B. Representative HPLC fluorescence chromatogram of almond ellagic acid fraction.
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Figure 3.5 Recovery of proanthocyanidins following A. acidic and B. alkaline hydrolysis of
defatted almond powder. Data are mean ± standard deviation of triplicate determinations, where
P=0.6514 for acidic and P = 0.0189 for alkaline hydrolysis, by one-way ANOVA.
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4.1 Abstract
Background: Stilbene polyphenols are present in some fruits and nuts, but their abundance in
many foods, such as almonds, is unknown.
Objectives: To develop UHPLC-MS methods to quantitate and characterize stilbenes content in
almond.
Design: Stilbenes in almond were characterized in Nonpareil, Carmel, and Butte almond
varieties from California, with n = 3 samples/variety.
Results: Stilbenes were isolated from ethanolic almond extracts by solid phase extraction and
identified with UHPLC–MS by comparison of retention times (RTs), mass spectra, insource CID
spectra, and enzymatic hydrolysis to authentic standards. Polydatin was identified in almond
extracts, with 7.19–8.52 µg/100 g almond. Piceatannol + oxyresveratrol was tentatively
identified in almond blanch water, at 0.19–2.55 µg/100 g almond. Polydatin was concentrated in
almond skins, which contained 95.6–97.5% of the total almond content.
Conclusion: Almonds contain the stilbene class of polyphenols in addition to the previously
identified proanthocyanidin, hydrolysable tannin, flavonoid, and phenolic acid classes.
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4.2 Introduction
Almonds (Prunus dulcis) contribute to dietary polyphenol intake, and are ranked as one of
the top 40 richest food sources of polyphenols (Perez-Jimenez, Neveu, Vos, & Scalbert, 2010).
Clinical and preclinical studies have demonstrated that almonds have antioxidant, anti-diabetic,
and hypocholesterolemic actions (Li, Jia et al. 2007, Li, Liu et al. 2011, Foster, Shantz et al.
2012).
The most abundant class of polyphenols in almonds is proanthocyanidins, followed by
hydrolysable tannins, flavonoids and phenolic acids (Bolling, Chen et al. 2011, Xie, Roto et al.
2012). Almond phenolic acids and flavonoids have been well-characterized, and are enriched in
almond skins (Milbury, Chen et al. 2006, Mandalari, Tomaino et al. 2010). Some almond
polyphenols are readily extractable, while a smaller proportion requires hydrolysis of the
extracted residue to be liberated from the food matrix (Xie, Roto et al. 2012).
The polyphenol diversity of many foods have been reported and indexed in databases such
as Phenol-Explorer (Neveu, Perez-Jiménez et al. 2010). Despite these efforts, a significant
portion of dietary polyphenols may be underestimated simply because previous analytical studies
have not targeted particular polyphenol classes for certain foods. A more complete
characterization almond polyphenols is desirable to relate almond bioactivities to its chemical
composition. For example, we recently reported that almonds contain ellagitannins and
gallotannins (Xie, Roto et al. 2012). Likewise, stilbenes are not well-characterized in nuts.
Stilbenes have been reported in peanuts and pistachios, but have yet to be identified in almonds,
Brazil nuts, hazelnuts, macadamias, pine nuts, or walnuts (Sobolev and Cole 1999, Tokuşoǧlu,
Ünal et al. 2005).
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Stilbenes are synthesized in plants through the shikimate and phenylalanine/polymalonate
pathways (Jeandet, Delaunois et al. 2010). The reported stilbene content of foods is generally
less than other polyphenols, e.g. flavonoids and tannins. Trans-resveratrol or its glucoside is the
most abundant stilbene in wine, grapes, peanuts and Vaccinium species (Cassidy, Hanley et al.
2000, Rimando, Kalt et al. 2004). Stilbenes may contribute to the health-promoting potential of
polyphenol-rich foods, through antioxidant or phytoestrogen activities (Cassidy, Hanley et al.
2000).
The content and distribution of stilbenes in almonds is unknown. Therefore, the objectives
of this study were to 1) develop a UHPLC-MS method for determining stilbenes in almonds; 2)
identify and quantitate stilbenes in Nonpareil, Carmel, and Butte California almonds, as these are
the

top

three

cultivated

varieties

of

California

almonds;

and

3)

determine

the

compartmentalization of stilbenes in almonds.

4.3 Materials and methods
4.3.1 Chemicals and plant materials
Methanol and formic acid were LC-MS grade and acetyl acetate was HPLC grade from
Fischer Scientific (Fair Lawn, NJ). Ethanol was absolute, anhydrous, ACS/USP grade from
Pharmco-AAPER (Brookfield, CT). Water was Type II ultrapure grade produced by Picopure®2
(Hydro Service and Supplies, Inc). β-D-glucosidase (49290-1G), and all other chemicals and
reagents were acquired from Sigma-Aldrich (St. Louis, MO) unless otherwise noted. Samples of
whole, unpasteurized Butte, Carmel, and Nonpareil California almonds from harvest year 2011
were provided by the Almond Board of California. Each variety had 3 unique samples
representing different orchards, for a total of n = 9 samples. Samples were not matched by
orchard location or geography. Almond samples were stored at -20 °C in darkness until analysis.
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4.3.2 Extraction of almond stilbenes.
Whole, frozen almonds were ground to a powder using an IKA A11 Basic Grinder (St.
Louis, MO). Extraction was based on methods previously described, with modifications (Sanders,
McMichael et al. 2000). First, 10 g of almond powder was homogenized in 20 mL of ethanol and
water (80:20, v/v) at 4 °C for 5 min using an IKA T-18 Basic Ultra-Turrax homogenizer at
power level 4 (Staufen, Germany). The homogenate was then centrifuged for 10 min at 4 °C and
3000 × g, and the supernatant was removed from the residue. The residue was homogenized and
supernatant removed as above, for a total of three extractions. The supernatants were then
combined and stored at -20 °C in darkness before clean-up. Before the clean-up step,
supernatants were spiked with internal standard 1 (IS1, trans-resveratrol).
For compartmentalization studies, almond skins were separated by hot water blanching
(Bolling, Dolnikowski et al. 2009). A sample of ~100 g whole almond was placed in a beaker
filled with 175 mL boiling water for 2 min. The blanch water was decanted, and its volume was
recorded. The blanched almond skins were manually removed from the seed, and the meat and
skins were dried at room temperature overnight. Almond meat, skins, and blanch water were
stored at -20 °C until analysis. For extraction, almond skins (1 g) or meat (10 g) was powdered
by a lab mill and homogenized in 20 mL of extraction solvent as described above. Blanch water
was filtered through a 2.0 µm nylon membrane, spiked with the appropriate internal standard 2
(IS2, pterostilbene), and analyzed directly by UHPLC-MS.

4.3.3 Clean-up of extract
The combined supernatant from whole-almond homogenate was cleaned-up by solid phase
extraction (SPE) (Sanders, McMichael et al. 2000). First, a 1 cm diameter column was packed
with 1 g of 1:1 (w/w) 50-200 µm neutral alumina and 40-63 µm, 60Å, endcapped C18 silica gel
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(Sorbent Technologies, Norcross, GA). The column was successively preconditioned with 10 mL
each of water, ethanol, and ethanol:water (80:20, v/v). The extract supernatant (3 mL) was
applied to the column and collected by vacuum (2 to 3 drops per second). An additional 6 mL of
80% ethanol was applied to the column and the eluate was collected. Both elutes were combined,
dried under nitrogen gas at 23 °C, then held at -80 °C until UHPLC-MS analysis.

4.3.4 UHPLC-MS analysis of stilbenes
The dried residue from SPE was reconstituted with 50 µL of methanol and spiked with the
appropriate internal standard (IS2) in 1 µL methanol. UHPLC-MS analysis was conducted using
a Shimadzu Nexera UHPLC equipped with DGU-20A5 Prominence Degasser, SIL-30AC Nexera
Auto Sampler, SPD-M20A Prominence Diode Array Detector, CTD-30A Nexera column oven,
and two LC-30AD pumps (Kyoto, Japan) equipped with a Phenomenex Kinetex PFP column
(1.7 µm, 100 Å, 2.1 × 50 mm, Torrance, CA, USA). The following gradient of water/formic acid
(99.05:0.5, v/v) (A) and methanol (B) was used: 0 min, 70% A and 30% B; 6 min, 10% A and 90%
B; 7 min, 10% A and 90% B; 8 min, 70% A and 30% B and held until the stop time at 10 min.
The flow was maintained at 0.2 mL/min and the sample injection volume was 1 µL. Absorbance
was monitored at 320 nm. Mass spectrometry analyses were performed using a Shimadzu
LCMS-2020 mass spectrometer equipped with ESI, APCI, and DUIS (dual ionization) modes.
The data were acquired in full-scan DUIS mode (MS) from m/z 100 to 500 in both positive and
negative polarity modes, with instrument settings as follows: detector voltage was 1.1 kV,
interface voltage was 4.5 V, nebulizing gas flow was 1.5 L/min, drying gas flow was 15.0 L/min,
desolvation line was 250°C, heat block was 500°C, and Q-array DC was varied according to
compounds of interest (Table 4.1). Signal (S) to noise (N) ratios were determined experimentally
using area under the curve (AUC) values of external standards. The limit of detection (LOD)
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(S/N > 3) and limit of quantification (LOQ) (S/N > 10) for standard compounds were determined
experimentally by at least 3 injections of 2-fold serial dilutions of the calibration curve, where
S/N = AUC/standard deviationAUC (Long and Winefordner 1983). Recovery was determined
using IS1, whereas IS2 was used to normalize AUC values for quantitation. Quantification was
based on MS AUC responses.

4.3.5 Enzymatic hydrolysis of stilbene glucosides
Almond extract was hydrolyzed as previously described (Rimando and Barney 2005) with
modification. Briefly, 10 mL of almond extract (Section 2.2) was dried to ~1 mL by a nitrogen
gas stream at 23 °C to remove ethanol. The pH of the extract was adjusted to 6 by using 0.1 M
sodium hydroxide. The solution was hydrolyzed by incubating 30 units of β-D-glucosidase for
18 h at 37 °C. The resulting solution was extracted three times with 6 mL ethyl acetate. The ethyl
acetate extracts were combined and dried under a nitrogen gas stream at 23 °C. The dried ethyl
acetate extract was resuspended in 3 mL ethanol:water (80:20, v/v) and subjected to SPE cleanup as above (Section 2.3).

4.3.6 Statistical analysis
Data are presented as mean ± standard deviation of triplicate analyses of n samples
indicated in tables and figures. Statistical significance was determined by two or one-way
ANOVA, followed by Tukey’s multiple comparison test using GraphPad Prism v 5.01 software
(GraphPad Software, Inc., La Jolla, CA). Differences were considered significant at P ≤ 0.05.
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4.4 Results
4.4.1 Method validation
As shown in Table 4.1, 11 standards of stilbenes and stilbenes analogous were screened.
Among them, trans-stilbene and E-resveratrol trimethyl ether could not be ionized under the
given condition. 5 of them, polydatin, piceatannol, trans-resveratrol, dienestrol and
oxyresveratrol, were ionized under negative model. Piceatannol and oxyresveratrol were eluted
under the same RT and m/z ratio. The other 4 standards, pterostilbene, cis-resveratrol, hexestrol
and d4-resveratrol were ionized under positive model. The condition of Q-array DC was also
optimized, which too high may breakdown the ionized structure, and too low may insufficient to
ionize the molecular. The on column LOD and LOQ of 4 common stilbenes: polydatin,
piceatannol, trans-resveratrol and pterostilbene were also determined. They were ranged from
0.38 pg/column to 24.41 pg/column, and from 1.53 pg/column to 146.48 pg/column.
Pterostilbene, the most sensitive standard, had a 64-fold greater LOD sensitivity and a 96-fold
greater LOQ sensitivity than trans-resveratrol. Comparing with its precursor, trans-resveratrol
had a 16-fold lesser LOD sensitivity and a 24-fold lesser LOQ sensitivity than polydatin.
The recovery rates for polydatin, piceatannol, trans-resveratrol, and pterostilbene were
determined by spiking homogenates with standards prior to SPE clean-up (Table 4.2). Stilbene
recoveries from SPE were 61 to 73%, except for piceatannol, which was not recovered.
Piceatannol is rarely reported in botanical analysis, because the alumina/C18 SPE methods
typically employed for stilbene clean-up give inadequate recovery of piceatannol (Sanders,
McMichael et al. 2000, Rudolf, Resurreccion et al. 2005). Piceatannol analysis requires either
direct injection or use of a C18 SPE clean-up method (Lin, Lien et al. 2007).
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The intraday and interday variation of IS1 and IS2 were 7.5% and 8.3%, and 3.6% and
1.4%, respectively.
Dienestrol, cis-resveratrol, hexesterol, and d4-resveratrol could not be used as internal
standards because of their incomplete resolution from compounds with the same m/z in almond
extracts. Oxyresveratrol was not a suitable internal standard, as it co-eluted with piceatannol at
an identical m/z ratio, and may be present in almonds (Section 3.2). Thus, none of these five
stilbenes was a suitable internal standard. Trans-resveratrol was not observed in any preparations
or samples run while characterizing almond stilbene content, and pterostilbene was not recovered
from almond extracts (Table 4.2). Therefore, we used trans-resveratrol (IS1), to determine
variance introduced by SPE and drying, and pterostilbene (IS2) to determine variance introduced
by UHPLC-MS.

4.4.2 Identification of almond stilbenes
Based on the mass spectra of almond extract (Figure 4.1), only polydatin was identified
based on the RT and m/z ratio. The other stilbene components were under the LOD.
Due to the limitation of the clean-up step, piceatannol might present in almonds. However,
it could not be determined based on the method used in this paper.
In contrast to almond extracts, which required SPE cleanup prior to UHPLC-MS analysis,
almond blanch water was analyzed directly after filtration. Therefore, we examined if
piceatannol was present in blanch water. Indeed, a peak corresponding to piceatannol was
identified at 3.5 min and [M-H]- m/z 243 (Figure A.4.1). Piceatannol and oxyresveratrol coeluted in our UHPLC-MS method, so we could not exclude its presence in almonds. Therefore
the piceatannol+oxyresveratrol content of almond varieties was 0.91-2.55 µg/100 g as
quantitated by a piceatannol standard (Table 4.3). When accounting for the blanch water
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recovery of piceatannol+oxyresveratrol, the total stilbenes content in almond were 8.33-9.60
µg/100 g almonds.

4.4.3 Polydatin identification and quantitation in almond.
As shown in Figure 4.7.1, both specific RT which equaled to 2.9 and m/z ratio at 389 can
testify the presentation of polydatin. However, other evidence should also be provided to rule out
the possibility of other similar components. Due to the content of polydatin in almonds were
insufficient for visible absorbance detection under 320 nm. A hydrolysis method was developed
for polydatin identification.
A β-D-glucosidase was chosen for hydrolyzing the β-D-glucosidic linkage between transresveratrol and glucoside on polydatin. As shown in Figure 4.2, an ionized peak at 4.0 min (RT)
and 227 m/z was shown on the chromatography of almond after hydrolysis. The peak had the
similar RT and m/z ratio as the ionized trans-resveratrol. In contrary, a smaller ionized polydatin
peak was also found, which indicated the polydatin in almond was hydrolyzed to transresveratrol.
By quantitative analysis of whole-almond ethanolic extracts, the polydatin content of
Nonpareil, Butte and Carmel almonds was 7.19-8.52 µg/100 g almond and not significantly
different between varieties (P = 0.8519) (Table 4.2).

4.4.4 Compartmentalization of almond stilbenes
Following almond blanching, the blanch water contained 96 to 98% of the total polydatin
content, which were markedly higher than what was recovered in the dried skin (2 to 3%) and
meat (~1%) after extraction (P <0.0001). When compartmentalized by blanching, polydatin
content was highest in Butte and Carmel skins and meat and Nonpareil blanch water (Table 4.3).
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4.5 Discussion
A UHPLC-MS method was developed to quantitate stilbenes in almonds. Commercially
available stilbenes or potential internal standards were examined for suitability for UHPLC-MS
analysis (Table 4.1). In our preliminary evaluation of standards by UHPLC-MS, pterostilbene,
cis-resveratrol, hexestrol and d4-resveratrol had better S/N responses in positive ionization than
negative ionization mode. In contrast, polydatin (resvatrol-3-O-β-glucoside), piceatannol, transresveratrol, dienestrol and oxyresveratrol had better S/N in negative ionization than positive
ionization mode. Other LC-MS quantitative methods for stilbenes have employed solely positive
or negative ionization of stilbenes by ESI analysis (Kammerer, Claus et al. 2004, Counet,
Callemien et al. 2006, Burkon and Somoza 2008).
The Q-array DC voltage was also optimized for available commercial standard compounds
(Table 4.1). In the Shimadzu LCMS2020, the Q-array is set after the ion source before the
quadrupole and can apply a voltage that focuses ions entering the quadrupole. Increasing Q-array
voltage may induce fragmentation of ions entering the quadrupole. The optimal Q-array voltages
to maximize S/N varied between stilbenes. Both cis- and trans-resveratrol along with polydatin
gave better responses at a Q-array of -30 V. Cycling Q-array voltage from -100 to 100 V did not
significantly improve detection of other stilbenes. Trans-stilbene and E-resveratrol trimethyl
ether were not ionized under a range of conditions tested (Q-array DC from -100 to 100 V).
Trans-stilbene was previously ionized by atmospheric-pressure chemical-ionization mass
spectrometry using benzene as a carrier solvent (Macha, McCarley et al. 1999). E-resveratrol
trimethyl ether cations were ionized by ESI using a methanol-water mixture with 10 mM
ammonium acetate and 0.2% formic acid (Ma, Liu et al. 2007).
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In ethanolic extracts of whole almonds, the stilbenes piceatannol, trans-resveratrol, and
pterostilbene were below the LOD (Figure 4.1). These stilbenes have previously been reported
in foods. For example, piceatannol was 0.14−0.42 µg/g dry weight in two Vaccinium species
(Rimando, Kalt et al. 2004, Rimando and Barney 2005). Trans-resveratrol was reported in
pistachio (0.09-1.67 µg/g), cocoa products (0.4-0.5 µg/g), peanut products (0.06-5.14 µg/g),
Vaccinium species (0.01-5.88 µg/g dry weight), and grape skins (11.1-123.0 µg/g dry weight)
(Sobolev and Cole 1999, Kammerer, Claus et al. 2004, Rimando, Kalt et al. 2004, Rimando and
Barney 2005, Tokuşoǧlu, Ünal et al. 2005, Counet, Callemien et al. 2006). Pterostilbene was also
reported in two Vaccinium species, at 0.1-0.5µg/g dry weight (Rimando, Kalt et al. 2004,
Rimando and Barney 2005). Therefore, in most stilbene-containing foods, trans-resveratrol
appears to be more abundant and widely distributed than other stilbenes.
Polydatin was identified in whole almond ethanolic extracts based on RT (2.9 min) and the
presence of the pseudomolecular ion [M-H]- at m/z 389, together with a peak corresponding to
the resveratrol daughter ion [M-H-glucose]- at m/z 227 matching with a reference standard
(Figure 4.1). We performed Q-array experiments to further confirm this peak as polydatin, as
MS scan spectra were not definitive due to the presence of co-eluting compounds. Based on the
presence of the m/z 227 (-) daughter ion at the same RT as polydatin, we assessed the
relationship of these peaks by increasing Q-array DC voltage. Increasing the Q-array DC reduced
the polydatin, and increased [M-glucose]- at m/z 227 at the same RT (Figure 4.2). A similar
result was obtained when increasing the Q-array voltage during injections of almond extracts
(Figure A.4.2). Therefore Q-array fragmentation and enzymatic hydrolysis of whole almond
extract corroborate peak the peak at 2.9 min as polydatin. A similar approach could be used to
screen for other polyphenol glucoside-conjugates by UHPLC-MS.
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We utilized a β-D-glucosidase hydrolysis method to identify other putative stilbene
glucosides in almond extracts. Enzymatic hydrolysis of almond extract reduced polydatin and
catalyzed the formation of trans-resveratrol, and eliminated putative resveratrol-containing peaks
at 1.2, 3.4, 5.2 and 5.7 min (Figure 4.2). Due to the presence of co-eluting peaks, MS scan data
did not provide further insight into the identity of these compounds. Further work utilizing
MS/MS methods is necessary to determine if these unidentified peaks are composed of
resveratrol glucosides. For example, grape cell suspension cultures produced resveratrol
diglucoside (Decendit, Waffo-Teguo et al. 2002) and stilbene dimers and dimer diglucosides
were isolated and characterized from wine (Baderschneider and Winterhalter 2000). Thus,
almond stilbene content may be more abundant and diverse than reported in the present study.
Polydatin was also previously quantitated in peanut (7-38 µg/100 g), cocoa (100-120 µg/g),
and pistachio (620 to 820 µg/100 g) (Counet, Callemien et al. 2006, Grippi, Crosta et al. 2008,
Potrebko and Resurreccion 2009). In previous studies resveratrol content varied 31% among 12
pistachio samples and ~90-fold among 15 peanut cultivars (Sanders, McMichael et al. 2000,
Grippi, Crosta et al. 2008). Further work is needed to determine the relationship of almond
stilbene content to climactic, genotype, seasonal, and geographical variance, as these variables
can influence polyphenol content of tree nuts (Bolling, Chen et al. 2011).
Polydatin was primarily present in almond skin, and readily extracted by hot water. Like
almonds, stilbenes are also concentrated in grape and peanut skins (Sanders, McMichael et al.
2000, Kammerer, Claus et al. 2004). For example, grape skins contained 86 and 77%
respectively, of total grape resveratrol and polydatin content (Kammerer, Claus et al. 2004).
In comparison to almond, the total stilbene content of peanuts and pistachios were 2.5-100
times more than almonds (Sanders, McMichael et al. 2000, Grippi, Crosta et al. 2008). In
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almonds, stilbenes appear to be less abundant than flavonoids, phenolic acids, ellagitannins, and
proanthocyanidins, which are present in milligram quantities (Bolling, Chen et al. 2011, Xie,
Roto et al. 2012). It should be noted that stilbenes have synergistic bioactivities with other
polyphenols present in almonds. Resveratrol was synergistic with ellagic acid and quercetin at
inducing caspase-3 activity in cultured human leukemia cells (Mertens-Talcott and Percival
2005). Resveratrol was also synergistic with epigallocatechin gallate and γ-tocotrienol in the
induction of quinone reductase activity in cultured MCF-7 breast cancer cells (Hsieh and Wu
2008). Almond extracts also induce quinone reductase activity in murine hepatocytes (Chen and
Blumberg 2008). In vivo, polydatin is metabolized to resveratrol-sulfate, resveratrol-disulfate
resveratrol glucuronide, and resveratrol diglucuronide (Burkon and Somoza 2008). Considering
the extensive metabolism of stilbenes and other polyphenols in vivo, further studies are needed to
determine relevant synergies between almond stilbenes and other polyphenols.

4.6 Conclusions
Polydatin was identified in almond extracts, and concentrated primarily in almond skins.
Piceatannol + oxyresveratrol was tentatively identified in almond blanch water, and less
abundant than polydatin. Further work is warranted to determine the identity of components in
almond extract with putative resveratrol daughter ions. Stilbene content was not significantly
different among extracts of Nonpareil, Butte, and Carmel California almond varieties. The
diversity of polyphenols in almonds and other polyphenol-rich foods suggests that attention
should be given to the contribution of less abundant constituents to the synergy or antagonism of
polyphenols.
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4.7 Chapter 4 Tables and Figures
Table 4.1 UHPLC-MS chromatography of various stilbene standards including instrument settings, limits of detection (LOD), and
limits of quantification (LOQ).
Standard Type

Stilbene

RT

m/z

Q-array DC

LOD

LOQ

(min)

(ionization)

(V)

(pg/column)

(pg/column)

93

external

polydatin

2.9

389 (-)

-30

1.53

6.10

external

piceatannol

3.4

243(-)

0

1.53

12.21

external

trans-resveratrol

4.0

227 (-)

-30

24.41

146.48

external

pterostilbene

6.2

257 (+)

0

0.38

1.53

external

cis-resveratrol

3.4

229 (+)

+30

--

--

internal

dienestrol

6.2

265 (-)

0

--

--

internal

hexestrol

5.4

271 (+)

0

--

--

internal

oxyresveratrol

3.4

243 (-)

0

--

--

internal

d4-resveratrol

4.0

233 (+)

+20

--

--

RT: Retention time

Table 4.2 Stilbene content of whole almonds and recovery of spiked standards determined by
UHPLC-MS analysis.
Compound

Content in Almond Variety

%

(µg/g)

from clean-up

Butte

Carmel

Nonpareil

polydatin

8.52 ± 3.47

7.44 ± 3.44

7.19 ± 2.19

73.0%

piceatannol+oxyresveratrol

NDA

ND

ND

0.0 %

trans-resveratrol

<LODB

<LOD

<LOD

67.0%

pterostilbene

<LOD

<LOD

<LOD

60.5%

recovery

Data is mean ± standard deviation of three independent samples from each almond variety (n =
9), P = 0.8519 for polydatin content between varieties by one-way ANOVA analysis. Recovery
of stilbenes was determined by spiking almond homogenate with internal standard prior to solid
phase extraction clean-up. AND, not determined as present method not suitable for quantitation;
B

content in almond extract below the limit of detection of 0.25 pg trans-resveratrol/g almond and

0.0039 pg pterostilbene/g almond.
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Table 4.3 Stilbene content and proportion of California almond cultivars.
Content in almond variety (µg/100 g almonds)

Almond
Compound
compartment

Nonpareil

Butte

Carmel

skin

polydatin

0.15 ± 0.01b

0.22 ± 0.01a

0.22 ± 0.00a

meat

polydatin

0.06 ± 0.00b

0.08 ± 0.00a

0.08 ± 0.00a

blanch water

polydatin

8.43 ± 0.27a

6.75 ± 0.07b

6.33 ± 0.20b

0.91 ± 0.12c

2.55 ± 0.22a

1.71 ± 0.06b

9.55 ± 0.37a

9.60 ± 0.16a

8.33 ± 0.19b

piceatannol
oxyresveratrol
sum

+
A

Data are mean ± standard deviation of a composite sample representing three orchards for each
almond cultivar. Within rows, values bearing different letters are significantly different by
ANOVA and Tukey’s multiple comparison test (P ≤ 0.05). Two-way ANOVA analysis of
almond stilbene content by almond compartment and cultivar is P < 0.0001 for compartment,
variety, and for their interaction. AQuantitated as piceatannol equivalents.
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Figure 4.1 Representative UHPLC-MS chromatograms of whole almond extract following solid
phase extraction clean-up or standard compounds following a 1 µL injection. A: resveratrol
standard at m/z 227 (-); B: piceatannol standard at m/z 243 (-); C: pterostilbene standard at m/z
257 (+); D: polydatin standard at m/z 389 (-); E: almond sample at m/z 227 (-); F: almond
sample at m/z 243 (-); H: almond sample at m/z 257 (+); G: almond sample at m/z 389 (-).
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Figure 4.2 Representative UHPLC-MS chromatogram of a 1 µL injection of almond extract
following solid phase extraction clean-up and before or after enzymatic hydrolysis with βglucosidase: A. m/z 227 (-) prior to hydrolysis; B. resveratrol [M-H]- m/z 227 after hydrolysis.
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Figure 4.3 Representative UHPLC-MS chromatograms at m/z 389 (-) and 227 (-) of 0.4 ng
polydatin on column at increasing Q-array DC voltages.
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Chapter 5: Bioavailability of anthocyanins and
colonic
polyphenol
metabolites
following
consumption
of
aronia
berry
extract
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5.1 Abstract
Background: Aronia berries are a rich food source of anthocyanins and other polyphenols,
which likely contribute to their putative health benefits.
Objectives: To develop UHPLC-MS methods to quantitate aronia berry polyphenols and their
metabolites in plasma and urine samples. To determine the bioavailability and pharmacokinetics
of aronia berry polyphenols in human.
Design: A single-dose pharmacokinetic trial was conducted in 6 adults to evaluate the acute
absorption and urinary excretion of anthocyanins and colonic polyphenol metabolites after
consumption of 500 mg encapsulated aronia berry extract.
Results: While anthocyanins were bioavailable, catabolites of phenolic acid by microbiota,
including phenylacetic acid, hippuric acid, ferulic acid, and benzoic acids, increased ~10-fold
more than total anthocyanins in plasma and urine. Among the anthocyanins, cyanidin-3-Ogalactoside was rapidly metabolized to peonidin-3-O-galactoside, and cyanidin-3-O-glucoside
was present in plasma and urine at greater concentrations than other unmetabolized glycosides.
Aronia polyphenols were absorbed and extensively metabolized with t max of anthocyanins and
other polyphenol catabolites from 1.0 h to 6.33 h in plasma and urine. Despite significant interindividual variation in pharmacokinetic parameters, concentrations of polyphenol metabolites in
plasma and urine at 24 h were positively correlated with total AUC in plasma and urine (r =
0.9275, and r = 0.9828, respectively).
Conclusion: The results suggested that blood and urine collections after supplemental aronia
extract consumption could be used to estimate its polyphenol bioavailability and metabolism.
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5.2 Introduction
Aronia berries are a rich source of dietary polyphenols, including anthocyanins,
hydroxycinnamic acids, and proanthocyanidins (Taheri, Connolly et al. 2013). Studies have
suggested that aronia berry consumption improves dyslipidemia, inhibits inflammation, and
reduces oxidative stress associated with chronic diseases in humans (Naruszewicz, Łaniewska et
al. 2007, Skoczyńska, Jedrychowska et al. 2007, Porȩba, Skoczyńska et al. 2009, Broncel,
Koziróg et al. 2010) and animals (Skoczyńska, Jedrychowska et al. 2007, Valcheva-Kuzmanova,
Kuzmanov et al. 2007, Kujawska, Ignatowicz et al. 2011, Kim, Ku et al. 2013). Polyphenols are
extensively metabolized and have apparently low bioavailability (Manach, Scalbert et al. 2004).
Therefore, further data are needed to reconcile aronia polyphenol bioavailability with its
apparent health effects.
The most abundant aronia polyphenols, i.e., anthocyanins and proanthocyanins, have less
than 6% bioavailability of the initial dose ingested (Miyazawa, Nakagawa et al. 1999, Cao,
Muccitelli et al. 2001, Wu, Cao et al. 2002). When considering colonic metabolites, the
bioavailability of anthocyanin and proanthocyanidins may range from 12% to 18% (Gonthier,
Donovan et al. 2003, Czank, Cassidy et al. 2013). Anthocyanins can be absorbed in the intestine,
and further subjected to phase II metabolism in the gut or liver (Wu, Cao et al. 2002, Kay 2006).
Also, spontaneous degradation or microbial catabolism of anthocyanins may lead to the
formation of phenolic acids, such as protocatechuic acid (Czank, Cassidy et al. 2013). Aronia
proanthocyanidins are primarily polymeric, which limits absorption to its microbial catabolites
(Déprez, Brezillon et al. 2000, Ou and Gu 2013). These catabolites include valerolactones,
hydroxyphenyl propionic acids, hydroxyphenyl acetic acids, and hydroxybenzoic acids that are
absorbed from the colon (Rios, Gonthier et al. 2003, Urpi-Sarda, Monagas et al. 2009).
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The bioavailability and excretion of aronia anthocyanins and its phase II metabolites
following juice and extract consumption has been prevoiously described (Kay, Mazza et al.
2004, Kay, Mazza et al. 2005, Woodward, Kroon et al. 2009, Wiczkowski, Romaszko et al.
2010). However, the bioavailability of major colonic catabolites has not been well-defined. The
catabolism of aronia polyphenols converges on several key intermediates, including hippuric
acid, protocatechuic acid, and phenylproprionic acids (Figure 5.1) (Wu, Cao et al. 2002, Prior
2003, Wu, Pittman et al. 2004, El Mohsen, Marks et al. 2006, Monagas, Urpi-Sarda et al. 2010,
Stalmach, Edwards et al. 2013). Therefore, the objectives of this study were to quantitate aronia
anthocyanins and colonic polyphenol catabolites in humans following consumption of aronia
extract. Furthermore, we describe the validation of analytical methods used to generate these
data.

5.3 Materials and methods
5.3.1 Reagents and materials
Methanol was LC-MS grade from Fischer Scientific (Fair Lawn, NJ, USA). Anthocyanin
standards with ≥98% purity were purchased from Wuxi App Tec Co. (Shanghai, China). All
other chemicals and reagents, including LC-MS grade formic acid and tribluoroacetic acid, were
acquired from Sigma-Aldrich (St. Louis, MO, USA). Aronia berry extract was purchased from
Artemis International (Fort Wayne, IA, USA) and packaged into opaque cellulose capsules
containing 250 mg extract ± 10% per capsule (Beehive Botanicals, Hayward, WI, USA).

5.3.2 Study participants and institutional approval
Baseline characteristics of healthy 18 to 60 year old adults participated in the study are
described in Table 5.1 Participants were part of a larger study evaluating the function of aronia
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berry supplementation in reducing cardiovascular disease risk in former smokers. All participants
consented to the study and the research protocol was approved by the University of Connecticut
Institutional Review Board as protocol #H11-311, and registered at ClinicalTrials.gov as
NCT01541826.

5.3.3 Inclusion criteria for study participants
Former smokers, defined as people whom previously smoked ≥10 cigarettes/day for at
least 1 year, and cessation for at least 6 months. The exclusion criteria used to screen for their
eligibility included: 1) previous diagnoses of CVD, diabetes, or arthritis (except for
osteoarthritis), 2) currently being treated for cancer (i.e., chemotherapy, radiation therapy), 3)
women with prescribed estrogen replacement therapy, 4) having slimming diets, 5) practicing
vegetarian diet, 6) currently taking vitamin or mineral supplements or plant pills, 7) alcohol
consumption exceeding the definition of moderate drinking (2 drinks/day or a total of 12/week
for men or 1 drink/day or a total of 7/week for women).

5.3.4 Study design
The participants were advised to consume a low polyphenol diet for at least 3 days before
the study began. Participants avoided polyphenol-rich foods and beverages (green or black tea,
fruit or vegetable juice, grape products, berries, and certain fruits) and dietary supplements. After
an overnight fast, baseline plasma and urine samples were collected from participants. The
participants then consumed two capsules of aronia extract with water, providing ~500 mg of
extract. Subsequent blood samples were taken at 0.5, 1, 2, 4, 6, 9, 12, and 24 h post-consumption
of the extract. Urine samples were also collected at 2, 4, 6, 9, 12, and 24 h post-consumption of
the extract. Over the course of the following 24 h, low polyphenol diets were provided to
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participants. Breakfast was provided after the consumption of the aronia capsules. Lunch was
provided between hours 4 to 6 and dinner was provided between hours 6 to 9 after consumption
of the aronia extract. Snacks were provided between meals. The low polyphenol diet and snacks
consisted of dairy products, tuna, chicken, banana, potato chips, white bread, and plain bagels.
Blood samples (20 mL) were drawn from a brachial vein into EDTA vacutainer tubes (BD,
Franklin Lakes, NJ, USA). The blood samples were immediately placed on ice, and then
centrifuged at 1,500 ×g for 15 min at 4°C to recover plasma. The plasma and urine samples were
then acidified to 0.5% HCl and centrifuged at 2,500 ×g for 15 min at 4 °C to recover polyphenols
(Woodward, Kroon et al. 2009). The supernatant was collect and stored at -80°C until analysis.

5.3.5 Analysis and composition of aronia extract
The polyphenol content of the aronia supplement was analyzed using methods previously
reported by our group (Taheri, Connolly et al. 2013). Briefly, anthocyanins, flavonols, and
hydroxycinnamic acids were quantitated by UHPLC-MS, proanthocyanidins by normal-phase
HPLC, and total phenols by the Folin-Ciocalteu assay.

5.3.6 Sample clean-up
The extraction of anthocyanins and polyphenol metabolites from plasma and urine was
adapted from the methods reported by others (Kay, Mazza et al. 2004). Solid phase extraction
(SPE) of biofluid was performed using HyperSep C18 cartridges (500 mg/3 mL, Thermo
Scientific, Waltham, MS) attached to a vacuum manifold. The SPE cartridge was preconditioned
with 6 mL each of 0.5% formic acid in methanol (v:v) (A), and then 0.5% formic acid in water
(v:v) (B). Plasma (1.5 mL) or urine (4 mL) was then applied to the cartridge. An additional 6 mL
of B was then applied to wash the cartridge. Subsequently, the elute was collected with 6 mL of
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A and dried under nitrogen gas at 23°C. The dried residue was held at −80°C until UHPLC–MS
analysis.

5.3.7 UHPLC-MS analysis
Dried residue from SPE clean-up of urine or plasma was reconstituted with 100 µL
methanol. UHPLC–MS analysis was conducted using a Shimadzu Nexera UHPLC equipped
with DGU-20A5 Prominence degasser, SIL-30AC Nexera autosampler, CTD-30A Nexera
column oven, two LC-30AD pumps (Shimadzu, Kyoto, Japan), LCMS-2020 mass spectrometer,
and a Kinetex PFP column (1.7 µm, 100 Å, 2.1 × 50 mm; Phenomenex, Torrance, CA). The
following chromatographic methods were developed to optimize resolution and detection of
aronia polyphenols and metabolites in the reconstituted samples:
3,4-Dihydroxybenzoic acid, 3,4-dihydroxyphenylacetic acid, hippuric acid, and ferulic
acid: A gradient of water with formic acid (99.5:0.5, v/v) (A) and methanol (B) started at: 92% A
and 8% B; increased to 10% B at 8 min; increased to 20% B at 9.6 min; increased to 30% B at 14
min; increased to 40% B at 18 min; increased to 100% B at 25 min; returned to 8% B at 39 min,
and was held until the stop time at 40 min. The flow was maintained at 0.2 mL/min and the
sample injection volume was 1 μL.
3-(4-Hydroxyphenyl)propionic acid: A gradient of water (A) and methanol (B) started at
95% A and 5% B; increased to 100% B at 12 min; and returned to 5% at 16 min, and held until
the stop time at 20 min. The flow was maintained at 0.2 mL/min and the sample injection
volume was 1 μL.
Cyanidin-3-O-glucoside,

cyanidin-3-O-galactoside,

cyanidin-3-O-arabinoside,

and

peonidin-3-O-galactoside: A gradient of water with trifluoroacetic acid (99.9:0.1, v/v) (A) and
methanol (B) started at 80% A and 20% B; increased to 40% B at 9 min; increased to 100% B at
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12 min; returned to 20% B at 18 min, and was held until the stop time at 20 min. The flow was
maintained at 0.2 mL/min and the sample injection volume was 5 μL.
For all chromatographic methods, the mass spectrometer was set to a nebulizing gas flow
of 1.5 L/min, a drying gas flow of 15.0 L/min, the desolvation line at 250 °C, the heat block at
500 °C, and the interface temperature at 350 °C. Other detector parameters were set to optimize
the response of individual compounds of interest (Table 5.7.2).
Signal (S) to noise (N) ratios, limits of detection (LOD), limits of quantification (LOQ)
were determined for each compound based on methods previously described (Xie and Bolling
2014). Quantitation was based on MS area under the curve (AUC) responses and comparison to
authentic standards.

5.3.8 Determination of recovery
Recovery was determined according to the method of previous study (Wiczkowski,
Romaszko et al. 2010). Briefly, blanks of plasma and urine samples were spiked with standard
compounds to concentrations within the expected ranges of anthocyanins and metabolites (0.0142.2 µmol/L) that have been previously observed in human samples following anthocyanin
consumption (Kay, Mazza et al. 2004, Kay, Mazza et al. 2005, Wiczkowski, Romaszko et al.
2010, Czank, Cassidy et al. 2013). Polyphenol concentrations of spiked samples were determined
by SPE clean-up and UHPLC-MS analysis as described above.

5.3.9 Creatinine analysis
The urine creatinine content was measured by an urinary creatinine colorimetric assay kit
(Cayman Chemical, Ann Arbor, MI).
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5.3.10 Pharmacokinetic and Statistical Analysis
Cmax, tmax, and AUC of anthocyanins and metabolites in plasma and urine were determined
as previously described (McKay, Chen et al. 2015). The results of plasma and urine variables
included 6 subjects and are presented as means ± SEM, unless otherwise noted. Pearson
correlation analysis with Fisher’s z transformation was conducted by SAS (9.4, SAS Institute,
Inc., Cary, NC). Other statistical analysis was performed using GraphPad Prism (GraphPad
Software, San Diego, CA, USA). Statistical significance was defined as P-value <0.05.

5.4 Results
5.4.1 Analysis of supplement
The supplement constitute were reported in the Table 5.4. Anthocyanins and
proanthocyanins were the most abundant polyphenol classes in aronia extract, accounting for
34% and 31% of the total polyphenol content, respectively. Anthocyanins were primarily
cyanidin-3-O-galactoside, cyanidin-3-O-glucoside, cyanidin-3-O-arabinoside, and cyanidn-3-Oxyloside. Proanthocyanidins were 0.2% monomers, 7.1% dimers, 32.2% trimers, and 60.4%
degree of polymerization (DP) >4. In total, a 500 mg dose of aronia berry extract provided 45.07
mg anthocyanins, 41.9 mg proanthocyanidins as catechin equivalents, 9.9 mg flavonols, 36.9 mg
hydroxycinnamic acids, and 306 mg total phenols as gallic acid equivalents.

5.4.2 UHPLC-MS conditions for polyphenols in plasma and urine
Mobile phase composition was essential for polyphenol detection and resolution in plasma
and urine. Acid modifiers suppressed 3-(4-hydroxyphenyl)propionic acid ionization in both
positive and negative operating modes. The use of 0.5% formic acid was adequate to resolve
most polyphenols, but 0.1% trifluoroacetic acid was required to resolve cyanidin-3-O-galactoside
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and cyanidin-3-O-glucoside. The range of recovery rates of protocatechuic acid, 3,4dihydroxyphenylacetic acid, hippuric acid, ferulic acid, 3-(4-hydroxyphenyl)propionic acid,
cyanidin-3-O-galactoside, cyanidin-3-O-glucoside, cyanidin-3-O-arabinoside, and peonidin-3-Ogalactoside was 70% to 110% from plasma, and 43% to 119% from urine (Table 5.3). The
intraday relative standard deviation (RSD) of analytes was from 0.83% to 10.83%, and the
interday RSD was 1.32% to 11.46% (Table 5.7.3).

5.4.3 Determination of anthocyanins and metabolites in plasma samples
The retention time (RT), mass to charge ratio (m/z), LOD and LOQ of aronia
anthocyanins and metabolites are reported in Table 5.2. Protocatechuic acid, hippuric acid, 3-(4hydroxyphenyl)propionic acid, cyanidin-3-O-glucoside, and peonidin-3-O-galactoside were
recovered in plasma after aronia consumption (Figure 5.2 & Figure 5.4). Concentrations of 3,4dihydroxyphenylacetic acid, ferulic acid, cyanidin-3-O-galactoside, and cyanidin-3-Oarabinoside, were not detected. Cyanidin-3-O-glucoside reached a peak concentration of 0.059 ±
0.024 µg/mL at 1.6 h post-consumption, whereas polyphenol metabolites peaked at 1 h for
protocatechuic acid, 2.67 h for peonidin-3-O-galactoside, 5.33 h for hippuric acid, and 6.33 h for
3-(4-hydroxyphenyl)propionic acid (Table 5.5). AUC can be used to describe the absolute
bioavailability of compounds (Lappin, Rowland et al. 2006). The plasma AUC ranged from
0.054 ± 0.013 µg×h/mL for protocatechuic acid to 22.4 ± 4.4 µg×h/mL for hippuric acid. Among
the plasma metabolites, hippuric acid accounted for 85.2% of the total quantitated polyphenols
by their AUCs, followed by 3-(4-hydroxyphenyl)propionic acid (10.4%), peonidin-3-Ogalactoside (2.39%), cyanidin-3-O-glucoside (1.76%), and protocatechuic acid (0.21%). Thus,
the microbial phenolic acid catabolites represented for around 95.8% of the total of increased
polyphenols after aronia consumption. In contrast, anthocyanins accounted for 4.2% of the
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increase in plasma polyphenols. Creatinine concentrations varied from 15.9 to 258 mg/dL in
urine samples.

5.4.4 Determination of anthocyanins and metabolites in urine samples
Protocatechuic acid, 3,4-dihydroxyphenylacetic acid, hippuric acid, ferulic acid, 3-(4hydroxyphenyl)propionic acid, cyanidin-3-O-galactoside, cyanidin-3-O-glucoside, cyanidin-3-Oarabinoside, and peonidin-3-O-galactoside were recovered in urine samples (Figure 5.3 &
Figure 5.5). Cyanidin-3-O-galactoside reached a peak concentration of 0.004 ± 0.001 mg/mg
creatinine at 4.67 h post-consumption. Also, the t max and Cmax for cyanidin-3-O-glucoside and
cyanidin-3-O-arabinoside were 6 h and 0.010 ± 0.006 mg/mg creatinine, and 4 h and 0.020 ±
0.006 m g/mg creatinine, respectively (Table 5.5).
protocatechuic

acid,

4.67

h

for

Phenolic acids peaked at 4 h for

peonidin-3-O-galactoside,

4.83

h

for

3-(4-

hydroxyphenyl)propionic acid, 5.33 h for ferulic acid, and 6.33 h for both 3,4dihydroxyphenylacetic acid and hippuric acid. The urine AUC ranged from 0.016 ± 0.005
mg×h/mg creatinine for cyanidin-3-O-galactoside to 2430 ± 360 µg×h/mg creatinine for hippuric
acid. Among the urinary metabolites, hippuric acid accounted for 98.5% of the total increase in
polyphenols

after

aronia supplementation, followed by ferulic

dihydroxyphenylacetic

acid

(0.46%),

protocatechuic

acid

acid

(0.80%), 3,4-

(0.15%),

3-(4-

hydroxyphenyl)propionic acid (0.09%), cyanidin-3-O-glucoside (0.004%), cyanidin-3-Oarabinoside (0.004%), peonidin-3-O-galactoside (0.002%), and cyanidin-3-O-galactoside
(0.001%). Thus, the polyphenol microbial catabolites represented nearly all of the increase in
urinary polyphenols after aronia consumption.
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5.4.5 Between-subjects differences
There was large between-subject variation in the pharmacokinetics of aronia polyphenols
and metabolites (Table 5.5). As a result, plasma anthocyanins were below the limit of detection
in 3 participants. The Cmax interindividual CV for plasma polyphenols was generally greater than
urinary polyphenols (20 - 65% vs 17 - 60%) except for hippuric acid, which had 23% and 34%
CV in the urine and plasma, respectively. Also, anthocyanins had higher Cmax variation than
phenolic acids in both urine and plasma. The interindividual Cmax range was largest for 3-(4hydroxyphenyl)propionic acid in plasma and urine, having 14- and 29-fold differences,
respectively.

5.4.6 Correlation Analysis
The utility of using overnight fasting samples of plasma or urine to estimate polyphenol
bioavailability and metabolism has not been validated. If the total AUC of polyphenols is not
correlated with fasting concentrations, we would expect fasting concentrations to be a poor
reflection of the previous exposure. Therefore, we determined the correlation of AUC values of
aronia polyphenols and metabolites with the 24 h concentrations after an overnight fast. All
metabolite concentrations in plasma and urine were significantly lower at 12-24 h post
consumption compared to the total AUC. The Pearson correlation coefficients between the sum
of polyphenols and metabolites in fasting plasma or urine and total AUC were 0.9275 (P <
0.0001) and 0.9828 (P < 0.0001), respectively. When hippuric acid was not included in the sum
of polyphenols and metabolites, the correlation between fasting plasma and total AUC was 0.1890 (P = 0.4046). In contrast, overnight urine and total AUC correlation of metabolites and
polyphenols without hippuric acid was still significant, at 0.9573 (P <0.0001).
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5.5 Discussion
The UHPLC-MS methods developed for polyphenol analysis in plasma and urine had
acceptable reproducibility and sensitivity. Routine RSD was ≤10% without including an internal
standard in the method. Including a stable isotope standard would be expected to further improve
precision. The recovery rates after SPE of plasma polyphenols were 10% to 20% higher than
previously reported, which was around 70% to 90% for other anthocyanin-rich foods (Zhang and
Zuo 2004, Wiczkowski, Romaszko et al. 2010). However, the SPE recovery of urine polyphenols
were 10% to 40% less than a previous study on aronia juice consumption (Wiczkowski,
Romaszko et al. 2010). This difference may be a result of increasing the urine volume used for
SPE.
The LODs of anthocyanins and their metabolites in this study were equivalent to 0.002 to
0.05 nmol/L and 0.003 to 0.02 nmol/L in the plasma and urine, respectively, and the LOQs were
equivalent to 0.004 to 0.1 and 0.01 to 0.04 nmol/L in the plasma and urine, respectively. This
result was consistent with other studies about the lowest detection on anthocyanins and phenolic
acids measured by HPLC or HPLC-MS, which was within a range of 0.01 to 0.2 nmol/L in
plasma (Kay, Mazza et al. 2004, Vitaglione, Donnarumma et al. 2007, Wiczkowski, Romaszko
et al. 2010). These results indicate the sensitivity of the UHPLC-MS is in range of prior studies.
The plasma tmax of 1.6 h for cyanidin-3-O-gluoside after aronia extract consumption was in
the range of 1.3 to 3.1 h, which was reported in previous studies (Wiczkowski, Romaszko et al.
2010). Plasma cyanidin-3-O-gluoside increased by 30 min post-consumption, which supports the
hypothesis that anthocyanins can be absorbed though the stomach (Fernandes, de Freitas et al.
2012). Fernandes, et al. (2012) demonstrated that cultured stomach cells absorbed anthocyanins
via a saturable transport mechanism without biotransformation. Passamonti, et al. (2002)
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proposed that bilitranslocase could be a high-affinity anthocyanin transporter in epithelial cells of
rat gastric mucosa. However, while rodents have stomach bilitranslocase, to the best of our
knowledge, it has not been identified in human stomach (Battiston, Macagno et al. 1999).
In the present study, plasma protocatechuic acid peaked as early as 1 h, which was
consistent with previous studies that reported tmax values of protocatechuic acid 1-2 h after
anthocyanin consumption (Vitaglione, Donnarumma et al. 2007, Keane, Bell et al. 2015). The
aronia supplement in the present study provided 1.2 mg of protocatechuic acid, which may
contribute to its early tmax. Also, other aronia polyphenols were also metabolized to
protocatechuic acid, e.g. chlorogenic acid, quercetin, and caffeic acid (Figure 5.7.1). Thus,
pharmacokinetic parameters of microbial polyphenol catabolites are likely botanical- or
composition-specific. Generally, the phenolic catabolites had later peaks than cyanidin-3-Oglucoside, which suggests these metabolites may be generated from colonic metabolism of
anthocyanins. Since the major aronia anthocyanin, cyanidin-3-O-galactoside, was not detected in
the plasma, it could be a major source of the colonic catabolites. Urinary colonic polyphenol
catabolite

concentrations

peaked

later

than

those

in

plasma,

except

for

3-(4-

hydroxyphenyl)propionic acid. The lower concentrations of anthocyanins in both plasma and
urine samples confirm their extensive metabolism and low bioavailability (Scalbert, Morand et
al. 2002).
The aronia supplement provided 45.07 mg anthocyanins, which was similar to the dose
provided by 250 mL juice in a prior pharmacokinetic study (Wiczkowski, Romaszko et al. 2010).
The peak plasma concentration of cyanidin-3-O-glucoside and peonidin-3-O-galactoside from
the aronia supplement was more than 10-fold greater than the previous study of juice, which was
~1.0 nmol/L. However, plasma peak concentration of cyanidin-3- O-galactoside was ~12.0
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nmol/L after juice consumption, while this was undetectable after extract consumption. This
suggests that cyanidin-3-O-galactoside in aronia extract is likely metabolized to peonidin-3-Ogalactoside more quickly than that in juice.
Participants had significant interindividual variation of polyphenol bioavailability after
aronia extract consumption. Data linking gender, age, and health status to polyphenol
bioavailability is very limited. Bioavailability and colonic polyphenol catabolism can be
influenced by intestinal enzyme activity, intestinal transit time, and colonic microbes (Sterchi,
Mills et al. 1990). Intestinal lactase-phlorizin hydrolase (LPH) may mediate the bioavailability of
cyanidin-3-O-glycosides and its activity varies significantly between individuals (Kay, Mazza et
al. 2004, Kay 2006). Van Duynhoven, et al. (van Duynhoven, Vaughan et al. 2011) also
proposed that the wide variation of polyphenol metabolism was because a result of the diversity
of the colonic microbiota. Thus, variable polyphenol bioavailability may result from a number of
factors. Besides differences in metabolic fate, the total bioavailability of polyphenols varies
between individuals. According to Czank, et al. (Czank, Cassidy et al. 2013), the recovery of 13C
in blood, urine, breath, and feces was in the range of 15.1 to 99.3% in 8 patients that consumed
500 mg

13

C labeled cyanidin-3-glucoside. Urpi-Sarda, et al. (Urpi-Sarda, Monagas et al. 2009)

have indicated that changes in human urinary levels of phenolic acids and flavanols vary from
0.001 to 59.43 nmol/mg creatinine in 21 subjects who consumed proanthocyanidin-rich cocoa
powder.
In this study, we quantitated aronia anthocyanins and polyphenol catabolites. It should be
noted that other metabolites are produced from aronia polyphenols beyond those measured in the
present study (Figure 5.1) (Manach, Williamson et al. 2005). A previous study have identified
22 metabolites of cyanidin-3-O-glucoside using an isotopic approach (Czank, Cassidy et al.
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2013). The metabolites of anthocyanins generated from intestine and liver include phase I, phase
II and colonic metabolites (Wu, Cao et al. 2002, Czank, Cassidy et al. 2013, de Ferrars, Czank et
al.

2014).

The

phase

I

metabolites

mainly

include

phloroglucinaldehyde,

3,4-

dihydroxybenzaldehyde, and hydroxybenzoic acid (Czank, Cassidy et al. 2013, de Ferrars, Czank
et al. 2014). The phase II metabolites are glucuronidated and methylated cyanidins (Wu, Cao et
al. 2002, Czank, Cassidy et al. 2013, de Ferrars, Czank et al. 2014). Colonic anthocyanin
metabolites include hydroxybenzoic acid, hippuric acid, phenylpropenoic acids, and ferulic acid
(Czank, Cassidy et al. 2013, de Ferrars, Czank et al. 2014). Thus, the present study did not
quantitate all plausible polyphenol metabolites due to the difficulty in obtaining standards.
Furthermore, the polyphenol catabolites in the present study could be products of multiple
polyphenol catabolic pathways. For example, hydroxybenzoic acid and ferulic acid are also the
major metabolites of proanthocyanins (Rios, Gonthier et al. 2003).
This study was a part of a larger study evaluating aronia berry polyphenol supplementation
on cardiovascular disease risk. The significant correlation between fasting plasma or urine
samples with total polyphenol AUC suggested that fasting polyphenol concentrations could be
used as a marker of compliance and/or catabolic fate of aronia extract polyphenols. However, the
correlation between plasma polyphenol AUC and fasting concentrations was low without
including hippuric acid. This may result from that the wide variation in hippuric acid, and fewer
types of metabolites observed in the plasma. Others have also suggested that urinary polyphenols
might be a better predictor of polyphenol intake than food frequency questionnaires in analysis
of association between polyphenol intake and all-cause of mortality in adults (Zamora-Ros,
Rabassa et al. 2013).
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5.6 Conclusions
In conclusion, we developed UHPLC-MS methods to determine bioavailability of aronia
extract polyphenols and metabolites. The current study indicates that aronia extract anthocyanins
are extensively metabolized. Total fasting plasma and urine polyphenols 24 h after aronia extract
consumption correlated with bioavailability so they could be used as a marker of polyphenol
metabolism in individuals when consuming a low-polyphenol diet. Future work should consider
the extent of the significant interindividual variation in aronia polyphenol metabolism when
determining intervention efficacy on health outcomes.
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5.7 Chapter 5 Tables and Figures
Table 5.1 Characteristics of participant population.
Characteristic

Male (n = 3)

Female (n = 3)

Age

22.3 ± 1.5

40.3 ± 7.3

SBP (mmHg)

112.7 ± 2.9

112.0 ± 6.4

DBP (mmHg)

70.7 ± 2.0

76.3 ± 2.7

Waist circumference (cm)

81.3 ± 5.5

75.0 ± 3.0

BMI (kg/m2)

24.9 ± 1.3

24.2 ± 1.4

Fasting TC (mg/dL)

160.7 ± 17.6

168.7 ± 24.5

Fasting HDL (mg/dL)

48.7 ± 2.8

65.3 ± 9.1

Fasting LDL (mg/dL)

92.7 ± 12.0

96.0 ± 12.5

Fasting TG (mg/dL)

96.7 ± 27.0

63.0 ± 11.5

Fasting glucose (mg/dL)

93.0 ± 4.6

99.3 ± 1.45

Data is mean ± SEM. SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total
cholesterol; TG: Triglyceride.
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Table 5.2 Optimized MS instrument parameters for UHPLC analysis of polyphenols from plasma and urine.
Method

1

Standard

IV

DV

IV

DLV

Q array DC Q array RF

(kV)

(kV)

(kV)

(V)

(V)

(V)

protocatechuic acid

-3.5

3.5

-3.5

-10

-10

20

3,4-dihydroxyphenylacetic

-5

3.5

-5

-70

-10

20

hippuric acid

-5

3.5

-5

-70

-10

20

ferulic acid

5

3

5

0

20

20

-3.5

-5

-70

-50

30

acid
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2

3-(4-hydroxyphenyl)propionic -5
acid

3

cyanidin-3-O-galactoside

4

3.5

4

100

0

50

cyanidin-3-O-glucoside

4

3.5

4

100

0

50

cyanidin-3-O-arabinoside

4

3.5

4

100

30

40

peonidin-3-O-galactoside

4

3.5

4
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DV: detector voltage; IV: interface voltage; DLV: desolvation line Voltage; Q array DC: Q array direct current; Q array RF: Q array
radio frequency. Method 1: formic acid (99.5:0.5, v/v) (A) and methanol (B); Method 2: water (A) and methanol (B); Method 3:
trifluoroacetic acid (99.9:0.1, v/v) (A) and methanol (B).

Table 5.3 Polyphenol retention time (RT), m/z ratio, LOD, LOQ and recovery rates of standards of optimized UHPLC-MS methods.
Standard

RT

m/z

LOD

LOQ

Recovery Recovery Intraday

(pg/column) (pg/column) rate

rate

(Plasma)

(Urine)

Interday

RSD

RSD

protocatechuic acid

3.7

(-)153

4.88

9.77

81%

73%

4.54%

7.29%

3,4-dihydroxyphenylacetic

4.0

(-)167

19.53

39.06

70%

92%

6.02%

5.35%

hippuric acid

5.4

(-)178

2.44

4.88

101%

104%

7.75%

11.46%

ferulic acid

17.4 (+)195 29.30

29.06

93%

114%

0.83%

6.42%

48.8

72%

119%

1.08&

7.29%

acid

121

3-(4-hydroxyphenyl)propionic 10.5 (-)165

24.4

acid
cyanidin-3-O-galactoside

8.8

(+)449 312.5

625.0

71%

43%

10.83%

9.10%

cyanidin-3-O-glucoside

9.3

(+)449 195.3

448.3

104%

43%

2.12%

9.98%

cyanidin-3-O-arabinoside

10.1 (+)419 58.6

73.2

110%

58%

6.34%

5.49%

peonidin-3-O-galactoside

10.3 (+)463 14.6

24.4

100%

63%

4.89%

1.32%

RT: retention time; m/z: mass to charge ratio.

Table 5.4 Polyphenol composition of aronia supplement.
Assay

Component

Chokeberry Supplement
(mg/500 mg)

polyphenols by UPLC- rutin

2.6 ± 0.0

MS

neochlorogenic acid

3.5 ± 0.0

chlorogenic acid

31.9 ± 0.3

protocatechuic acid

1.2 ± 0.0

caffeic acid

0.3 ± 0.0

quercetin-3-galactoside

3.6 ± 0.1

quercetin-3-glucoside

2.9 ± 0.1

quercetin

0.8 ± 0.0

cyanidin-3-galactoside

+ 32.52 ± 0.7

cyanidin-3-glucoside

proanthocyanidins

cyanidin-3-arabinoside

11.79 ± 0.3

cyanidn-3-xyloside

0.76 ± 0.0

by (+)-catechin equivalents

41.9 ± 0.4

by (+)-catechin equivalents

2.6 ± 0.1

DMAC
proanthocyanidins
HPLC
% monomers

0.2 ± 0.0 (%)

% dimers

7.1 ± 0.3 (%)

% trimers

32.2 ± 0.7 (%)

% 4-mers

24.2 ± 0.5 (%)
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% 5-mers

14.9 ± 1.0 (%)

% 6-mers

6.5 ± 0.5 (%)

% 7-mers

3.1 ±0.3 (%)

% 8-mers

1.2 ±0.1 (%)

% ≥ 9-mers

10.5 ±1.1 (%)

total phenol by Folin gallic acid equivalents
assay
Data is mean ± SD of at least duplicate determinations.
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306.0 ± 4.11

Table 5.5 Pharmacokinetic parameters of anthocyanins and metabolites in plasma and urine
samples in n = 6 individuals consuming 500 mg aronia extract.

Plasma

t max

Cmax (range)

AUC

h

µg/mL

μg×h/mL

0.005 ± 0.001
Protocatechuic acid

1.00 ± 0.00

0.054 ± 0.013
(0.004-0.007)*
2.169 ± 0.495

Hippuric acid

5.33 ± 0.67

22.350 ± 4.441
(0.873 to 3.488)

3-(4-hydroxyphenyl)propionic

0.211 ± 0.135
6.33 ± 1.45

acid

2.725 ± 2.391
(0.033-0.475)
0.059 ± 0.024

Cyanidin-3-O-glucoside

1.60 ± 0.24

0.462 ± 0.170
(0.014-0.180)
0.075 ± 0.049

Peonidin-3-O-galacoside

2 67 ± 0.67

0.627 ± 0.198
(0.029-0.266)

Urine

h

mg/mg creatinine

mg×h/mg creatinine

0.431 ± 0.075
Protocatechuic acid

4.00 ± 0.52

(0.208-0.650)

3.682 ± 0.587

0.700 ± 0.130
3,4-dihydroxyphenylacetic acid 6.33 ± 2.25

(0.552-1.238)

11/426 ± 0.881

190.156 ± 42.136
Hippuric acid

6.33 ± 2.25

(59.966-316.070)

2429.852 ± 360.197

1.773 ± 0.609
Ferulic acid

5.33 ± 3.50

(0.323-4.137)
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19.770 ± 6.167

3-(4-hydroxyphenyl)propionic
acid

0.477 ± 0.222
4.83 ± 2.04

(0.023-0.643)

2.299 ± 0.715

0.004 ± 0.001
Cyanidin-3-O-galactoside

4.67 ± 1.03

(0.002-0.010)

0.016 ± 0.005

0.010 ± 0.006
Cyanidin-3-O-glucoside

6.00 ± 3.35

(0.002-0.004)

0.118 ± 0.070

0.020 ± 0.006
Cyanidin-3-O-arabinoside

4.00 ± 1.26

(0.002-0.038)

0.088 ± 0.031

0.010 ± 0.002
Peonidin-3-O-galactoside

4.67 ± 1.03

(0.003-0.014)

0.053 ± 0.012

Data is mean ± SEM (n=6). The data were collected from participants whom consumed 500 mg
of a polyphenol-rich aronia supplement within 24 hour after consumption.
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Figure 5.1 Proposed metabolic pathway of aronia polyphenols determined in the present study.
Red lines represent colonic catabolic steps, while blue lines represent tissue metabolism. (Wu,
Cao et al. 2002, Prior 2003, Wu, Pittman et al. 2004, Monagas, Urpi-Sarda et al. 2010, Stalmach,
Edwards et al. 2013).
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Figure 5.2 Plasma concentrations of (A) cyanidin-3-O-glucoside, (B) peonidin-3-O-galactoside,
(C) protocatechuic acid, (D) 3-(4-hydroxyphenyl)propionic acid, and (E) Hippuric acid,
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following consumption of 500 mg of a polyphenol-rich aronia supplement. Data is mean ± SEM
of n = 6 participants.
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Figure 5.3 Cumulative urinary excretion of aronia polyphenols and catabolites following
consumption of 500 mg of a polyphenol-rich aronia supplement.
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Figure 5.4 Chromatograms of (A) polyphenol standards and (B) representative plasma samples.
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Figure 5.5 Chromatograms of (A) polyphenol standards and (B) representative urine samples.
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Chapter 6: Aronia berry polyphenol consumption
reduces plasma LDL and total cholesterol in
former smokers without lowering biomarkers of
inflammation or oxidative stress
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6.1 Abstract
Background: Former smokers are at increased risk of cardiovascular disease (CVD). Little is
known about the ability of dietary polyphenols to reduce CVD risk in former smokers. Aronia
berry is a rich source of anthocyanins, hydroxycinnamic acids, and proanthocyanidins. Upon
consumption, these polyphenols are extensively metabolized. The significant interindividual
variation of polyphenol metabolism may modulate the ability of aronia consumption to reduce
CVD risk.
Objective: We hypothesized that dietary aronia polyphenols would reduce CVD risk factors and
improve biomarkers of inflammation and oxidative stress in former smokers. We also tested if
these effects were associated with interindividual differences in polyphenol metabolism and
bioavailability.
Design: A 12-week multiple-dose, randomized, placebo-controlled trial was conducted in 49
adults (n = 24/placebo, n = 25/aronia) to evaluate if consumption of 500 mg aronia extract per
day modulates plasma lipids, plasma biomarkers of inflammation, oxidative stress biomarkers in
plasma and urine, and lipid transport genes of peripheral blood mononuclear cells (PBMCs).
Results: Aronia consumption reduced fasting plasma total cholesterol (TC) level by 8% during
the 12-week treatment (P = 0.0140) compared with placebo group, and reduced plasma lowdensity lipoprotein cholesterol (LDL-C) level by 7 % and 11% at both 6 wks and 12 wks
compared with placebo group, respectively (P = 0.0285). Increases in the urinary polyphenol
metabolites peonidin-3-O-galactoside, 3-(4-hydroxyphenyl)propionic acid, and unmetabolized
anthocyanin cyanidin-3-O-galactoside were associated with lower plasma TC and LDL-C in the
aronia group. Participants in the aronia group who showed the largest decreases in TC had
stronger correlations of urinary peonidin-3-O-galactoside and cyanidin-3-O-galactoside than
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those who did not respond to the intervention. However, aronia and placebo consumption did not
change biomarkers of inflammation and oxidative stress.
Conclusion: Aronia polyphenols reduced total and LDL-C in former smokers but did not
improve biomarkers of oxidative stress and chronic inflammation. The total cholesterol-lowering
effect of aronia polyphenols was most closely associated with the tissue and microbial
metabolism of aronia polyphenols, particularly the formation of peonidin-3-O-galactoside.
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6.2 Introduction
Cigarette smoking increases oxidative stress and inflammation, which increases
cardiovascular disease (CVD) risk through vasomotor dysfunction, leukocyte and platelet
activation, lipid peroxidation, adhesion and inflammatory molecules activation, and smooth
muscle proliferation (Ambrose and Barua 2004). In the last decade, smoking cessation has
increased, and in the United States, former smokers outnumber current smokers (Services 2014).
Although smoking cessation reduces CVD risk, CVD risk in former smokers remains elevated
for 10 to 15 years compared with never-smokers (Tilloy, Cottel et al. 2010, Godtfredsen and
Prescott 2011). Former smokers also have compromised vascular and antioxidant function,
suggesting the need for additional strategies to further reduce CVD risk (Helmersson, Larsson et
al. , Jin, Webb-Robertson et al. 2011).
Aronia berry consumption may reduce CVD risk by improving dyslipidemia, inhibiting
inflammation, and reducing oxidative stress (Naruszewicz, Łaniewska et al. 2007, Skoczyńska,
Jedrychowska et al. 2007, Valcheva-Kuzmanova, Kuzmanov et al. 2007, Jurgoński, Juśkiewicz
et al. 2008, Porȩba, Skoczyńska et al. 2009, Broncel, Koziróg et al. 2010, Kujawska, Ignatowicz
et al. 2011, Kim, Ku et al. 2013). Aronia berries has high levels of polyphenols, and its
anthocyanins, hydroxycinnamic acids, and proanthocyanidins may mediate its putative health
benefits (Taheri, Connolly et al. 2013). Increased aronia berry polyphenol intake reduces
biomarkers of CVD risk in some populations. Daily consumption of 300 mg aronia extract for 2
months decreases blood pressure, total cholesterol (TC), low-density lipoprotein cholesterol
(LDL-C) and total triglyceride (TG), and increased antioxidant enzyme activity in adults with
metabolic syndrome (Broncel, Koziróg et al. 2010). Similarly, patients that survived a
myocardial infarction and were prescribed statins whole also consuming 255 mg aronia extract
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per day for 6 weeks demonstrated reduced blood pressure, oxidized low-density lipoprotein (oxLDL), high-sensitivity C reactive protein (hsCRP) and monocyte chemoattractant protein 1
(MCP-1) when compared to patients that consumed a placebo (Naruszewicz, Łaniewska et al.
2007). Other anthocyanin-rich interventions modulate lipids and improve other biomarkers of
CVD risk in individuals with dyslipidemia or metabolic syndrome (Qin, Xia et al. 2009, Basu,
Du et al. 2010, Basu, Betts et al. 2011). Therefore, the consumption of aronia berries and other
dietary anthocyanins appear to be a promising intervention for populations at higher risk of
CVD.
Anthocyanins and polyphenols from aronia and other berries have limited bioavailability
and are extensively metabolized (Manach, Scalbert et al. 2004). The interindividual variability of
polyphenol pharmacokinetics is considerable (Manach, Williamson et al. 2005). Interindividual
variability in polyphenol metabolism is due in part to genetic polymorphisms in xenobiotic
metabolizing enzymes and transporters, as well as variation in gut microbial catabolism
(Scheline 1999, Barnes 2008). The extent to which individual differences in polyphenol
metabolism are associated with the efficacy of dietary polyphenol interventions for reducing
CVD risk is largely unknown. Therefore, the primary objective of this study was to determine
the ability of aronia polyphenols to reduce plasma lipids and biomarkers of oxidative stress and
inflammation in former smokers, while the secondary objective was to determine the extent in
which aronia polyphenol bioavailability is associated with changes in CVD risk biomarkers.

6.3 Materials and methods
6.3.1 Participants
Interested participants were recruited from Storrs, CT area from July 2012 to May 2015.
Participants were pre-screened by phone, and then visited the University of Connecticut
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Nutritional Sciences Department to provide informed consent and subsequent eligibility
screening. The screening consisted of a standard medical history questionnaire and determination
of height, weight, BMI, waist circumference, blood pressure, and a routine laboratory analysis of
a fasting blood sample for blood sugar and TC. The inclusion criteria were: former smokers who
had previously smoked ≥3 cigarettes/day for at least 1 year and ceased for at least 6 months;
healthy male or female between 18-65 years of age; premenopausal status for women; serum TC
<240 mg/dL and serum TG <150 mg/dL; resting blood pressure <140/90 mm Hg; stable body
weight (± 5 lb) during the prior 2 months with a BMI between 18.5 kg/m 2 and 39 kg/m2;
willingness to maintain a normal exercise level (<7 h/wk) and avoid exercise 24 h prior to blood
sampling; and willingness to ingest an aronia berry supplement or placebo daily for 12 wks. The
exclusion criteria of this study were: previous diagnosis of CVD, diabetes, or arthritis (except for
osteo-arthritis); current treatment for cancer; women with perimenopausal or menopausal
symptoms or prescribed estrogen replacement therapy; adherence to a slimming or vegetarian
diet; current consumption of vitamin, mineral, or botanical supplements; and consumption of
alcohol exceeding the definition of moderate drinking (2 drinks/day or a total of 12/week for
men or 1 drink/day or a total of 7/week for women). All participants consented to the study. The
research protocol was approved by the University of Connecticut Institutional Review Board as
protocol #H11-311, and listed at ClinicalTrials.gov as NCT01541826.

6.3.2 Study design
The participants were advised to consume a low polyphenol diet for a minimum of 4 weeks
before the intervention and were randomly assigned to consume 500 mg of aronia berry extract
or the placebo. The supplements were opaque, color-matched, and provided 250 mg of extract or
placebo per capsule. The participants and study personnel were blinded to the composition of the
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intervention material. The aronia extract provided 45.07 mg anthocyanins, 35.73 mg
hydroxycinnamic acids, and 41.9 mg proanthocyanidins per 500 mg dose. The placebo was
composed of rice powder with 0.2% beet juice concentrate. The extract and placebo passed
quality control measures of microbial pathogens, heavy metals, pesticides, and residual solvents.
The compositions of the aforementioned intervention materials are further described in Table 6.1
and Table 5.4. The polyphenol content of placebo and supplement changed less than 10% over
the course of the study.
Participants completed a three-day dietary record during the run-in period prior to the
intervention. At the start of the intervention and again at week 12, participants completed an
overnight fast, and baseline blood and urine samples were collected the following morning.
Study personnel subsequently determined height, weight, and blood pressure. At week 6,
participants were again asked to fast overnight for 12 h prior to arriving at the study center for
anthropometric measurements and collection of fasting blood samples. All participants were
advised to consume a low polyphenol diet, moderate alcohol consumption, and maintain their
normal physical activity throughout the course of intervention.

6.3.3 Preparation of biological samples
Blood samples (80 mL) were drawn from a brachial vein into EDTA vacutainer tubes (BD,
Franklin Lakes, NJ, USA) to recover plasma and peripheral blood mononuclear cells (PBMCs).
Another 10 mL blood sample was drawn from a brachial vein into evacuated glass tubes (BD,
Franklin Lakes, NJ, USA) to recover serum. The blood samples were immediately placed on ice,
and centrifuged at 1,500 ×g for 15 min at 4 °C to recover plasma. For serum collection, the blood
samples were allowed to clot at room temperature for 25 min and then centrifuged at 1000 ×g for
15 min at 4 °C. Plasma and urine aliquots for polyphenol analysis were acidified using 0.5% HCl
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and centrifuged at 2,500 ×g for 15 min at 4 °C. The supernatants were collected and stored at -80
°C until analysis. PBMCs were isolated from whole blood samples using Ficoll-Paque premium
(GE Healthcare, Pittsburgh, PA, USA) by density gradient centrifugation. Whole blood samples
were diluted 1:1 with sterile PBS, and the diluted blood samples were layered over 2:1 with
Ficoll-Paque premium, and centrifuged at 700 ×g for 20 min to separate the PBMCs. The buffy
coat-containing PBMCs were collected, washed twice with PBS, and the cells were resuspended
in ice-cold FBS. The cell suspensions were diluted 1:1 with cryopreservation media (fetal bovine
serum, 20% dimethyl sulfoxide) to a final concentration of 107 cells/mL and frozen in CoolCell
containers (BioCision, LLC, Larkspur, CA, USA) at −80 °C for 24 h. The plasma were then
transferred to liquid nitrogen for storage.

6.3.4 Anthropometric measurements
In a quiet location, participants were seated for at least 10 min in a chair with their back
supported, feet on the floor, legs uncrossed, having an empty bladder, and the upper arm
supported at heart level (Pickering, Hall et al. 2005). Before all visits, participants were asked to
refrain from exercise or ingesting caffeine the day of the measurement. Blood pressure (BP) was
measured in the left arm using an Omron HEM-780 automatic BP monitor (Omron Healthcare,
Inc., Bannockburn, IL, 60015) three times with one minute intervals between measurements. If
the readings were within 5 mmHg, the readings were averaged and recorded as resting systolic
and diastolic blood pressure. If a difference of > 5 mmHg between readings occurred, the
measurements were repeated until three readings were within 5 mmHg. Body weight and height
were measured on a digital physician scale (Detecto 758C, Cardinal Scale Manufacturing
Company). Waist circumference was determined by placing a measuring tape evenly around a
bare abdomen at hipbone level.
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6.3.5 Plasma lipid analysis
As previously described, plasma lipid concentrations were determined enzymatically using
Cholesterol Reagent (Pointe Scientific, Canton, MI) and a L-Type TG M kit (Wako Chemical,
Richmond, VA) for TC and TG, respectively (Kim, Ku et al. 2013). High-density lipoprotein
cholesterol (HDL-C) was measured after precipitation of apolipoprotein B-containing lipoprotein
in plasma, and non-HDL-C was calculated by subtraction of HDL-C from TC. Precinorm L
(Roche, Indianapolis, IN) was used as a control. The Friedeman LDL formula was used to
determine LDL-C concentration (Equation 1).
Equation 1:

LDL-C = TC – HDL – TG/5

6.3.6 Analysis of inflammatory biomarkers
Inflammatory biomarkers were measured in plasma samples by ELISA. Plasma adiponectin
(eBioscience, San Diego, CA), interleukin-6 (IL-6) (eBioscience, San Diego, CA), interleukin-1β
(IL-1β) (eBioscience, San Diego, CA), MCP-1 (eBioscience, San Diego, CA), tumor necrosis
factors-α (TNF-α) (eBioscience, San Diego, CA), and C-reactive protein (CRP) (eBioscience,
San Diego, CA) were determined as described by the respective manufacturers’ protocols.

6.3.7 Analysis of biomarkers related to oxidative status
Biomarkers of oxidative stress and total antioxidant activity were measured in both plasma
and urine to investigate the antioxidant effects of aronia polyphenol supplementation. Assay kits
were used following manufacturers' instructions to measure plasma oxidized LDL by
immunoassay (MyBiosource, San Diego, CA), catalase activity (Cayman Chemical, Ann Arbor,
MI), glutathione peroxidase (GSH-PX) activity (Cayman Chemical, Ann Arbor, MI), and
superoxide dismutase (SOD) activity (Cayman Chemical, Ann Arbor, MI). Plasma total
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antioxidant capacity was measured using the 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic
acid) (ABTS) radical scavenging assay and expressed as mg vitamin C equivalent (VCE)/mL as
previously described (Wang, Yang et al.). Urinary 8-isoprostanes were also measured by
immunoassay (Cayman Chemical, Ann Arbor, MI) and the amount was normalized with urinary
creatinine.

6.3.8 Analysis of plasma biomarkers of vascular reactivity
Concentrations of cell adhesion molecules including inter-cellular adhesion molecule-1
(ICAM-1), vascular adhesion molecule-1 (VCAM-1), and P-selectin in serum were measured
using assay kits for Bio-Plex Magpix multiplex reader with xPotent software (Luminex, Austin,
TX).

6.3.9 Gene expression analysis by quantitative realtime PCR (qRT-PCR)
Cryopreserved PBMCs were thawed and slowly added to 15 mL of phosphate-buffered
saline (PBS), and then 0.25 mL of 1 mg/mL DNAse were added to prevent PBMC clumping.
Pelleted PBMCs were obtained by centrifugation at 300 ×g for 6 min. Total RNA was isolated
from pelleted PBMCs using TRIzol reagent (Invitrogen, Grand Island, NY, USA) and qRT-PCR
analysis of gene expression was conducted as previously described using the SYBR Green
procedure and CFX96 realtime PCR detection system (Bio-Rad, Hercules, CA) (Park,
Rasmussen et al. 2008, Rasmussen, Blobaum et al. 2008). Primer sequences were designed
according to GeneBank database using the Beacon Designer software (Premier Biosoft, Palo
Alto, CA) (Rasmussen, Blobaum et al. 2008). GAPDH was used as an internal control.
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6.3.10 Western blot analysis
Protein was extracted from pelleted PBMCs as previously described (Rasmussen, Blobaum
et al. 2008). Western blot analysis was performed using antibodies against 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) and -actin (Sigma, St. Louis, MO) as previously
described (Rasmussen, Blobaum et al. 2008). The blots were developed using a horseradish
peroxidase system (Pierce), and densitometry analysis was performed using a Chemidoc XRS+
(Bio-Rad) and Image Lab software (Bio-Rad). -Actin was used as a loading control.

6.3.11 Urinary creatinine analysis
The urine creatinine was measured by a urinary creatinine colorimetric assay (Cayman
Chemical, Ann Arbor, MI). Creatinine concentrations varied from 15.26 to 573.92 mg/dL in
urine samples.

6.3.12 Plasma and urinary polyphenol analysis
Polyphenols were isolated from plasma and urine by solid phase extraction (SPE) and
quantitated by UHPLC-MS as we previously described in Chapter 5. Briefly, plasma and urine
samples were applied to HyperSep C18 SPE cartridges (Thermo Scientific, Waltham, MS)
attached to a vacuum manifold. The eluate was collected with 0.5% formic acid in methanol
(v:v) and dried under nitrogen gas. Dried residue was reconstituted with methanol. UHPLC–MS
analysis was conducted using a Shimadzu Nexera UHPLC equipped with LCMS-2020 mass
spectrometer. Separate chromatographic methods were used to detect 3,4-dihydroxybenzoic acid,
3,4-dihydroxyphenylacetic acid, hippuric acid, and ferulic acid; 3-(4-hydroxyphenyl)propionic
acid; and cyanidin-3-O-glucoside, cyanidin-3-O-galactoside, cyanidin-3-O-arabinoside, and
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peonidin-3-O-galactoside. Limits of detection (LOD), limits of quantification (LOQ), and intraand inter-day variance have been listed in Chapter 5.

6.3.13 Statistics
Changes in plasma lipids and anthropometric markers after supplementation were logtransformed and analyzed by a repeated measures MANOVA model using JMP ® Pro 11 (SAS
Institute, Inc., Cary, NC). All other data were analyzed using SAS (9.4, SAS Institute, Inc., Cary,
NC). Baseline differences between the placebo and treatment groups were analyzed by two
sample t-test and chi square test. Group differences in biomarkers over time were analyzed by
repeated measures ANOVA and assuming 100% compliance. For these data, a univariate
approach was applied when the sphericity assumption was violated. A multivariate approach was
applied when the sphericity assumption was not violated (Austin). A log transformation was
applied when the normal assumption was violated. Principle component analysis and Pearson
correlation were used to measure the association of changes in urinary polyphenol and plasma
lipids. Data was expressed as mean ± standard error of mean.

6.4 Results
6.4.1 Participant characteristics
After informed consent, 56 participants were enrolled and randomized (26 men and 30
women) and 49 participants completed the study (Figure 6.1). The reasons for drop-out included
not responding to communication from study personnel (n = 2 placebo, and n = 3 supplement),
weight gain (n = 1 placebo), and headache (n = 1 placebo). Participant characteristics are listed
in Table 6.2. There were no significant differences between the two groups, other than the
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average years of smoking in the aronia group that was five years less than that of the placebo
group.

6.4.2 Anthropometric measurements
Participant waist circumferences were 85.57 ± 2.87 cm for the aronia group and 86.16 ±
4.86 cm for the placebo group at baseline (P = 0.9163) (Table 6.2). Over the course of the study
participant waist circumferences were reduced with the aronia and placebo groups having 1 and
5% lower waist circumference, respectively, at week 12 (P = 0.0075) (Table 6.4). At baseline,
systolic blood pressures were not different between groups, at 117 ± 3 and 121 ± 3 mmHg in the
aronia and placebo groups, respectively (P = 0.3643). However, the placebo group had lower
diastolic pressure than the aronia group at week 6 (74.8 ± 1.8 vs 80.2 ± 2.2 mmHg) (P = 0.0331)
which had persisted through week 12. The BMI of both groups were not different at baseline, but
the placebo group mean BMI decreased from 27.0 ± 0.9 to 26.8 ± 0.9 over the course of the
study (P = 0.0354).

6.4.3 Plasma lipids
Participants had borderline high TC at baseline with 220.11 ± 12.59 mg/dL for the aronia
group and 203.41 ± 7.25 mg/dL for the placebo group (P = 0.2037). Aronia polyphenol
consumption reduced TC by 8 % at 12 wks, compared to no significant change in the placebo
group (P = 0.0140) (Table 6.3). The mean LDL-C for each group was above optimal, with
175.42 ± 10.80 and 158.26 ± 6.07 mg/dL for the aronia and placebo group, respectively (P =
0.1289). The aronia group had 7 and 11% less LDL-C at both 6 and 12 wks from baseline, with
no significant changes to LDL-C in the placebo group (P = 0.0285). Participants had low TG
with 89.58 ± 9.08 mg/dL for the aronia group and 82.08 ± 7.62 mg/dL for the placebo group (P =
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0.4858), and low HDL with 26.77 ± 1.52 mg/dL for the aronia group and 28.75 ± 1.25 mg/dL for
the placebo group (P = 0.2715). Neither intervention significantly changed HDL-C or TG from
baseline values.

6.4.4 Expression of hepatic genes involved in lipid metabolism
LDL receptor (LDLR) and HMGR mRNA expression of PBMCs were not different
between the placebo and aronia groups at baseline or 12 wk (Table 6.5). However, aronia
supplement consumption reduced LDLR protein in PBMCs 56 % from baseline at 12 wk (P =
0.0036). In contrast, LDLR protein of PBMCs in the placebo group was unchanged from
baseline at 12 wk.

6.4.5 Other biomarkers relevant to CVD risk
Plasma cytokines (IL-6, IL-1β, and TNF-α), CRP, adiponectin, vascular adhesion
molecules (sICAM and sVCAM), chemokines (MCP-1), antioxidant enzyme activity (CAT,
GSH-Px, and SOD), and markers of lipid oxidation (urinary 8-isoprostanes and oxLDL) were
determined at baseline, 6, and 12 wk in both groups (Table 6.5). None of these biomarkers
significantly changed in either group at 6 and 12 wk.

6.4.6 Urinary and plasma polyphenols
Analysis of dietary records did not reveal differences of polyphenol intake between the
groups at any time point (Table A.6.1). Aronia polyphenols and their key intermediates were
determined in plasma and urine to evaluate the relative enrichment and metabolism of the
supplemental polyphenols in participants. The baseline level of peonidin-3-O-galactoside and
sum of anthocyanins in aronia group were 6.2 μg/mg creatine and 0.332 mg/mg creatine, 7-8
times higher than that in placebo group (P = 0.0461 and P = 0.0441) (Table 6.6). At 12 wk,
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protocatechuic acid, 3,4-dihydroxyphenylacetic acid, hippuric and ferulic acid were detected in
all individuals in both groups without differences at the baseline. However, at least 25% of
participants did not accumulate urinary 3-(4-hydroxyphenyl)propionic acid, cyanidin-3-Oglucoside, cyanidin-3-O-galactoside, cyanidin-3-O-arabinoside or peonidin-3-O-galactoside in
significant quantities, as all were below the LOD. At 12 wk, the change from baseline of total
urinary polyphenol excretion was not significantly different for either intervention. However, the
polyphenol profiles of the aronia and placebo group could be distinguished by canonical
discriminate analysis with 80% confidence (Figure A.6.1). At baseline and 12 wk, fasting
plasma polyphenols were lower than the LOD for most of the participants in both placebo and
aronia groups, except for hippuric acid (Table 6.7). The range of plasma polyphenol and
metabolite concentrations for the aronia group was similar to those of the placebo group.

6.4.7 Association of urinary polyphenols and lipids changes in aronia group
A multivariate approach was used to determine the association of urinary polyphenols to
changes in plasma lipids at 12 wk from baseline. In the aronia group, changes of urinary
polyphenol and its metabolites were associated with the changes of lipid in the plasma (Figure
6.2). Cohen’s standard was used to determine the strength of the correlation between the
difference of plasma lipids and urinary polyphenols at 12 wk from baseline (Δ), where
correlation coefficients between 0.10 and 0.29, 0.30 and 0.49, and greater than 0.50 represented
small, medium and large associations, respectively. Peonidin-3-O-galactoside Δ had a medium
inverse association with plasma TC Δ and LDL-C Δ (P-value = 0.0645 and P-value = 0.1104,
respectively). Cyanidin-3-O-galactoside Δ and 3-(4-hydroxyphenyl)propionic acid Δ both had
small inverse associations with plasma TC Δ (P-value = 0.1912 and P-value =0.4993,
respectively) and LDL-C Δ (P-value = 0.2586 and P-value = 0.4176, respectively). A strong
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positive association was observed between 3,4-dihydroxyphenylacetic acid Δ and plasma HDL-C
Δ. A medium positive association was observed between protocatechuic acid Δ and plasma
HDL-C Δ. Hippuric acid Δ and ferulic acid Δ also had small positive associations with plasma
HDL-C Δ. Cyanidin-3-O-glucoside Δ was strongly inversely associated with plasma TG Δ.
Small inverse associations were also observed between plasma TG Δ and urinary polyphenol
metabolites including ferulic acid Δ, cyanidin-3-O-galactoside Δ, cyanidin-3-O-arabinoside Δ,
and peonidin-3-O-galactoside Δ. In contrast, the placebo group did not have medium or large
associations between urinary polyphenols Δ and plasma lipids Δ.

6.4.8 Analysis by respondent to total cholesterol
To further examine participant response to aronia consumption, we also classified
participants as responders or non-responders to the intervention. An aronia responder was
defined as a participant who lost more than 10 mg TC/dL from baseline at 12 wk, and an aronia
non-responder was a participant who lost less than 10 mg TC/dL. Aronia responders (n = 14) had
higher baseline TC at baseline (248.09 ± 17.06 vs 188.96 ± 13.12 mg/dL, P = 0.0117) as well as
a slightly higher urinary peonidin-3-O-galactoside Δ (0.01577 ± 0.00890 vs -0.00400 ± 0.00222,
P = 0.0998). Aronia responders had a medium association of peonidin-3-O-galactoside Δ and
plasma TC Δ, whereas these were not associated in non-responders (Figure 6.3). In addition,
responders consuming aronia extract had distinct polyphenol metabolite profiles from nonresponder. Particularly, responders had more closely correlated peonidin-3-O-galactoside Δ and
cyandin-3-O-galactoside Δ than non-responders (Figure 6.4).
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6.5 Discussion
In the present study, consumption of 500 mg of an anthocyanin-rich aronia berry extract
daily for 12 weeks did not change plasma biomarkers of chronic inflammation in former smokers
(Table 6.5). This contrasts prior studies that have characterized the mechanism by which
anthocyanins may inhibit chronic inflammation. Increased anthocyanin consumption or direct
application of anthocyanins to cells reduces NF-κB activation, thereby inhibiting the expression
of pro-inflammatory chemokines and cytokines (Blanco-Colio, Valderrama et al. 2000, Kim,
Tsoy et al. 2006, Karlsen, Retterstøl et al. 2007, Xia, Ling et al. 2007, Martin, Taheri et al.
2014). Anthocyanins can also inhibit the pathogenesis of atherosclerosis and plaque formation by
reducing IL-6, IL-8, MCP-1 and ICAM-1 induced by TNF-α and CD40 in human endothelial
cells (Atalay, Gordillo et al. 2003, García-Alonso, Rimbach et al. 2004, Xia, Ling et al. 2007).
Anthocyanin pretreatment of cultured human umbilical vein endothelial cells inhibited VCAM-1,
nuclear GATA-4, nuclear GATA-6 and nuclear interferon regulatory transcription factor-1 (IRF1) expression in human, which suggests a role of the Jak/STAT pathway in preventing monocyte
adhesion and subsequent inflammation (Nizamutdinova, Kim et al. 2009). Large doses of
anthocyanin-rich foods or extracts reduce biomarkers of inflammation in healthy individuals.
Daily consumption of 280 g cherries reduced plasma CRP after 4 weeks of intervention (Kelley,
Rasooly et al. 2006). Additionally, a single 12 g dose of an anthocyanin-rich extract from red
wine grape decreased plasma level of MCP-1 24 h after intake (Garcia-Alonso, Minihane et al.
2009).
Aronia berry consumption has an inconsistent anti-inflammatory effect among participants
with increased CVD risk. Participants with metabolic syndrome that consumed a 300 mg dose of
aronia berry extract per day did not have significant changes in CRP from a baseline of 2.62 ±
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2.5 mg/dL after 8 weeks (Broncel, Koziróg et al. 2010). However, participants who had suffered
myocardial infraction and consumed 255 mg of aronia berry extract and statins daily for 6 weeks,
had 23% lower CRP from a baseline of 4.48 ± 2.56 mg/L (Naruszewicz, Łaniewska et al. 2007).
In the same study, aronia consumption reduced MCP-1 by 23% from a baseline of 305.9 ± 87.5
pg/mL (Naruszewicz, Łaniewska et al. 2007). The former smokers in the present study had
baseline levels of CRP and MCP-1 that were at least 70% lower than the population of
participants that suffered a myocardial infarction (7). Thus, aronia consumption may only have
an anti-inflammatory effect in populations with relatively higher levels of chronic inflammation.
Aronia berry extract consumption did not modulate markers of antioxidant function and
oxidative stress in former smokers. However, over 8 wk, aronia berry extract consumption
modulates the serum antioxidant capacity of participants with metabolic syndrome by reducing
erythrocyte CAT activity and increasing erythrocyte SOD and GSH-Px activities (Broncel,
Koziróg et al. 2010). Blueberry anthocyanins (1.2 g) consumed with high-fat meals for 7 days
improves serum antioxidant capacity (oxygen radical absorbance capacity) of healthy male
individuals compared with placebo consumption, with the change positively correlated to serum
anthocyanin content (Mazza, Kay et al. 2002). Anthocyanins may directly protect membrane
fatty acids of endothelial cells from oxidation and DNA cleavage induced by increased
inflammation (Youdim, McDonald et al. 2002, Acquaviva, Russo et al. 2003). The 500 mg dose
of the anthocyanin-rich aronia extract used in the present study did not appear to sufficiently
enrich plasma to exert antioxidant activity, as peak concentrations were 0.004 to 3.488 µg/mL. In
contrast, a lower dose of aronia berry extract reduces plasma ox-LDL and urinary 8-isoprostanes
in participants that suffered from myocardial infarction (Naruszewicz, Łaniewska et al. 2007).
The ox-LDL and 8-isoprostanes reported by Naruszewicz, et al (Naruszewicz, Łaniewska et al.
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2007) are not comparable to the present study due to significant differences in analytical
methods. However, when compared to a report using similar methods, urinary isoprostanes of
former smokers in the present study was 3-fold lower than that of participants with coronary
artery disease (Kim, Hyun et al. 2008, Noriega, Pennanen et al. 2009). Former smokers in the
present study had less oxidative stress and more favorable plasma lipid profiles (lower plasma
LDL-C, TG, and TC and higher HDL-C) than participants in other trials where aronia intake
improved antioxidant function (Naruszewicz, Łaniewska et al. 2007, Broncel, Koziróg et al.
2010).
Consumption of anthocyanin-rich foods also lowered TC, LDL-C, and TG in previous
studies (Qin, Xia et al. 2009, Basu, Du et al. 2010, Broncel, Koziróg et al. 2010, Basu, Betts et
al. 2011). Low CVD risk is defined as TC less than 200 mg/dL, LDL-C between 100 to 120
mg/dL, and HDL-C more than 40 mg/dL (Services). The former smokers in the present study
had increased risk of CVD due to greater than optimal levels of TC and LDL-C. Aronia extract
consumption lowered plasma LDL-C level at 6 and 12 wks, and TC at 12 wk. Responders to the
aronia intervention had higher baseline TC than non-responders, suggesting that individuals with
hypercholesterolemia may benefit the most from increased polyphenol consumption. Our prior
pre-clinical work suggests that aronia berry polyphenols reduce TC through mechanisms
independent of the modulation of hepatic mRNA expression of lipid-metabolizing genes, and
possibly by intestinal mechanism of cholesterol efflux (Kim, Ku et al. 2013, Martin, Taheri et al.
2014). In the present study, LDLR protein of PBMCs was reduced by aronia extract consumption
without a corresponding change of LDLR mRNA. Post-translational regulation of LDLR protein
by proprotein convertase subtilisin/kexin type 9 (PCSK9) might explain this observation (Park,
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Moon et al. 2004), but further studies are needed to identify how aronia polyphenols modulate
LDLR expression.
Aronia berry consumption reduced blood pressure, waist circumference, and BMI of
participant with metabolic syndrome or abdominal obesity (Kardum, Petrovi et al. 2014, Sikora,
Broncel et al. 2014). These parameters were not affected by aronia consumption in the present
study. The mean blood pressure of the aronia group met the criteria of prehypertension (120139/80-89 mm Hg) (Association). However, in trials where aronia reduced blood pressure,
participants had higher blood pressure (127.6 ± 16.9/83.5 ± 9.9 to 136.8 ± 10.9/86.8 ± 16.0
mmHg), larger waist circumference (95.0 ± 9.4 cm to 104.8 ± 10.1 cm) and greater BMI (30.9 ±
3.7 kg/m2 to 36.1 ± 4.4 kg/m2) (Kardum, Petrovi et al. 2014, Sikora, Broncel et al. 2014). It was
suggested that aronia juice and polyphenols could reduce the blood pressure of spontaneously
hypertensive rat model (Hellström, Shikov et al. 2010). The observed effect might result from of
the angiotensin converting enzyme (ACE)-inhibitory activity of cyanidin-3-O-glucoside,
proanthocyanidin oligomers and phenolic metabolites of aronia polyphenols (Ottaviani, ActisGoretta et al. 2006, Hellström, Shikov et al. 2010, Hidalgo, Martin-Santamaria et al. 2012).
Under well-controlled dietary conditions, the dose of aronia polyphenols consumed in the
present study could increase transient accumulation and excretion of polyphenols. However, the
same dose did not significantly enrich aronia polyphenols and microbial metabolites in these
biofluids after 12 wk consumption. Given the low abundance in plasma, urinary excretion of
polyphenols and metabolites are a better indicator of polyphenol bioavailability than plasma
concentrations (Tresserra-Rimbau, Rimm et al. 2014).
Although polyphenol-rich aronia berries may have atheroprotective effects, compounds or
metabolites may be associated with these effects are unknown. Within the aronia group, greater
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reductions of plasma TC and LDL-C were associated with increases in urinary cyanidin-3-Ogalactoside, peonidin-3-O-galactoside, and 3-(4-hydroxyphenyl)propionic acid. Thus, aronia
polyphenol metabolites peonidin-3-O-galactoside and 3-(4-hydroxyphenyl)propionic acid and
parent compounds (cyanidin-3-O-galactoside) were associated with the cholesterol-lowering
mechanism of aronia berry. A precursor of 3,4-dihydroxyphenylacetic acid and ferulic acid, 3-(4hydroxyphenyl)propionic acid can also be derived from microbial metabolism of aronia
anthocyanins, chlorogenic acid, or proanthocyanidins. 3-(4-Hydroxyphenyl)propionic acid
catabolites have the potential to reduce plasma TC and LDL-C levels in rodents (Lee, Park et al.
2007). Thus, 3-(4-hydroxyphenyl)propionic acid might be a functional precursor to cholesterolmodulating compounds. A large inverse association was found between cyanidin-3-O-glucoside
and plasma TG levels in the aronia group, which was also observed in another study that
suggested cyanidin-3-O-glucoside could improve TG metabolism by the activation of lipoprotein
lipase (LPL) activity in plasma and skeletal muscle but suppression of LPL activity in visceral
adipose (Wei, Wang et al. 2011). Comparative data on anthocyanin structure-function activity
and mechanisms of lipid metabolism are lacking. However, even minor structural differences can
alter anthocyanin anti-inflammatory activity in vitro (Martin, Taheri et al. 2014).
There were several limitations of this study. First, participants did not synchronize daily
consumption of the intervention. The interindividual variation of fasting urinary and plasma
polyphenol concentrations could result from the time of consumption and do not solely reflect
bioavailability. Furthermore, participants did not strictly adhere to low-polyphenol diets, as
anthocyanins were detected at the baseline. Therefore, consumption of other polyphenolcontaining foods might significantly affect polyphenol excretion.
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6.6 Conclusions
Consumption of 500 mg aronia berry extract for 12 wks improved biomarkers of CVD risk
in former smokers by reducing LDL-C by 10% and TC by 8%. However, this intervention did
not change CRP, 8-isoprostane, and other biomarkers of chronic inflammation and oxidative
stress. Regular consumption of aronia extract in high dose may be impractical, and given the
apparently lower baseline markers of inflammatory and oxidative stress, have limited benefits.
Increased excretion of peonidin-3-O-galactoside, and to a lesser extent, cyanidin-3-O-galactoside
and 3-(4-hydroxyphenyl)propionic acid were most associated with reductions in TC and LDL-C,
which suggested host and microbial metabolism have a role in the cholesterol-lowering
mechanism of aronia berry extract consumption. These specific associations could arise from
structure-function differences between polyphenols and metabolites and may begin to explain
why polyphenol-interventions are more effective in some individuals with metabolic pathways
favoring production of these compounds.
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6.7 Chapter 6 Tables and Figures
Table 6.1 Non-polyphenol contents analysis in aronia berry supplement
Assay

Aronia berry
Supplement (mg/500
mg)

Total sugar

7.5

Total Sugar Alcohol

4.1

Vitamin C

< 0.005

Minerals

< 0.4

Vitamin B

< 0.02

Organic Acids

< 4.9

Sterol

< 0.005
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Table 6.2 Baseline characteristics of study population
Measurement

Placebo

Aronia

P Value

(n=24)

(n=25)

Age

37.37 ± 3.02

32.6 ± 2.57

0.2337

Gender (%Male)

46%

52%

0.6660

Average years of Smoking

14.85 ± 2.43

8.96 ± 1.34

0.0404

3-5 Cigarettes/d

2

4

0.5447

6-10 Cigarettes/d

4

7

11-15 Cigarettes/d

4

4

16-20 Cigarettes/d

11

6

>20 Cigarettes/d

3

4

Height (cm)

172.97 ± 1.88

171.44 ± 1.66

0.5447

Weight (kg)

81.64 ± 3.47

77.18 ± 4.15

0.4151

BMI (kg/m2)

27.04 ± 0.93

25.64 ± 1.15

0.3429

Waist Circumference (cm)

85.57 ± 2.87

86.16 ± 4.86

0.9163

Systole

121.00 ± 2.95

116.96 ± 3.29

0.3643

Diastole

76.00 ± 2.12

75.28 ± 2.41

0.8224

Total Cholesterol (mg/dL)

203.41 ± 7.25

220.11 ± 12.59

0.2037

HDL-C (mg/dL)

28.75 ± 1.25

26.77 ± 1.52

0.2715

Triglycerides (mg/dL)

82.08 ± 7.62

89.58 ± 9.08

0.4858

LDL-C (mg/dL)

158.26 ± 6.07

175.42 ± 10.80

0.1289

Average Num. of Cigarettes/d

Blood Pressure (mmHg)
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TC/HDL Ratio

7.27 ± 0.31

8.54 ± 0.53

Data was expressed as mean ± standard error of mean and analyzed by t-test.
*P < 0.05.
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0.0284*

Table 6.3 Changes in plasma lipids in former smokers after daily consumption of 500 mg aronia
extract or a placebo

Biomarker

Total

Δ baseline (mg/dL)

P-value RM-MANOVA

Aronia (n =

Placebo (n =

Group

25)

24)

6

1.4 ± 2.5

-0.1 ± 4.6

12

-17.9 ± 7.6

-1.3 ± 6.4

6

-12.6 ± 5.4

0.9 ± 4.2

12

-18.5 ± 8.0

-0.4 ± 5.9

6

0.2 ± 0.8

-0.9 ±1.0

12

0.2 ± 0.8

-0.7 ± 1.4

6

1.0 ± 5.9

-0.6 ± 2.7

12

2.0 ± 8.5

-1.0 ± 5.9

Week

Time

Time*Gro
up

0.2300

0.0016*

0.0140*

0.0285*

0.1046

0.4547

0.4181

0.8881

0.9153

0.7534

0.2326

0.8699

Cholesterol

LDL-C

HDL-C

TG

Data was expressed as mean ± standard error of mean, transformed and analyzed by repeated
measures MANOVA.
*P < 0.05.
TG, triglycerides
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Table 6.4 Changes in anthropometric measures following of consumption of placebo or 500 mg aronia extract/d for 12 wk
Marker

Week

Δ baseline
Aronia (n =

P-value RM-MANOVA
Placebo (n = 24)

Group

Time

25)

p
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Weight

6

0.5 ± 0.3

0.7 ± 0.6

(kg)

12

0.5 ± 0.5

-0.1 ± 0.6

BMI

6

0.3 ± 0.4

0.2 ± 0.2

(kg/m2)

12

0.5 ± 0.4

-0.2 ± 0.3

Waist

6

0.0 ± 1.2

1.5 ± 1.1

0.7364

0.0775

0.1842

0.3800

0.0354*

0.0464*

0.8832

0.0619
0.0075*

circumference
(cm)

Time*Grou

12

-0.8 ± 1.0

-1.4 ± 0.7

Systole

6

2.8 ± 1.7

-0.8 ± 1.5

(mmHg)

12

1.2 ± 2.4

0.2 ± 2.9

Diastole

6

5.0 ± 1.3

-1.2 ± 2.4

(mmHg)

12

2.0 ± 1.5

-1.1 ± 1.7

Blood pressure
0.3606

0.5179

0.5002

0.0331*

0.6855

0.1661

Data were expressed as mean ± standard error of mean, transformed and analyzed by repeated measures MANOVA. *P-value < 0.05.

Table 6.5 Changes in peripheral blood mononuclear cell gene and protein expression, and biomarkers of inflammation and antioxidant
function following of consumption of placebo or 500 mg aronia extract per day for 12 wk
Placebo (n=24)

HMGR

Aronia (n=25)

P

Baseline

6 wk

12 wk

Baseline

6 wk

12 wk

value

0.90 ± 0.06

ND

1.16 ± 0.28

0.91 ± 0.06

ND

0.79 ± 0.12

0.3781

0.90 ± 0.07

ND

0.93 ± 0.22

0.84 ± 0.07

ND

0.88 ± 0.26

0.9666

1.71 ± 0.33

ND

2.47 ± 0.80

1.45 ± 0.58

ND

0.64 ± 0.07

0.0036

mRNA (fold
change relate
to baseline)
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LDLR mRNA
(fold change
relate to
baseline)
LDLR protein
(fold change
relate to
baseline)

*

Adiponectin

13.21 ± 1.92

14.15 ± 2.01

12.45 ± 1.64

12.75 ± 1.54

13.82 ± 1.68

13.24 ± 1.47

0.9994

IL-1β (pg/mL) 9.33 ± 2.43

9.50 ± 2.73

10.08 ± 3.04

16.20 ± 8.55

17.03 ± 9.67

14.74 ± 7.38

0.4438

IL-6 (pg/mL)

1.94 ± 0.34

1.87 ± 0.38

1.76 ± 0.29

4.68 ± 1.34

5.16 ± 1.54

5.34 ± 1.52

0.0782

MCP-1

97.01 ± 5.78

96.41 ± 5.24

90.93 ± 5.32

132.76 ± 31.15

166.85 ± 42.74

140.99 ± 26.78

0.0679

4.36 ± 1.83

4.70 ± 1.89

4.86 ± 1.85

5.90 ± 1.63

6.44 ± 1.83

6.10 ± 1.72

0.5977

CRP (pg/mL)

2.54 ± 0.60

2.18 ± 0.42

2.24 ± 0.38

2.01 ± 0.34

2.32 ± 0.39

2.29 ± 0.49

0.7222

sICAM

97.06 ± 7.19

97.63 ± 7.16

100.12 ± 7.70

96.59 ± 5.40

99.42 ± 5.68

97.52 ± 5.82

0.4613

585.43 ± 22.55

603.93 ± 22.86

604.11 ± 25.53

601.09 ± 31.04

621.97 ± 30.91

599.35 ± 27.24

0.5902

129.95 ± 13.39

110.66 ± 10.92

130.82 ± 11.41

123.76 ± 11.77

126.60 ± 11.75

144.61 ± 16.75

0.1321

209.55 ± 3.70

214.26 ± 3.44

209.16 ± 3.97

207.66 ± 3.24

211.43 ± 3.42

206.57 ± 4.41

0.5701

(µg/mL)

(pg/mL)
TNF-α
(pg/mL)
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(ng/mL)
sVCAM
(ng/mL)
P-selectin
(ng/mL)
OxLDL

(ng/mL)
TAC (µg

210.46 ± 4.51

215.70 ± 4.00

214.49 3.28

221.20 ± 4.51

225.87 ± 4.66

224.31 ± 4.90

0.0775

41.71 ± 1.36

36.53 ± 1.17

41.65 ± 2.28

41.07 ± 2.13

38.68 ± 1.52

41.20 ± 1.84

0.2552

2554. 35 ±

2561.51 ±

2468.65 ±

2554.37 ±

2497.00 ±

2654.65 ±

0.8323

133.91

110.19

143.63

163.72

186.52

VCE/mL)
CAT
(nmol/min/mL
)
GSH-Px

(nmol/min/mL 139.90
165

)
SOD (U/mL)

1186.69 ± 54.27

1192.81 ± 51.87 1158.84 ± 58.25 1181.85 ± 40.92 1160.11 ± 43.85 1160.19 ± 39.76 0.8479

Isoprostane

71.01 ± 8.09

ND

81.59 ± 7.81

58.60 ± 7.00

ND

68.42 ± 8.98

(ng/mmol
creatinine)
Data was expressed as mean ± standard error of mean, transformed and analyzed by repeated measures ANOVA.
*

P-value < 0.05.

ND: Not determined.

0.1715

Abbreviations: HMGR: 3-hydroxy-3-methyl-glutaryl-CoA reductase; IL1β, Interleukin 1 beta; IL6, Interleukin 6; MCP1, monocyte
chemoattractant protein 1; LDLR: Low-Density Lipoprotein (LDL) Receptor; OxLDL, oxidized low density lipoprotein; TAC, total
antioxidant capacity; TNF-α, tumor necrosis factor alpha; CAT, catalase; CRP, C-reactive protein; GSH-Px, glutathione peroxidase;
sICAM, soluble intercellular adhesion molecule 1; sVCAM, soluble vascular cell adhesion molecule1; SOD, superoxide dismutase.

166

Table 6.6 Overnight urinary polyphenols and metabolites at baseline and 12 weeks following daily consumption of 500 mg aronia
berry extract or placebo.
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Placebo (mg/mg creatinine)

Supplement (mg/mg creatinine)

Baseline

12 wk

Baseline

12 wk

Polyphenol/Metabolite

mean

Q1

Q2

Q3

mean

Q1

Q2

Q3

protocatechuic acid

1.89 ± 0.41

0.94

1.38

2.08

1.41 ± 0.20

0.64

1.20

2.03

3,4-dihydroxyphenylacetic acid

4.85 ± 0.92

2.36

5.04

7.45

4.93 ± 0.81

2.18

4.56

9.09

hippuric acid

161 ± 22

104

133

234

208 ± 40

62

138

292

ferulic acid

5.81 ± 4.57

0.242

0.684

1.20

1.71 ± 0.48

0.233

0.709

3.571

3-(4-hydroxyphenyl)propionic

5.56 ± 1.28

ND**

3.91

9.95

4.93 ± 0.14

ND

3.36

9.68

cyanidin-3-O-glucoside

0.036 ± 0.017

ND

ND

0.055

0.170 ± 0.094

ND

0.00907

0.1993

cyanidin-3-O-galactoside

0.004 ± 0.003

ND

ND

0.014

0.0175 ± 0.0081

ND

0.00466

0.0341

cyanidin-3-O-arabinoside

0.0090 ± 0.0057

ND

ND

0.011

0.138 ± 0.073

ND

ND

0.053

peonidin-3-O-galactoside

0.000796 ±

ND

ND

ND

0.006159 ± 0.002571*

acid

0.000547

0.00075
ND

6

0.0106

Sum anthocyanins

0.051 ± 0.022

ND

0.014

0.091

0.332 ± 0.136*

Data are mean ± standard error of mean of n = 24 placebo, n = 25 aronia extract with non-missing value.
*P < 0.05 by 2-tailed paired t-test vs 4 wk control group.
**ND: less than LOD and not detectable, assumed to be 0 for calculation of mean

0.028

0.134

0.442
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Table 6.7 Fasting plasma polyphenols and metabolites at baseline, 6 weeks, and 12 weeks following daily consumption of 500 mg
aronia berry extract or placebo.
Placebo (mg/mL plasma)
Baseline
Polyphenol/Metabolite

6 wk

Supplement (mg/mL plasma)
12 wk

Baseline

6 wk

12 wk

range (number of detections lower than the LOD)
0.0017-0.0042

0.0010-0.0016

0.0015-0.0053

0.0024

0.0016-0.0038

0.0028-0.0091

(22)

(22)

(18)

(24)

(21)

(22)

0.0571

0.0540

0.0407

0.0191

0.0156-0.0335

-

(23)

(23)

(23)

(23)

(23)

(25)

0.0968-2.0232

0.0643-2.2765

0.0319-2.3277

0.0362-1.3358

0.0694-3.0580

0.0636-1.2587

(0)

(0)

(0)

(0)

(0)

(0)

0.0028-0.0190

0.0025-0.0477

0.0024-0.0300

0.0039-0.1368

0.0035-0.0372

0.0030-0.0224

ferulic acid

(8)

(7)

(8)

(13)

(14)

(15)

3-(4-hydroxyphenyl)propionic

0.1237-0.1806

0.2107-0.2536

0.1782-0.2059

0.1468-0.1581

0.1347-0.2470

0.2311

acid

(20)

(22)

(21)

(23)

(22)

(24)

cyanidin-3-O-glucoside

-

-

-

-

-

-

protocatechuic acid
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3,4-dihydroxyphenylacetic acid

hippuric acid

cyanidin-3-O-galactoside

cyanidin-3-O-arabinoside

peonidin-3-O-galactoside
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Sum anthocyanins

(24)

(24)

(24)

(25)

(25)

(24)

-

-

0.0095-0.0153

0.0025-0.0316

0.0002-0.0065

-

(24)

(24)

(22)

(22)

(23)

(24)

-

-

-

-

0.0069

-

(24)

(24)

(24)

(25)

(24)

(24)

-

0.0001-0.0009

-

0.0005

0.0003

-

(24)

(21)

(24)

(24)

(24)

(24)

-

0.0001-0.0009

0.0095-0.0153

0.0005-0.0316

0.0002-0.0009

-

(24)

(21)

(22)

(21)

(22)

(24)

Enrollment

Assessed for eligibility (n=68)

Excluded (n=12)
¨ Not meeting inclusion criteria (n=12)
¨ Declined to participate (n=0)
¨ Other reasons (n=0)

Randomized (n=56)

Allocation
Allocated to placebo (n= 28)
¨ Received allocated intervention (n=28)
¨ Did not receive allocated intervention (Other
reasons) (n=0)

Allocated to supplement (n=28)
¨ Received allocated intervention (n=28)
¨ Did not receive allocated intervention (Other
reasons) (n=0)

Follow-Up
Lost to follow-up (no contact) (n=2)
Discontinued intervention (negative effect) (n=2)

Lost to follow-up (no contact) (n=3)
Discontinued intervention (Other reasons) (n=0)

Analysis
Analysed (n=24)
¨ Excluded from analysis (Other reasons) (n=0)

Analysed (n=25)
¨ Excluded from analysis (Other reasons) (n=0)

Figure 6.1 Flowchart of enrollment.
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A

1.0

DHPA
Cy3Glu

Second Component (18.4%)

0.5

PCA
HA

LDL-C

Cy3A

TC

HDL-C
Cy3Gal

0.0

Peo3Gal
FA

TG

-0.5

-1.0
-1.0

HPPA

-0.5

0.0

0.5

1.0

First Component (23.5%)

B
Peo3Gal
Cy3Gal
HPPA
FA
DHPA
Cy3A
PCA
HA
Cy3Glu

TC
-0.3833
-0.2763
-0.1449
-0.0880
-0.0366
0.0307
0.0358
0.0705
0.2750

LDL-C
-0.3342
-0.2400
-0.1734
-0.0776
-0.0753
0.0711
0.0103
0.0471
0.3750

HDL-C
-0.0889
0.0321
0.0025
0.1781
0.5398
0.0480
0.4043
0.1371
0.0671

TG
-0.1144
-0.1318
0.1613
-0.1145
-0.0620
-0.2185
-0.0753
0.0324
-0.5549

Figure 6.2 Principle component analysis correlation of urinary polyphenol and lipid changes A)
loading plot and B) correlation coefficients of participants in the aronia extract supplemented
group.
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A

TC

1.0

LDL-C

HDL-C

Second Component (17.8%)

0.5

Cy3Glu
Peo3Gal

0.0

HPPA

Cy3A

PCA
DHPA

Cy3Gal

HA

TG

FA

-0.5

-1.0
-1.0

-0.5

0.0

0.5

1.0

First Component (27.7%)

B
Cy3Glu
FA
HA
Peo3Gal
HPPA
Cy3Gal
Cy3A
PCA
DHPA

TC
-0.0720
-0.0437
0.0095
0.0690
0.0750
0.1416
0.1652
0.1668
0.1744

LDL-C
-0.07220
-0.03260
0.09890
0.09020
0.09650
0.16180
0.12180
0.12850
0.16530

HDL-C
0.24130
0.13000
-0.06890
-0.10710
-0.11380
-0.11960
0.15010
0.34560
0.22280

TG
-0.3078
-0.2231
-0.3609
0.0477
0.0562
0.0975
0.1131
-0.1370
0.1369

Figure 6.3 Principle component analysis correlation of urinary polyphenol and lipid changes A)
loading plot and B) correlation coefficients of participants in the placebo group.
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A

1.0

3-(4-hydroxyphenyl)propionic acid
cya-3-glu

Second Component (22.5%)

0.5

peo-3-gala
cya-3-gala
cya-3-ara
ferulic acid

0.0

hippuric acid
-0.5

3,4-dihydroxyphenylacetic acid
protocatechuic acid

-1.0
-1.0

-0.5

0.0

0.5

1.0

First Component (42.7%)

B

1.0

cya-3-ara

3,4-dihydroxyphenylacetic acid
hippuric acid

3-(4-hydroxyphenyl)propionic acid

Second Component (21.3%)

0.5

cya-3-gala
protocatechuic acid
cya-3-glu

0.0

ferulic acid

-0.5

peo-3-gala

-1.0
-1.0

-0.5

0.0

0.5

1.0

First Component (26.8%)

Figure 6.4 Principle component analysis of urinary polyphenol change in aronia supplement
group A) responder and B) non-responder.
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The bioefficacy of polyphenols is often assessed by in vitro cell models. In these studies,
cells are treated with either polyphenol aglycones or polyphenol-rich extracts derived from plants
and foods. However, after consumption, human plasma and tissues are not exposed to these
forms of polyphenols. Table 7.1 indicates the potential metabolic fates of polyphenols in
humans. Based on human studies, only phenolic acids and flavonoids are present as parent
compounds in human fluids in significant quantities after consumption. Polyphenols mainly exist
as metabolites in the human body after consumption (Shahrzad and Bitsch 1998, Shahrzad,
Aoyagi et al. 2001, Holt, Lazarus et al. 2002, Rechner, Kuhnle et al. 2002, Scalbert, Morand et
al. 2002, Setchell, Brown et al. 2002, Olthof, Hollman et al. 2003, Rios, Gonthier et al. 2003,
Sano, Yamakoshi et al. 2003, Talavéra, Felgines et al. 2003, Walle, Hsieh et al. 2004, Seeram,
Henning et al. 2006, Fernandes, de Freitas et al. 2012, Czank, Cassidy et al. 2013). Thus, the
overall hypothesis for this study was that polyphenol metabolites contribute more to bioactivity
than their dietary polyphenol parent compounds. The rationale for this hypothesis is that 1) few
dietary polyphenols are absorbed intact; 2) for those that are absorbed intact, the rate of first-pass
and microbial metabolism leads to a much larger pool of metabolites than parent polyphenols; 3)
chronic polyphenol consumption will reduce biomarkers of chronic disease and polyphenol
metabolites would be most closely associated with efficacy.

Table 7.1 Metabolic fates of polyphenols (Shahrzad and Bitsch 1998, Shahrzad, Aoyagi et al.
2001, Holt, Lazarus et al. 2002, Setchell, Brown et al. 2002, Bowey, Adlercreutz et al. 2003, Lu,
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Meng et al. 2003, Olthof, Hollman et al. 2003, Rios, Gonthier et al. 2003, Sano, Yamakoshi et al.
2003, Walle, Hsieh et al. 2004, Seeram, Henning et al. 2006, Czank, Cassidy et al. 2013).

Classes

Location

Metabolites

Phenolic acids

Small intestine

NE1

Colon

parental compounds, phenolic acids

Liver

parental compounds, phenolic acids

Small intestine

parental compounds, flavonoid glucuronide conjugates,

Flavonoids

flavonoid sulfate conjugates, flavonoid methyl conjugates
Colon

flavonoid aglycones, phenolic acids

Liver

parental compounds, flavonoid glucuronide conjugates,
flavonoid sulfate conjugates, flavonoid methyl conjugates

Stilbenes

Lignans

Hydrolysable tannins

Small intestine

stilbene glucuronide conjugates, stilbene sulfate conjugates

Colon

stilbene reductive products

Liver

stilbene glucuronide conjugates, stilbene sulfate conjugates

Small intestine

lignan glucuronide conjugates

Colon

lignan reductive products

Liver

lignan glucuronide conjugates

Small intestine

NE

Colon

tannic acid, hydrolysable tannin reductive products

Liver

tannic acid, tannic acid methyl conjugates, tannic acid
glucuronide conjugates

Condensed tannins

1

Small intestine

PAC dimers

Colon

PAC dimers, phenolic acids

Liver

NE

NE: No evidence
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In order to develop a more accurate assessment of the potential pool of dietary metabolized
polyphenols, we characterized tannins and stilbenes in almond (Prunus dulcis). Almonds
contribute to dietary polyphenol intake, and are ranked as one of the top 40 richest food sources
of polyphenols (Perez-Jimenez, Neveu, Vos, & Scalbert, 2010). A prior study identified more
almond flavonoids and phenolic acids than reported in prior studies (Bolling, Chen et al. 2011).
This study demonstrated the need to more thoroughly characterize specific polyphenol classes in
almonds and other foods. Accurate compositional data are needed to understand polyphenol
bioactivity and metabolism. Almond phenolic acids and flavonoids have been well-characterized
(Table 7.2) (Milbury, Chen et al. 2006, Bolling, Dolnikowski et al. 2010). Eighteen flavonoids
and two phenolic acids, a total of 25.04 mg/100 mg, were reported, which were catechin,
epicatechin,

isorhamnetin,

isorhamnetin-3-O-rutinoside,

isorhamnetin-3-O-glucoside,

isorhamnetin-3-O-galactoside, quercetin, quercetin-3-O-galactoside, quercetin-3-O-rutinoside,
quercetin-3-O-glucoside, kaempferol, kaempferol-3-O-rutinoside, kaempferol-3-O-galactoside,
kaempferol-3-O-glucoside, dihydroxykaempferol, eriodictyol, naringenin, naringenin-7-Oglucoside, procatechuic acid, and vanillic acid. These two polyphenol classes would be expected
to contribute a minor portion of parent compounds and a major portion of phase II metabolites
and microbial catabolites in humans after consumption (Table 7.1). Almond also has lignan
polyphenols (Table 7.2) (Smeds, Eklund et al. 2007). However, lignans are extensively
metabolized, and parent compounds are not observed after consumption (Table 7.1). Although,
proanthocyanidins (PACs) in almond has also been determined (Gu, Kelm et al. 2004), almond
PAC content may be underestimated because solvent extraction does not completely liberate
polyphenols covalently bound to cell walls (Arranz, Saura-Calixto et al. 2009). Furthermore,
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almond stilbenes and hydrolysable tannins have not been determined previously, and may
significantly contribute to almond polyphenol content.
The studies undertaken in Chapters 3 and 4 expanded the knowledge of the polyphenol
content of almonds. In Chapter 3, bound PACs were recovered from almonds that contributed 321% of the total PAC content among three almond varieties. Also, a significant quantity of
hydrolysable tannins, ellagitannins (27.4 mg/100 mg almond, ellagic acid equivalents) and
gallotannins (54.7 mg/100 mg almond, gallic acid equivalents), were characterized in almond. In
Chapter 4, we report the presence of stilbenes (8.33-9.55 µg/100 g almond) in almond. Polydatin
(resveratrol-3-glucoside) was the most abundant stilbene in almond, and piceatannol or
oxyresveratrol were also tentatively identified in almond. To our knowledge, these were the first
reports of both hydrolysable tannins and stilbenes are in almond. Thus, this research has
redefined almond polyphenol abundance, with proanthocyanidins being the most abundant class
followed by hydrolysable tannins, flavonoids, lignans, phenolic acids, and stilbenes.
Hydrolysable tannins and bound PACs have limited bioavailability and only their microbial
catabolites are absorbed. Stilbenes circulate mainly as phase II metabolites. (Table 7.1). Only
dimers of extractable PACs can be absorbed as their intact form in the small intestine and colon
(Holt, Lazarus et al. 2002, Sano, Yamakoshi et al. 2003). Extractable PACs have degree of
polymerization more than 2 are metabolized in colon and absorbed as phenolic acids (Rios,
Gonthier et al. 2003). The metabolic fate of bound PACs is still unknown, but if liberated in
digestion, these would also be subjected to extensive microbial catabolism. Hydrolysable tannins
are metabolized by colon to corresponding phenolic acids and colonic metabolites, such as
urolithins (Seeram, Henning et al. 2006). Similar, only daughter compounds of stilbenes were
found in human plasma (Walle, Hsieh et al. 2004). Thus, PACs, stilbenes and hydrolysable
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tannins constitute of the pool of parent polyphenols compounds with limited or no
bioavailability.
Chapter 3 and 4 largely support the hypothesis that few almond polyphenols remain
unmetabolized after absorption. Although the polyphenol databanks such as USDA databank and
Phenol-explore provide comprehensive database on polyphenol contents in food (Neveu, PerezJiménez et al. 2010, Bhagwat, Haytowitz et al. 2013), these studies developed a more
comprehensive understanding of the almond polyphenol profile. Many nuts, berries, and other
polyphenol-rich foods have not been well characterized. Utilizing a similar analytical approach
can likely improve the compositional data for other foods.
Next, we hypothesized thatplasma and urinary polyphenol metabolite concentrations would
be greater than bioavailable unmetabolized polyphenols in adults that consumed a polyphenolrich aronia berry extract,. This hypothesis was strongly supported by data presented in Chapter 5.
The polyphenol profile in aronia berry supplements is listed in Table 5.4, which contained 36.9
mg/500 mg phenolic acid (neochlorogenic acid, chlorogenic acid, protocatechuic acid, and
caffeic acid), 9.9 mg/500 mg flavonoids (quercetin, quercetin-3-glucoside, quercetin-3galactoside, and quercetin-3-rutinoside), 45.07 mg/500 mg anthocyanins (cyanindin-3-glucoside,
cyanidin-3-galactoside, cyanidin-3-arabinoside, and cyanidin-3-xyloside), and 41.9 mg/500 mg
PACs. Previous studies suggested quercetin aglycone and glycoside consumption mainly
generated daughter compounds such as quercetin-3-glucuronide, methyl-quercetin-3-glucuronide
and quercetin-3-sulfate in plasma (Day, Mellon et al. 2001, Sesink, O’Leary et al. 2001).
Chlorogenic acid ingested by humans is hydrolyzed into caffeic acid and quinic acid (Plumb,
Garcia-Conesa et al. 1999). Only 1.7 % of ingested chlorogenic acid was recovered in urine
unmetabolized (Olthof, Hollman et al. 2003). Caffeic acid is an intermediate metabolite of many
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polyphenols, including chlorogenic acid (Table 5.1) (Stalmach, Mullen et al. 2009).
Protocatechuic acid is an abundant metabolite of anthocyanins (Vitaglione, Donnarumma et al.
2007). Anthocyanins are extensively metabolized to phenolic acids, phase I metabolites and
conjugated anthocyanins, and more than 99% of the bioavailable portion of anthocyanins are
metabolites (Czank, Cassidy et al. 2013). However, it is unclear the polyphenol metabolism
profile in human consumed polyphenol rich food. Thus, in this study, polyphenol metabolism
and pharmacokinetics were determined in adults that consumed an anthocyanin and PAC -rich
aronia berry extract.
In Chapter 5, after former smokers consumed a 500 mg dose of aronia berry extract,
polyphenol metabolites constituted at least 99% of the total polyphenol pool measured in plasma
and urine. This is likely because the aronia extract had abundant condensed tannins and
anthocyanins, which are highly metabolized (Sano, Yamakoshi et al. 2003, Czank, Cassidy et al.
2013). This result suggested plasma and urinary polyphenol metabolite concentrations would be
greater than bioavailable unmetabolized polyphenols in adults consumed aronia berries extract.
The Cmax of hippuric acid was the highest among the studied compounds, followed by 3-(4hydroxyphenyl)propionic acid peonidin-3-glucoside, cyanidin-3-glucoside, and protocatechuic
acid in the plasma, subjected the concentration of polyphenol metabolites is higher than that of
the parent compounds. Studies utilizing isotopically-labelled polyphenols are needed to more
specifically track the metabolic fate of polyphenols. Also, this method can be applied to other
types of polyphenol rich food.
Our hypothesis for Objective 3 was that chronic consumption of polyphenols would reduce
biomarkers of CVD risk and that increases in polyphenol metabolites would be more associated
with modulating these biomarkers than unmetabolized polyphenols. This hypothesis was
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partially supported by the results of the study described in Chapter 6. The aronia supplement
significantly reduced fasting plasma total cholesterol in former smokers after the 12-week
treatment, and reduced plasma LDL-C level by 6 weeks of consumption.

Peonidin-3-O-

galactoside, a phase II metabolite of cyanidin-3-O-galactoside, was associated with lower plasma
total cholesterol and LDL-C in the aronia supplemented group. It is presently unclear why
peonidin-3-O-galactoside has more bioactivity than cyanidin-3-O-galactoside, and further studies
are needed to resolve its potential cholesterol-lowering mechanism. Despite changes in
polyphenol excretion after supplementation, the increase of total urinary polyphenols from
baseline was not significantly different between the placebo and aronia-supplemented groups.
This implies that the bioavailability of aronia polyphenols was insufficient to lead to significant
polyphenol accumulation beyond the background diet. Also, aronia berry supplement
consumption did not change biomarkers of inflammation and oxidative stress, which might be a
function of the participant population having lower oxidative stress and more favorable plasma
lipid profiles (lower plasma LDL-C, TG, and total cholesterol and higher HDL-C) than
participants in other trials where aronia intake improved antioxidant function (Naruszewicz,
Łaniewska et al. 2007, Broncel, Koziróg et al. 2010). Future studies should consider examining
the specific function of polyphenol metabolites.
Thus, this dissertation supports the central hypothesis that the sum of polyphenol
metabolites is more responsible than polyphenol parental compounds for in vivo bioactivity.
Also, despite efforts to databank polyphenol values, there is still a strong need to utilize
analytical chemistry to define the polyphenol composition of foods. The polyphenol contents of
foods may be more abundant than previously reported. Large interindividual differences were
observed for polyphenol metabolism in Chapter 5, which is informs the new field of personalized
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nutrition, as individuals have apparently unique polyphenol profiles after consuming aronia
berry. Colonic polyphenol metabolism and peonidin-3-galactoside were related to cholesterollowering activity of aronia berry polyphenols in former smokers. Although we cannot suggest a
causal relationship for these compounds, studies of these compounds should be pursued to
identify their intrinsic cholesterol-lowering activities and mechanisms.
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Figure A.4.3 Chromatogram of almond sample under different condition
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A.2 Appendix Materials for Chapter 6
Table A.6.1 Baseline characteristics of nutrients intake
Nutrient

Placebo

Aronia

P-Value

Macronutrients
Energy (kcal/d)

1952.7 ± 525.8

0.146

237.9 ± 9.1

241.1 ± 8.5

0.791

Protein (g/d)

89.2 ± 3.3

90.3 ± 3.1

0.812

Fat (g/d)

87.8 ± 4.0

77.6 ± 29.5

0.553

Fiber (g/d)

23.5 ± 1.6

21.0 ± 1.5

0.282

Carbohydrate (g/d)

2225.6 ± 734.8

Micronutrients
Sodium (mg/d)

3490.3 ± 156.1

3479.7 ± 146.2

0.961

Calcium (mg/d)

946.5 ± 58.2

1066.8 ± 53.2

0.139

16.9 ± 1.3

16.9 ± 1.2

0.974

5.0 ± 0.9

7.1 ± 0.8

0.109

Vitamin E (α-tocopherol mg/d)

10.6 ± 1.1

10.8 ± 1.1

0.904

Vitamin C

80.9 ± 12.9

90.9 ± 12.1

0.579

3278.0 ± 738.0

2688.5 ± 691.3

0.566

Iron (mg/d)
Vitamin D (mg/d)

Vitamin A (retinol equiv mcg/d)
Polyhenols
Isoflavones (mg/d)

3.86 ± 2.7

8.5 ± 2.6

0.233

Flavanols (mg/d)

73.9 ± 20.0

81.7 ± 18.7

0.779

Flavones (mg/d)

54.1 ± 29.1

50.3 ± 27.2

0.924

Flavanones (mg/d)

28.8 ± 11.4

22.4 ± 10.7

0.686
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Flavan-3ols (mg/d)

20.6 ± 7.4

26.0 ± 6.9

0.601

Anthocyanins (mg/d)

18.2 ± 5.2

26.6 ± 4.8

0.247

Proanthocyanins (mg/d)

221.8 ± 162.4

417.9 ± 152.1

0.388

Data are mean ± standard error of mean of n = 24 placebo, n = 25 aronia extract with nonmissing value.
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Figure A.6.1 canonical discriminate analysis based on respondent
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